Sporeforming probiotic strains, methods and uses thereof

ABSTRACT

The present disclosure relates to the isolation, identification and characterization of novel sporeforming probiotic strain(s) with NSPase (Non-Starch Polysaccharides-active hydrolases) activity isolated from fish gut microbiota, methods and uses thereof. The sporeforming probiotic strain(s) with NSPase activity now disclosed are able of producing carbohydrate-active enzymes (CAZymes) that hydrolyse non-starch polysaccharides (NSPs) and accesses their potential as probiotics (PRO) for use in particular in aquafeeds.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a U.S. National Stage Application under 35 U.S.C. § 371 of International Patent Application No. PCT/M2019/059131, filed Oct. 24, 2019, which claims priority to Portugal Patent Application No. 115101, filed Oct. 24, 2018, which are hereby incorporated by reference in their respective entireties.

TECHNICAL FIELD

The present disclosure relates to the isolation, identification and characterization of novel sporeforming probiotic strain(s) with NSPase (Non-Starch Polysaccharides-active hydrolases) activity isolated from fish gut microbiota, methods and uses thereof.

The sporeforming probiotic strain(s) with NSPase activity now disclosed are able of producing carbohydrate-active enzymes (CAZymes) that hydrolyse non-starch polysaccharides (NSPs) and accesses their potential as probiotics (PRO) for use in particular in aquafeeds.

BACKGROUND ART

The gastrointestinal microbial community plays a critical role on vertebrates' health and metabolism, impacting host metabolism, immune status and health/disease balance. In the last decade, this relationship has received increased attention particularly in humans, where it is known to control local (at the gut level) health status as well as systemic health. The gut microbiota of vertebrates, ranging from mammals to teleost fish, is involved in host appetite control and obesity development [1], protection against pathogens, immunity enhancement or inflammatory processes [2]. Additionally, gut microorganisms respond to a wide range of factors, including dietary composition, and harbor a relevant and diversified enzymatic repertoire that might interfere with host metabolism [3, 4]. This is particularly important in fish nutrition, because fish do not possess all of the necessary enzymes to cope with the current aquaculture dietary challenges [4].

A main difficulty within fish nutrition is its dependence on fish meal (FM), an unsustainable commodity and a source of organic pollutants. The most obvious sustainable alternatives to fish meal are plant feedstuffs, but their nutritive value is limited by the presence of high levels of non-starch polysaccharides (NSPs) which are not metabolized by fish.

These facts are disclosed to illustrate the technical problem addressed by the present disclosure.

GENERAL DESCRIPTION

Aquaculture output is growing rapidly and has already surpassed fisheries in terms of providing food to meet the growing human population [5]. Aquaculture is greatly dependent on FM, an unsustainable commodity and a source of organic pollutants, almost exclusively provided by fisheries. This is particularly obvious in carnivorous fish production due to their high dietary protein requirement (40-50%), which is mainly provided by FM. Plant feedstuffs (PF) are sustainable alternatives to FM, and among them, soybean meal (SBM), rapeseed meal (RSM), and sunflower meal (SFM), have been acknowledged as the most promising due to their high protein level, world-wide availability, and reasonable price. However, the nutritive value of PF is limited by the presence of several anti-nutritional factors, including high levels of non-starch polysaccharides (NSPs) which are not digested by fish [6]. NSPs content in SBM, RSM, and SFM averages 22-24% and the major NSPs components are pectic polysaccharides with arabinose, galactose, and xylose residues predominating. Yet, the proportion of these sugar residues varies between PF with galactose being predominant in SBM, arabinose in RSM, and xylose in SFM.

In fish, the carbohydrate-active enzymes (CAZymes) able to hydrolyze the β-glycosidic bonds of NSPs are scarce or non-existent. Thus, dietary NSPs remain indigestible and cannot be used as energy source. Moreover, indigestible NSPs might have detrimental effects on fish performance and nutrient digestibility and on fish health [7]. These adverse effects are associated with the viscous nature of NSPs and their interaction with gut epithelium, mucus, and microbiota, which ultimately result on physiological and inflammatory imbalances [7]. Additionally, and contrary to other animal species, such as pigs and poultry, the supplementation of PF based diets with exogenous carbohydrases does not necessarily translate into an effective strategy for improving NSPs utilization, as diverging results on their impact on fish growth performance and feed utilization have been reported. Therefore, gut microorganisms characterized by a rich secretome are a potential source of in loch carbohydrases that may help fish to overcome the mentioned constraints.

Live microorganisms that confer a health benefit to the host when administered in adequate amounts are denominated probiotics (PRO) [8]. In particular, PRO decrease the incidence of diseases by competing with pathogens for adhesion sites/nutrients; produce natural antimicrobial compounds that inhibit pathogens growth; contribute to a balanced gut microbiota; improve host growth; enhance host immune system and gastrointestinal histomorphology. PRO have also been implicated in bioremediation and water quality improvement by reducing antibiotic usage, contributing to aquaculture sustainability.

Among the bacterial species currently used as PRO, sporeformers show critical advantages: bacterial spores are remarkably resistant dormant structures [9], permitting good shelf-storage; spores are easily produced in large scale and can be dehydrated, facilitating feed incorporation without losing characteristics. Importantly, spores survive gut transit since they are acid and bile tolerant and become successfully established in the gut [10]. In particular, Bacillus subtilis spores, which enjoy GRAS (Generally Regarded As Safe) status from the U.S. Food and Drug Administration (FDA) and are included in the European Food Safety Authority (EFSA) list of Qualified Presumption of Safety (QPS) [11], experience exponentially growing applications in biomedicine and biotechnology (as oral vaccines, disinfectants, PRO or display systems) [12]. In fact, different sporeformers are nowadays used as human and animal PRO [12-13], but within European Union (EU) just one PRO has been authorised for use in aquaculture (Bactocell®, LALLEMAND Inc., Canada).

The role of gut microbiota in shaping human and animal health is well established, and the potential health benefit of manipulating the gut ecosystem using PRO is increasingly being accepted. In carnivorous fish, such as European sea bass, an ideal PRO should not only enhance resistance to pathogens, i.e. by competitive exclusion, the most common criteria for selection of PRO strains, but also help fish in their current dietary challenges, including the utilization of PF. In this disclosure, the application of a PF-based dietary pressure to modulate European sea bass gut microbiota composition and corresponding metabolic functions revealed to be a successful strategy to find carbohydrate-active bacteria with PRO potential. In particular, it was targeted and isolated spore-forming Bacilli, commonly used in PRO preparations, mainly due to their extreme resistance characteristics and indefinitely survival, advantageous for industrial applications [9-10, 12-13, 17].

The composition of the gut microbial communities of fish have been demonstrated to adapt when the host is fed different dietary ingredients [1, 3, 4]. Thus, a selective pressure of plant-based diets on fish gut microbiota, can be a beneficial strategy for an enrichment of bacteria with a secretome able to mobilize the dietary NSPs. By targeting bacterial sporulating isolates with diverse carbohydrase activities from the gut of European sea bass (Dicentrarchus labrax), isolates with high probiotic potential were obtained. By inferring the adaptive fitness to the fish gut and the amenability to industrial processing, the best two candidates were identified to become industrially valuable PRO for improvement of fish health and utilization of dietary NSPs, contributing for sustainable and more cost-effective aquaculture practices.

Thus, the present disclosure relates to screening fish gut microbiota for bacteria capable of producing extracellular digestive enzymes that hydrolyse NSPs present in PF, in particular mannans, glucans, xylans, arabinans, and galactans.

Gut microbiota isolates showing promising metabolic traits and absence of safety concerns can be used as PRO in cost-effective and environmental-friendly diets by allowing the host to obtain energy from otherwise indigestible dietary constituents. In fact, native bacteria with PRO potential will be more apt to become established and persist in the fish gut environment after withdrawal from the diet.

The present disclosure provides several advantages, namely: it solves the incapability of fish to efficiently digest and utilize PF as alternative protein source to FM; compared to exogenous purified enzymes (the only available technology, with poor results in fish), this disclosure has the added value of being also an autochthonous PRO that besides helping fish with the digestive challenges also contributes to fish health and welfare by antagonizing fish pathogens, having a dual positive effect on fish performance. Additionally, this product, by being a sporeformer, is more robust and resistant than the other PRO in EU market, allowing feed incorporation without losing characteristics and storage without refrigeration.

The present disclosure relates to ABP1 which was received on 8 Jun. 2018 and accepted for deposit for patent purposes at the Coleccion Espanola de Cultivos Tipo (CECT)—International Depositary Authority under the Budapest Treaty—under the accession number CECT 9675.

The present disclosure also relates to ABP2 which was received on 8 Jun. 2018 and accepted for deposit for patent purposes at the Coleccion Espanola de Cultivos Tipo (CECT)—International Depositary Authority under the Budapest Treaty—under the accession number CECT 9676.

The present disclosure therefore relates to a bacterial strain selected from ABP1 with a deposit under the accession number CECT 9675, of 8 Jun. 2018, at Coleccion Espanola de Cultivos Tipo, and/or from ABP2 with a deposit under the accession number CECT 9676, of 8 Jun. 2018, at Coleccion Espanola de Cultivos Tipo.

Furthermore, the present disclosure also relates to a composition for aquatic animal feed comprising a bacterial strain selected from ABP1 with a deposit under the accession number CECT 9675, of 8 Jun. 2018, at Coleccion Espanola de Cultivos Tipo, and/or from ABP2 with a deposit under the accession number CECT 9676, of 8 Jun. 2018, at Coleccion Espanola de Cultivos Tipo.

In an embodiment, said composition may comprise 1×10⁵-1×10¹² of colony forming units of the bacterial strain per gram of the composition, preferably said composition may comprise 1×10⁷-1×10¹⁰ colony forming units of the bacterial strain per gram of the composition, more preferably said composition may comprise 2×10⁹ colony forming units of the bacterial strain per gram of the composition.

In an embodiment, said composition may further comprise a preservative.

In an embodiment, said composition may be a granulate form; a powdered form or a pellet.

In an embodiment, said composition may be a granulate form wherein the granulate form is coated, in particular wherein the coating comprises a salt and/or wax and/or a flour.

The present disclosure also relates to a method for feeding an aquatic animal present in an aquaculture comprising the step of feeding the aquatic animal with the composition now disclosed.

In an embodiment, the step of feeding the aquatic animal may be carried out during the life span of the aquatic animal.

In an embodiment, the aquatic animal may be selected from the following list: a shellfish, fish, amberjack, arapaima, barb, bass, bluefish, bocachico, bream, bullhead, cachama, carp, catfish, catla, chanos, char, cichlid, cobia, cod, crappie, dorada, drum, eel, goby, goldfish, gourami, grouper, guapote, halibut, java, labeo, lai, loach, mackerel, milkfish, mojarra, mudfish, mullet, paco, pearlspot, pejerrey, perch, pike, pompano, roach, Atlantic salmon, salmon, sampa, sauger, sea bass, European sea bass, seabream, gilthead seabream, white seabream, shiner, sleeper, snakehead, snapper, snook, sole, spinefoot, sturgeon, sunfish, sweetfish, tench, terror, tilapia, trout, tuna, turbot, vendace, walleye, halibut, whitefish or shrimp.

This disclosure also relates to the use of a bacterial strain selected from ABP1 with a deposit under the accession number CECT 9675, of 8 Jun. 2018, at Coleccion Espanola de Cultivos Tipo, and/or from ABP2 with a deposit under the accession number CECT 9676, of 8 Jun. 2018, at Coleccion Espanola de Cultivos Tipo, as a probiotic.

This disclosure also relates to the use of a bacterial strain selected from ABP1 with a deposit under the accession number CECT 9675, of 8 Jun. 2018, at Coleccion Espanola de Cultivos Tipo, and/or from ABP2 with a deposit under the accession number CECT 9676, of 8 Jun. 2018, at Coleccion Espanola de Cultivos Tipo, as a supplement to feedstuff, preferably as a supplement to feedstuff for fish or shellfish.

Furthermore, the present disclosure also relates to an isolated polynucleotide or polypeptide from ABP1 with a deposit under the accession number CECT 9675, of 8 Jun. 2018, at Coleccion Espanola de Cultivos Tipo, wherein the isolated polynucleotide is selected from the following list: SEQ. ID. No. 19 (ABP10666), SEQ. ID. No. 20 (ABP10667), SEQ. ID. No. 7 (ABP10654), SEQ. ID. No. 24 (ABP10671), SEQ. ID. No. 36 (ABP10829), SEQ. ID. No. 37 (ABP10830), or combinations thereof, wherein the isolated polynucleotide encodes for a polypeptide that hydrolyses a non-starch polysaccharide, preferably non-starch polysaccharides present in plant feedstuffs, preferably wherein the non-starch polysaccharide is mannan, glucan, xylan, arabinan, and/or galactan.

The present disclosure also relates to an isolated polynucleotide or polypeptide from ABP2 with a deposit under the accession number CECT 9676, of 8 Jun. 2018, at Coleccion Espanola de Cultivos Tipo, wherein the isolated polynucleotide is selected from the following list: SEQ. ID. No. 160 (ABP24564), SEQ. ID. No. 161 (ABP24565), SEQ. ID. No. 162 (ABP24566), SEQ. ID. No. 163 (ABP24567) or combinations thereof, wherein the isolated polynucleotide encodes for a polypeptide that hydrolyses a non-starch polysaccharide, preferably non-starch polysaccharides present in plant feedstuffs, preferably wherein the non-starch polysaccharide is mannan, glucan, xylan, arabinan, and/or galactan.

BRIEF DESCRIPTION OF THE DRAWINGS

The following figures provide preferred embodiments for illustrating the description and should not be seen as limiting the scope of the present disclosure.

FIG. 1 . Morphological diversity (Panels A-J) of representative sporeforming fish isolates obtained from European sea bass gut contents. Photographs of colonies grown 24 h in LB (Luria-Bertani) agar medium, are at the same scale defined in Panel J (0.5 cm). Panel K depicts a representative image of the different development stages of sporulation [(a) vegetative cell, (b) sporulating cell (forespore engulfed by the mother cell) and (c) free spore] that were observed in each sporeforming isolate by phase-contrast microscopy. Sporulation was induced by nutrient exhaustion in solid Difco Sporulation Medium (DSM).

FIG. 2 . (A) Diversity of sporeforming genera obtained from European sea bass digesta samples. (B) Distribution of bacterial species within the Bacillus genus depicted in panel A.

FIG. 3 . Carbohydrolitic profile of representative sporeformers (A-L) isolated from the gut of European sea bass, when cultured on solid minimal medium (M9) alone or supplemented with D-glucose (Gluc), D-fructose (Fruct), D-xylose (Xyl), L-arabinose (Arab), D-galactose (Galact), D-mannose (Mann), Xylooligosaccharides (XOS) and Galactooligosaccharides (GOS).

FIG. 4 . (A) Carbohydrolitic profile of the best 11 sporeformers (codes in the x axis) isolated from European sea bass gut, when cultured in liquid minimal medium supplemented with D-glucose, D-fructose, D-xylose, L-arabinose, D-galactose, D-mannose, Xylooligosaccharides (XOS) and Galactooligosaccharides (GOS) for 24 h at 37° C. with agitation. Growth was quantified by measuring the optical density (OD) at an absorbance of 600 nm. The results presented are the average of three independent experiments with error bars representing the standard deviation. (B) PCR detection of genes coding for β-glucanase (bglS), levanase or β-D-fructofuranosidase (sacC), mannan endo-1,4-β-mannosidase (gmuG), endo-1,5-α-L-arabinanase (abnA) and arabinoxylan arabinofuranohydrolase (xynD) carbohydrases in the genome of fish isolates (FI numbers on top of the figure). The amplicon size, in base pairs (bp) is depicted on the right.

FIG. 5 . Titer of viable cells present in 24 h DSM (Difco Sporulation Medium) cultures of each sporeformer fish isolate (codes in x axis) before (grey, total cells) and after (black, sporulating or heat resistant cells) a 20 min heat treatment at 80° C. Sporulation was induced by nutrient exhaustion in liquid DSM at 37° C., 150 rpm. Numbers on top of the panel correspond to the percentages (%) of sporulation calculated as the ratio between sporulating cells and total cells. Bacillus subtilis 168 was used as control and the results are the average of three independent experiments with error bars representing the standard deviation.

FIG. 6 . Viability of spores from each sporeformer isolate (codes in x axis) when exposed for 4 h (T4, dark grey) to simulated stomach conditions (0.85% NaCl, pH 2, containing 3 mg ml⁻¹ pepsin) followed by 24 h (T24, black) exposition to simulated gut condition (Luria-Bertani, L B, pH 8 containing 1 mg ml⁻¹ pancreatin and 0.3% bile salts). The initial viable counts (time 0 or TO) are depicted in light grey. B. subtilis 168 was used as control and the results are the average of three independent experiments with error bars representing the standard deviation.

FIG. 7 . Antimicrobial activity of sporeforming fish isolates ABP1, ABP20, ABP27 and ABP2 against different fish pathogens (Staphylococcus aureus, Photobacterium damselae, Vibrio harveyi, Aeromonas bivalvium and Tenacibaculum maritimum). (A) Growth inhibition screened by a colony overlay assay, where the producer strains were inoculated as spots on Luria-Bertani agar plates, grown for 24 h and then covered by Soft Marine Agar (for Tenacibaculum maritimum) or Soft Brain Heart Infusion Agar (for all the other) inoculated with indicator pathogenic strains. (B) Growth Inhibition screened by a cell-free supernatant assay in which a Marine Agar plate seeded with Tenacibaculum maritimum was perforated with 0.5 cm holes and filled with 100 μl of filtered culture medium from overnight grown sporeforming isolates. B. subtilis 168 (Bsub) was used as control. All photographs are to scale.

FIG. 8 . Germination of populations of purified spores of sporeformers fish isolates ABP7, ABP1, ABP20, ABP27, ABP34 and ABP2 at 37° C. in 50 mM Tris-HCl, pH7.5 (control, black circles) or in response to the addition of 100 mM L-alanine (dark grey circles) or a mixture of 100 mM KCl, 56 mM glucose, 56 mM fructose and 33 mM L-asparagine (AGFK, light grey circles). B. subtilis 168 was used as control.

DETAILED DESCRIPTION

The present disclosure relates to the isolation, identification and characterization of novel sporeforming probiotic strain(s) with NSPase (Non-Starch Polysaccharides-active hydrolases) activity isolated from fish gut microbiota, methods and uses thereof.

In an embodiment, sporeformers were isolated from the gut of European sea bass juveniles challenged with PF diets based on SBM, RSM or SFM, which have different NSPs profiles. European sea bass was the model species chosen due to its high commercial importance in European aquaculture and its carnivorous feeding habits, thus being more challenging to cope with PF-based diets. However, other models could be equally used such as gilthead seabream (Sparus aurata) or white seabream (Diplodus sargus) or Atlantic salmon (Salmo salar).

Providing fish with self-gut bacteria capable of producing carbohydrate-active extracellular enzymes that hydrolyse NSPs emerge as a strategy with enormous potential to overcome PF-diets limitations. The bacterial strains now disclosed were isolated with this purpose and their genome sequences support their view as potential NSPs-hydrolyzers that might help aquaculture fish on using high PF-diets.

Having in mind the enhanced adaptability of gut microbial communities, a selective pressure of plant-based diets on fish gut microbiota was carried out for an enrichment of bacteria with a secretome able to mobilize the dietary NSPs. By targeting bacterial spores, remarkably resistant dormant structures with increasing applications in animal health, namely as vaccines or PRO, it was possible to isolate carbohydrate-active gut bacterial strains, from European sea bass, with PRO potential. By inferring the adaptive fitness to the fish gut and the amenability to industrial processing, the best candidates were identified to become industrially valuable PRO for improvement of fish health and utilization of dietary NSPs, contributing for sustainable and more cost-effective aquaculture practices.

In an embodiment, the PRO were isolated and purified, identified to the species level, fully characterised, namely its safety following EFSA guidelines, NSPase activity, antimicrobial activity against important fish-pathogens, adaptive fitness to the fish gut and the amenability to industrial processing. The complete genome has been sequenced.

In an embodiment, there is a need for further research namely addressing the in vivo efficacy in improving PF utilization by fish and disease resistance in bacterial infection models. A preliminary assay using challenging plant-based diets (CTR−), revealed that supplementation with ABP1, or ABP1 and ABP2 (Mix) has a positive effect on the final body weight, the weight gain, the feed efficiency and the protein efficiency ratio of European sea bass juveniles, with a tendency to get closer to a FM-based diet (CTR+) (Table 1). Future analyses including digestive enzymes activity and gut microbiota modulation, might help explain the results obtained. Furthermore, a comprehensive screening of ABP1 and ABP2 genomes will potentially allow the identification of new carbohydrases or antimicrobial molecules.

TABLE 1 Growth performance and feed utilization efficiency of European sea bass fed the experimental diets¹. Diets CTR− ABP1 ABP2 Mix CTR+ Final body weight (g) 74.0 ± 4.8^(a)  83.0 ± 1.6^(ab) 73.7 ± 6.8^(a) 80.0 ± 12.0^(ab)  97.0 ± 2.0^(b) Weight gain (% IBW^(†)) 155.4 ± 16.6^(a)  185.3 ± 5.4^(ab) 160.5 ± 23.2^(a) 176.0 ± 41.3^(ab)  233.8 ± 6.7^(b ) Daily growth index² 17.3 ± 0.1  19.8 ± 0.0 17.7 ± 0.2  18.9 ± 0.3   23.4 ± 0.1 Feed intake (g kg ABW^(−1§) day⁻¹) 15.4 ± 1.4  16.7 ± 0.3 15.6 ± 0.2  15.8 ± 1.3   17.5 ± 0.1 Feed efficiency³  0.82 ± 0.03^(a)   0.86 ± 0.02^(ab)   0.84 ± 0.03^(ab) 0.87 ± 0.06^(ab)   0.94 ± 0.01^(b) Protein efficiency ratio⁴  1.82 ± 0.08^(a)   1.86 ± 0.05^(ab)  1.84 ± 0.07^(a) 1.88 ± 0.12^(ab)   2.09 ± 0.02^(b) ^(†)IBW: initial body weight. ^(§)ABW: average body weight (initial body weight + final body weight)/2. ¹Mean values and standard deviation (±SD) are presented for each parameter (n = 3). Significant differences within the diets are indicated by different letters (Tukey test, P < 0.05). ²DGI: ((final body weight^(1/3) − initial body weight^(1/3))/time in days) × 100. ³FE: (wet weight gain/dry feed intake). ⁴PER: (wet weight gain/crude protein intake).

In an embodiment, the fermentation of the strains can be easily reproduced by another practitioner. Furthermore, regarding commercial applications, companies within the aquaculture and feed industry may be potentially interested in acquiring these strains for the development of new PRO with digestive added-value.

In an embodiment, diet composition was formulated. Three experimental diets were formulated to be isonitrogenous (47% crude protein), isolipidic (17% crude lipid) and to contain 30% of soy bean meal (SBM diet), 30% of rapeseed meal (RSM diet) or 30% of sunflower meal (SFM diet). A FM-based diet was used as the control diet (CTR diet). Fish oil and pregelatinized maize starch were the main lipid and carbohydrate sources, respectively. Bicalcium phosphate was added to adjust dietary phosphorus level. All diet ingredients were thoroughly mixed and dry-pelleted in a laboratory pellet mill (California Pellet Mill, CPM Crawfordsville, Ind., USA), through a 3.0 mm die. Pellets were dried in an oven at 50° C. for 24 h, and then stored at −20° C. until used. Ingredients and proximate composition of the experimental diets are presented in Table 2.

TABLE 2 Ingredients composition and proximate analysis of experimental diets Diets^(a) CTR SBM RSM SFM Ingredients (% dry weight) Fish meal^(b) 60.2 38.7 45.2 48.1 Soy bean meal^(c) — 30.0 — — Rapeseed meal^(d) — — 30.0 — Sunflower meal^(e) — — — 30.0 Pregelatinized maize starch^(f) 23.2 11.6 8.0 4.8 Fish oil 12.1 13.6 12.4 13.0 Bicalcium phosphate^(g) 1.0 2.6 1.0 0.6 Choline chloride (50%) 0.5 0.5 0.5 0.5 Vitamin premix^(h) 1.0 1.0 1.0 1.0 Mineral premix^(i) 1.0 1.0 1.0 1.0 Binder^(j) 1.0 1.0 1.0 1.0 Proximate analysis (% dry weight) Dry matter 91.5 92.4 92.7 93.5 Crude protein 46.9 46.5 46.3 46.4 Crude lipids 17.3 16.1 16.6 16.8 Ash 11.3 11.7 11.3 11.1 DM dry matter, CP crude protein, CL crude lipid ^(a)CTR, control fishmeal-based diet; SBM, soybean meal-based diet; RSM, rapeseed meal-based diet; SFM, sunflower meal-based diet ^(b)Steam Dried LT fish meal, Pesquera Diamante, Austral Group, S.A Perú (CP: 74.7% DM; GL: 9.8% DM) ^(c)Sorgal, S.A. Ovar, Portugal (CP: 53.7% DM; GL: 2.1% DM) ^(d)Sorgal, S.A. Ovar, Portugal (CP: 37.5% DM; GL: 4.0% DM) ^(e)Sorgal, S.A. Ovar, Portugal (CP: 30.3% DM; GL: 1.0% DM) ^(f)C-Gel Instant-12016, Cerestar, Mechelen, Belgium ^(g)Premix, Portugal (Calcium: 24%; Total phosphorus: 18%) ^(h)Vitamins (mg kg¹ diet): retinol acetate, 18,000 (IU kg⁻¹ diet); cholecalciferol, 2000 (IU kg⁻¹ diet); alfa tocopherol acetate, 35; sodium menadione bisulphate, 10; thiamine-HCl, 15; riboflavin, 25; calcium pantothenate, 50; nicotinic acid, 200; pyridoxine HCl, 5; folic acid, 10; cyanocobalamin, 0.02; biotin, 1.5; ascorbic acid, 50; inositol, 400 ^(i)Minerals (mg kg⁻¹ diet): cobalt sulphate, 1.91; copper sulphate, 19.6; iron sulphate, 200; sodium fluoride, 2.21; potassium iodide, 078; magnesium oxide, 830; manganese oxide, 26; sodium selenite, 0.66; zinc oxide, 37.5; dibasic calcium phosphate, 8.02 (g kg⁻¹ diet); potassium chloride, 1.15 (g kg⁻¹ diet); sodium chloride, 0.44 (g kg⁻¹ diet) ^(j)Aquacube (guar gum, polymethyl carbamide, manioc starch blend, hydrate calcium sulphate) Agil, UK.

In an embodiment, the animal experiment was performed at the Marine Zoology Station, Porto University, Portugal, with European sea bass, juveniles obtained from a commercial fish farm (Maresa S. A., Ayamonte, Huelva, Spain). After transportation to the experimental facilities fish were first submitted to a quarantine period of 30 days before transfer to the experimental system where they were allowed to adapt for 15 days. Before the experimental period, fish were fed a commercial diet (48% protein, 11% lipids, 5% starch). The trial was performed in a recirculating water system equipped with 12 cylindrical fiberglass tanks of 100 l water capacity and thermo-regulated to 22.0±1.0° C. Tanks were supplied with continuous flow of filtered seawater (2.5-3.5 l min⁻¹) of 34.0±1.0 g I⁻¹ salinity and dissolved oxygen was kept near saturation (7 mg I⁻¹). Thereafter, 20 European sea bass with an initial mean body weight of 34.4 g were distributed to each tank and the experimental diets randomly assigned to triplicate groups. The trial lasted 45 days and fish were fed by hand, twice daily, 6 days a week, until apparent visual satiation. The experiment was performed by accredited scientists (following FELASA category C recommendations) and was conducted according to the EU directive 2010/63/EU on the protection of animals for scientific purposes.

In an embodiment, sampling was carried out as follows. Fish in each tank were bulk-weighed at the beginning and at the end of the trial, after 1 day of feed deprivation. For that purpose, fish were slightly anaesthetized with 0.3 ml I⁻¹ ethylene glycol monophenyl ether (Sigma-Aldrich, Steinheim, Germany). On the sampling days (at day 15 after the beginning of the trial and at the end of the trial or day 45), fish were fed several times over the day to guarantee that gut was full at sampling time. At 4 h after the first meal, 3 fish per tank were randomly sacrificed with an overdose of ethylene glycol monophenyl ether, for collection of biological samples under aseptic conditions. To overcome inter-fish variation, the resulting material was pooled into one sample per tank to assess differences between dietary groups. Whole-gut (without pyloric caeca) were aseptically excised and squeezed to collect the digesta contents.

In an embodiment, the isolation of sporeforming bacteria was performed as follows. Each sample of digesta (1 g) obtained from fish fed the different dietary treatments was homogenized in 9 ml of buffered saline solution (0.9%). Serial dilutions were prepared in Bott & Wilson (B&W) salts and 100 μl aliquots spread on the surface of LB agar medium, after 20 min heat treatment at 65° C., for sporeformers selection. Plates were incubated at 30° C. in aerobic conditions for up to 5 days. Following selection, sporeformers were isolated and characterized for morphology in DSM, to confirm spore production by phase-contrast microscopy. Colonies representing different morphologies were picked at random and purified by restreaking on agar plates of the same media, before storage at −80° C. in LB broth with 30% glycerol. Sporeformers isolates were routinely grown aerobically at 37° C. in LB or DSM. The laboratory strain B. subtilis 168 [14] was used as a control in most of the experiments described in the present disclosure.

In an embodiment, screening sporeforming bacteria for carbohydrates metabolization was carried out as follows. Each sporeformer isolate was cultured on solid M9 minimal medium [15] supplemented with 0.2% (w/v) of each of the following carbohydrates: D-glucose (G7528), D-fructose (F3510), D-xylose (X3877), L-arabinose (A3256), D-galactose (G0750), D-mannose (63580), all purchased from Sigma-Aldrich, Steinheim, Germany-Aldrich Co. LLC. The Xylooligosaccharides (XOS) and Galactooligosaccharides (GOS) are commercially available prebiotics from Qingdao FTZ United International Inc. (Quingdao, China) that were added at the same concentration (0.2%). Growth after 24 h at 37° C. was recorded by photographing colonies in a Gel Doc XR System (Bio-Rad) using the Image Lab software v.4.0.1 (Bio-Rad). Growth quantification was assessed by measuring the colony volume on fixed areas with local background subtraction (adjusted volume=[CNT*mm²] data counts/mm²) using the Quantity One software v.4.6.9 (Bio-Rad). Quantification of carbohydrates utilization in liquid M9 was performed after an overnight enrichment in liquid LB at 37° C. with agitation. Each isolate was diluted to an initial optical density (OD₆₀₀; absorbance measured at 600 nm) of 0.1 in liquid M9 minimal medium alone or supplemented with 0.2% of the different carbohydrates previously tested. Bacterial growth was followed during 48 h and quantified by measuring the OD₆₀₀. In both solid and liquid medium assays, results presented were corrected by subtracting the colony volume/OD₆₀₀ measured in M9 alone.

In an embodiment, the taxonomic identification of PRO isolates was performed as follows. Identification was carried out for all the isolates with promising extracellular carbohydrolytic activities. Total genomic DNA extraction was performed from overnight LB cultures, using the EZNA bacterial DNA purification kit (Omega Bio-Tek, USA), according to the manufacturer's instructions and quantified with the Qubit 2.0 Fluorometer (Invitrogen, Oregon, USA). PCR amplification of the small-subunit rRNA (16S rRNA) was carried at an annealing temperature of 55° C. using primers 27F and 1492R. Each 20 μl reaction contained 1× DreamTaq Buffer (Thermo Scientific, Vilnius, Lithuania), 0.2 mM of each dNTP (Thermo Scientific, Vilnius, Lithuania), 0.2 μM of each primer (STAB Vida, Lisboa, Portugal), 1 U of DreamTaq DNA Polymerase (Thermo Scientific, Vilnius, Lithuania) and 25 ng of DNA template. The Bioinformatics Resources Sequence Match package of the Ribosomal Database Project 11 (http://rdp.cme.msu.edu) and BLAST of the GenBank nonredundant (nr) nucleotide database (http://www.ncbi.nlm.nih.gov) were used to analyse the sequencing data.

In an embodiment, the screening of PRO isolates for NSPases was performed as follows: to tentatively obtain a set of primers specific for the genes encoding NSPs degrading enzymes (NSPases), an initial search was conducted at the Protein Knowledgebase—UniProtKB with terms “family:hydrolase AND annotation:(type:location AND secreted) AND taxonomy: “Bacteria”. A file containing bacterial secreted glycosyl hydrolases (GH) was then created and the ones involved in the utilization of NSPs of interest were chosen for further analysis. Enzymes chosen included mannanases, mannosidases, arabinofuranosidases, arabinanases, glucosidases, glucanases, fructosidases (fructanases), fructafuranosidases, galactorunases, xylosidases, and xylanases. The protein sequence of each individual enzyme was used to search for similar proteins in the translated nucleotide database (tblastn) (http://www.ncbi.nlm.nih.gov) and to make nucleotide alignments between the sequences obtained with ClustalW algorithm using Geneious R7 v7.1.7 (Biomatters, Auckland, New Zealand). Regions of sequence conservation were chosen to design primer pairs (Table 4) with the Vector NTI 10 software (Invitrogen, Carlsbad, Calif.), with a calculated annealing temperature of approximately 55° C. and an amplicon size of 200 to 250 base pairs (bp). PCR amplification was done essentially as described for the 16S rRNA (previous section), adjusting the annealing temperature to 55° C. and the extension time to 30 s.

In an embodiment, biosafety issues in particular antibiotics susceptibility and hemolytic activity were also evaluated. Antimicrobial resistance was studied by testing susceptibility of sporeforming isolates to different classes of antibiotics, namely Macrolides (Erythromycin, EM), Aminoglycosides (Kanamycin, KM, Streptomycin, S M, and Gentamycin, GM), Tetracyclines (Tetracycline, TC), Glycopeptides (Vancomycin, VA) and Cloramphenicol (CL), following the recommendations of the EFSA Panel on Additives and Products or Substances used in Animal Feed [16]. Minimal inhibitory concentrations (MIC) were determined using Etest® (bioMérieux, inc.). Hemolysis was determined on Columbia 5% sheep blood agar plates streaked with colonies from fresh LB plates, after incubation at 37° C. for 24, 48 and 72 h.

In an embodiment, antimicrobial activity screening assays were performed as follows. The antimicrobial activity of selected sporeforming isolates was assessed by a colony overlay assay using as targets different fish pathogens. Zones of growth inhibition around the producer strains spots after 24 h incubation at 25° C. (for Photobacterium damselae, Vibrio harveyi, Tenacibaculum maritimum and Aeromonas bivalvium) or 37° C. (for Staphylococcus aureus) were considered as positives and the corresponding growth-inhibition halos diameter measured (mm). A cell-free supernatant screening assay was performed by inoculating BHI or Marine Agar (for T. maritimum) plates with overnight cultures of indicator strains, assuring a uniform and complete coverage of the agar plate. After 15 min rest to allow plates to dry, 1 cm holes where done in the agar and consequently filled with 200 μl of cell-free supernatant of each producer strain, previously centrifuged and filtered through a 0.2 μm cellulose filter, from stationary phase LB cultures (grown overnight at 37° C.). Zones of growth inhibition around the producer strains supernatant holes obtained after 24 h incubation at 25° C. or 37° C. (as before) were considered as positive. All observations were recorded by photographing in a Gel Doc XR System (Bio-Rad) using the Image Lab Software (Bio-Rad).

In an embodiment, sporulation, germination and resistance to gut environment were also carried out as follows. The kinetics of spore formation and germination was quantified using adaptations of well-established methods [15, 17]. Sporulation occurred in DSM for 24 h at 37° C. in an orbital shaker at 200 rpm, and its efficiency was determined by plating serial dilutions made in B&W isotonic buffer (Bott and Wilson salts: 1.24% K₂HPO₄, 0.76% H₂PO₄, 0.1% trisodium citrate, 0.6% [NH₄]₂SO₄, pH 6.7) on LB agar, before and after a 20 min heat treatment at 80° C. to eliminate vegetative cells. Following 24 h incubation at 37° C., visible colonies were counted, and sporulation efficiency calculated as the titre of colony forming units (CFU ml⁻¹) before and after the heat treatment.

Preparation of highly purified spores was done as follows: in brief, 48 h spores preparations (in liquid DSM) of each isolate were centrifuged for 10 min at 10000 g and 4° C. Cell pellets were suspended in 50 mM Tris-HCl (pH 7.2) containing 50 μg ml⁻¹ of lysozyme, and incubated for 1 h at 37° C. After a single wash with 1 volume of distilled water (10 min at 10000 g, 4° C.), cell pellets were suspended in 0.05% SDS, followed by three washes with distilled water and finally suspended in 1 volume of distilled water. Spores purity and recovery yields were determined by plating serial dilutions on LB agar, before and after a 20 min heat treatment at 80° C.

Spore germination in response to the addition of 100 mM L-alanine or to a mixture of 100 mM KCl, 56 mM glucose, 56 mM fructose and 33 mM L-asparagine (AGFK), was performed at 37° C. in 50 mM Tris-HCl, pH 7.5.

Potential resistance to gut transit was evaluated by determining the acid and bile tolerance of each selected isolate. For that purpose, 48 h DSM spores preparations were heat-treated for 20 min at 80° C. to eliminate vegetative cells and harvested by centrifugation. After a double wash with Phosphate-buffered saline (PBS), serial dilutions made in B&W salts were plated onto LB agar plates to determine the initial bacterial counts. Spores were then diluted in 1 volume of 0.85% NaCl, pH 2, containing 3 mg ml⁻¹ pepsin (Sigma-Aldrich, Steinheim, Germany), to mimic stomach conditions. Following 4 h incubation at 37° C. with agitation, serial dilutions made in B&W were again plated onto LB agar plates to determine bacterial counts, and, after a single wash with PBS, spores were resuspended in LB, pH 8 containing 1 mg ml⁻¹ pancreatin (Sigma-Aldrich, Steinheim, Germany) and 0.3% bile salts (Sigma-Aldrich, Steinheim, Germany). Bacterial incubation continued for 24 h at 37° C. with agitation to mimic passage through the gut. Finally, serial dilutions made in B&W were again plated onto LB agar plates to determine the final bacterial counts. All plates were incubated at 37° C. during 24 h prior to colonies count.

In an embodiment, shotgun genome sequencing was carried out at the Research and Testing Laboratory (Lubbock, Tex., USA) using the PacBio RSII sequencer (Pacific Biosciences, CA, USA). A total of 78,219 and 96,855 reads (with a mean read length of 13,383 and 15,478 base pairs) were obtained for ABP1 and ABP2, respectively, using as reference the Bacillus subtilis subsp. subtilis str. 168 (AL009126.3) [14]. The raw sequences were assembled using Pacific Biosciences SMRT Analysis v2.3.0. The total size of the assembly was around 4,068 Mb (2 final contigs) for ABP1 and 4,308 Mb (3 final contigs) for ABP2. A BLAST analysis against the RefSeq_genome database (NCBI) revealed that the best match for ABP1 is the Bacillus subtilis subsp. subtilis str. BSP1 (CP003695.1; (11)) while for ABP2 a best match is Bacillus sp. LM 4-2 (CP011101.1; (12)). The BLAST version used was the 2.7.1.

Both assemblies were analysed by using the Rapid Annotation Subsystem Technology (RAST) server. The amino acid sequences of each gene identified in RAST were processed using BLASTP+ against the RefSeq_Protein (NCBI), RefSeq_RNA (NCBI) and All-tRNA [4] (http://gtrnadb.ucsc.edu/) databases and then passed along the DAVID web service to determine other crucial annotation data such as GO Terms, PFAMs, TIGRFAMS, EC numbers or KEGG Pathways.

In an embodiment, statistical analysis was conducted by one-way ANOVA using the SPSS 21 software package for Windows (IBM® SPSS® Statistics, New York, USA). Data were tested for normality and homogeneity of variances by the Shapiro-Wilk and Levene's test, respectively. When normality was not verified, data were transformed prior to ANOVA. Significant differences among groups were determined by the Tukey's multiple range test. The probability level of 0.05 was used for rejection of the null hypothesis.

More than 200 bacterial isolates were obtained from the heat-treated gut contents of European sea bass fed each dietary situation (CTR, SBM, RSM and SFM). Following purification, 160 isolates representing different samples and colony morphologies (illustrated in FIG. 1 , Panels A to J) were chosen for analysis. Spore production of each isolate, induced by nutrient exhaustion on Difco Sporulation medium, was confirmed by phase-contrast microscopy (FIG. 1 , Panel K). All isolates were identified by partially sequencing the 16S rRNA gene revealing a predominance (60%) of Bacillus species among European sea bass gut contents (FIG. 2A). Oceanobacillus were also present, although to a lower extent (˜10%), with the remaining isolates distributed between the genera Lysinibacillus and Sporosarcina (with 5% each), Aneurinibacillus and Virgibacillus (with less than 1% of the isolated population, each). Identification to the species level was in most cases inconclusive. Nevertheless, the great majority (>60%) of the isolates belonging to the Bacillus genus fall in the B. cereus group (B. cereus, B. anthracis, B. thuringiensis, B. mycoides, B. pseudomycoides, B. weihenstephanensis, and B. cytotoxicus) or in the B. subtilis-B. licheniformis clade (B. subtilis, B. vallismortis, B. mojavensis, B. atrophaeus, B. amyloliquefaciens, B. licheniformis, B. sonorensis, and B. tequilensis) (FIG. 28 ).

In an embodiment, the carbohydrolytic activity of gut sporeformes was evaluated. The entire collection of 160 isolates was screened for their carbohydrolytic potential by substrate specific culture-based methods, and different profiles of carbohydrate utilization could be assigned to different isolates, as illustrated in FIG. 3 . The great majority of isolates grew well on glucose-supplemented medium, but not in the other carbohydrates tested. The quantification of each colony density or volume revealed the 43 isolates with higher and/or broader carbohydrolytic capacity (FIG. 8 ).

In an embodiment, the carbohydrate-active gut sporeformes were testes as PRO for aquaculture as follows. The selected 43 isolates were checked for minimal biosafety requirements to be considered as PRO, following the guidelines from the EFSA and the World Health Organization (WHO) [8, 17]. The majority (33) of the isolates exhibited some degree of hemolytic activity when cultivated on 5% sheep blood agar plates, with 14 isolates showing strong or β hemolysis (Table 3). Half of the isolates revealed to be resistant to at least 1 antimicrobial, and 10 isolates were resistant to 2 or more antimicrobials, defined as MR in Table 3 and detailed in Table 5. These tests allowed selecting a strict group of 11 isolates as good candidates to become a PRO for European sea bass (Table 3, highlighted in bold lettering), as isolates showing strong hemolytic activity or any antimicrobial resistance to the different classes of antibiotics tested were not further studied.

TABLE 3 Characterization and identification of the 43 isolates with broader carbohydrate-activity 16S rRNA sequence analysis Isolate^(a) Diet^(b) Spores^(c) Catalase^(d) Hemolysis^(e) AbR^(f) Closest known species^(g) % ID ABP3 CTR + + β — B. thuringiensis; B. cereus 100 ABP4 CTR + + γ — Bacillus sp. 99.2 ABP5 CTR + + γ — B. subtilis 98.2 ABP6 SFM + + β — B. cereus 100 ABP7 SFM + + α — B. pumilus; B. safensis 100 ABP8 SFM + + α MR B. licheniformis 100 ABP9 SFM + +\− β — B. cereus 100 ABP10 SFM + + β — B. simplex; B. macroides 100 ABP1 SFM + + α — B. subtilis 100 ABP11 SBM + + β R B. sp 99.2 ABP12 SBM + + α R B. safensis 99.8 ABP13 RSM + + α MR B. licheniformis 100 ABP14 RSM + + α R B. pumilus 99 ABP15 RSM + + β R B. cereus; B. subtilis 99.6 ABP16 RSM + + α R B. safensis; B. pumilus 100 ABP17 CTR + + β — B. subtilis; B. mojavensis 99.2 ABP18 CTR + + α MR B. licheniformis; B. aerius 100 ABP19 CTR + + β — B. subtilis 99.6 ABP20 SBM + + α — B. subtilis; B. amyloliquefaciens 100 ABP21 RSM + + α MR B. licheniformis 100 ABP22 RSM + + γ MR B. licheniformis; B. aerius 86.2 ABP23 RSM + + α MR B. licheniformis 100 ABP24 RSM + + α MR B. licheniformis 100 ABP25 RSM + + α R B. pumilus 99.9 ABP26 RSM + + β — B. licheniformis 100 ABP27 SFM + + α — B. subtilis; B. amyloliquefaciens 100 ABP28 SFM + + β R B. cereus 100 ABP29 SFM + + α MR B. licheniformis; B. aerius 100 ABP30 SFM + +\− β R B. cereus 100 ABP31 CTR + + β — B. cytotoxicus 97.8 APB32 SFM + + γ MR B. licheniformis 100 ABP33 SFM + + α R B. safensis 99.5 ABP34 SFM + + α — Bacillus sp. 100 ABP35 SBM + + γ MR B. licheniformis 100 ABP2 SBM + + α — B. subtilis 100 ABP36 SBM + + γ — B. simplex; B. macroides 100 ABP37 SBM + + β — B. subtilis 76.1 ABP38 SFM + + γ — Bacillus sp. 99.5 ABP39 SFM + + γ R Bacillus sp. 100 ABP40 RSM + + α — Bacillus sp. 98.7 ABP41 SFM + + γ R B. licheniformis 100 ABP42 SBM + + γ R B. licheniformis 100 ABP43 RSM + + β — B. thuringiensis; B. cereus 100 ^(a)In underlined lettering are the isolates showing strong hemolytic activity or any antimicrobial resistance, discarded from the rest of the disclosure and in bold the 11 isolates used in subsequent tests. ^(b)CTR, control fishmeal-based diet; SBM, soybean meal-based diet; RSM, rapeseed meal-based diet; SFM, sunflower meal-based diet. ^(c)Spores detected by phase-contrast microscopy of 24 h cultures in DSM agar. ^(d)Catalase activity tested by resuspending a colony in a 3% solution of hydrogen peroxide (Sigma). ^(e)Hemolysis determined on Columbia 5% sheep blood agar plates after incubation at 37° C. for 24, 48 and 72 h (shown is the final reading at 72 h incubation). β-hemolysis, the bacterial hemolytic enzymes completely break down the blood cells; α-hemolysis, the bacterial hemolytic enzymes only partially break down the blood cells; γ-hemolysis corresponds to essentially no hemolytic activity detected. ^(f)AbR-Antimicrobial resistance determined by the E-test method against several antibiotics (Table 5). R—resistance to one antimicrobial; MR—resistance to 2 or more antimicrobials; — no resistance phenotype detected. ^(g)Closest known species found using RDP based on partial sequences (600 to 800 nt) of the 16S rRNA gene.

The selected 11 isolates were then simultaneously cultured in M9 liquid medium to quantify bacteria growth after 24 h in liquid M9 supplemented with the different carbohydrates (FIG. 4A). The results from 3 independent experiments (FIG. 4A) allowed to eliminate fish isolates ABP4 and ABP5 from the follow-up tests, after revealing the lowest capacity to metabolize the carbohydrates tested.

The presence of specific carbohydrases coding genes in these 11 isolates was investigated by using oligonucleotide primers specifically designed to target the genes coding for β-glucanase (bgIS), levanase or β-D-fructofuranosidase (sacC), mannan endo-1,4-β-mannosidase (gmuG), endo-1,5-α-L-ara binanase (abnA), and arabinoxylan arabinofuranohydrolase (xynD) (Table 4). Their broad carbohydrolytic phenotype could not be correlated with the presence of the target genes, since no PCR amplification was obtained for the most promising isolates (ABP38 and ABP40) while all target genes seem to be present in the worst fish isolates ABP4 and ABP5 (FIG. 4B).

TABLE 4 Oligonucleotide primers used in the present disclosure Target enzyme^(a)/gene^(b) Primer Name Primer Sequence (5′-3′) β-glucanase (GH16-EC 3.2.1.73 /bglS BglS-339F AGGGATCGTTTCATCGTTCT BglS-553R TAATAGAGTTTGGCTGCCAATC Levanase (β-D-fructofuranosidase) (GH32 - EC SacC-106F CCTCAATATCACTTCACACCGGAG 3.2.1.80)/sacC SacC-336R ATCTACAACTGCGCTTCCAGAAAA Mannan endo-1,4-β-mannosidase (GH26-EC GmuG-563F TCAGGCCGCTGCATGAAATGAACG 3.2.1.78)/gmuG GmuG-786R AATATCCACGTAAGACGCGCCCGG Endo-1,5-α-L-arabinanase (GH43 - EC:3.2.1.99)/ AbnA-311F GGGCGCCGGACATCCAATACTATA abnA AbnA-564R AGTCAGCTTAATGCCGCTCCAAAA Arabinoxylan arabinofuranohydrolase (GH43 - XynD-361F AAATGGGCAGGTGCGTCATGGGC EC:3.2.1.55)/xynD XynD-591R GTCGTCATCTACAAATACTGCCGG ^(a)The enzyme Glycoside Hydrolase Family (GH) number and the EC number are providing in brackets ^(b)gene name in B. subtilis strain 168 genome, whose sequence was used to design the oligonucleotide primers

TABLE 5 Susceptibility of selected isolates to various antimicrobial agents MiC^(a) (μg ml⁻¹) Isolate^(b) CL TC EM KM VA GM SM ABP3 6 1.5 0.19 1.5 3 0.38 1.5-2 ABP4 4 0.094 0.094 0.75 0.75 0.125 4.-6 ABP5 4 0.125 0.094 0.75 1 0.125 4 ABP6 4 0.75 0.125 3 2 0.75 0.75 ABP7 5 0.75 0.142 0.625 0.375 0.094 0.75 ABP8 >256 4 >256 3 8 0.75 24 ABP9 4 0.38 0.125 2 2 0.28 0.38 ABP10 1.5 0.047 0.032 0.25 0.094 0.094 0.75-1.0 ABP1 3.5 0.22 0.0945 0.625 0.625 0.1095 1.875 ABP11 4 0.75 0.125 3 8 0.75 1.5 ABP12 8 0.5 0.094 1 0.25 0.38 1.5 ABP13 >256 4 >256 2.-3 4 0.75 16-24 ABP14 12 0.5 1 1.5 0.38 0.125 1.5 ABP15 4 0.75 0.125 2 4 0.38 2 ABP16 12 0.38 0.5 1.5 0.5 0.19 2,-3 ABP17 6 4 0.19 1 1 0.064 4 ABP18 >256 4-6 >256 3 4 0.5 24 ABP19 6 3.-4 0.125 0.75 1 0.125 4 ABP20 3.5 1.75 0.1095 0.875 0.875 0.1095 2.5 ABP21 >256 2 >256 1.5-4 (?) 6 0.75 32 ABP22 14 0.315 >256 1.75 2.75 0.565 3 ABP23 >256 2 >256 4 6 0.75 32 ABP24 >256 2 >256 12 4 0.5 19 ABP25 16 0.5 0.75 1.5 0.5 0.125 3 ABP26 6 1.5 0.125 0.75 1 0.125 2 ABP27 3 1.5 0.125 0.875 1.125 0.172 2.5 ABP28 6 0.5 0.19 2 4 0.38 0.75-2 ABP29 >256 4 >256 3 6 0.5 16 ABP30 6 0.75 0.125 2 6 0.38 1.5 ABP31 3 0.094 0.125 0.75 1.5 0.25 0.5 APB32 12 0.25 0.5 2 3 0.5 8 ABP33 8 0.625 0.315 0.875 0.315 0.1095 0.625 ABP34 3 4.5 0.1095 0.315 1 0.079 1.75 ABP35 32 4.-6 >256 2 2.-3 0.38 48 ABP2 3.5 6 0.1095 0.75 1.125 0.094 7 ABP36 5.5 20.625 2.032 0.3125 1 0.0585 4.25 ABP37 4 0.094 0.094 0.38 0.75 0.094 1 ABP38 4.5 0.1875 0.0705 0.875 0.22 0.094 2.5 ABP39 8 0.047 0.064 0.38 0.125 0.016 0.75 ABP40 2 0.625 0.1095 3 3 0.315 0.565 ABP41 3 0.22 0.25 1.5 4 0.845 2.5 ABP42 48 0.19 0.25 1.5 1.5 0.38 4 ABP43 4 0.5 0.125 4 3 0.38 1.5 ^(a)MICs were determined by the Etest® method and in bold numbering are the MIC values above the reference breakpoint (EFSA-FEEDAP, 2012). CL, Chloramphenicol; TC, Tetracyclin, EM, Erythromycin; KM, Kanamycin; VA, Vancomycin; GM, Gentamycin; SM, Streptomycin. ^(b)Highlighted in underlined lettering are the isolates showing resistance to 2 or more antimicrobials. All isolates showing any antimicrobial resistance were discarded.

In an embodiment, sporeforming isolates ABP7, ABP1, ABP20, ABP27, ABP34, ABP2, ABP36, ABP38, and ABP40, that simultaneously met the minimal safety requirements to be eligible as PRO and were the most efficient isolates in metabolizing the carbohydrates tested, were further characterized to determine their sporulation efficiency, an important characteristic for future industrial production and feed incorporation.

In an embodiment and by comparison with the well-studied standard strain B. subtilis 168 [14], isolates ABP36, ABP38, and ABP40 did not reach a minimum titer of 107 ml⁻¹ heat-resistant cells, after 24 h sporulation induction by nutrient exhaustion in DSM liquid medium (FIG. 5 ) and were discarded from the subsequent tests. Furthermore, ABP38, and ABP40 did not even reach that minimum level of total (viable) cells, revealing to be inadequate for future industrial applications. With the exception of ABP20, the remaining six isolates presented an efficiency of sporulation higher than 70%, which anticipates a high suitability for cost-effective spore production (FIG. 5 ).

In an embodiment, the potential to survive passage through the gastrointestinal tract, important for in vivo efficacy, was determined by exposure to sequential simulated stomach and gut conditions. Purified spores of isolates ABP7, ABP1, ABP20, ABP27, ABP34 and ABP2 were first subjected during 4 h to acidified NaCl containing pepsin, to mimic stomach conditions, followed by 24 h exposure to alkalinized LB medium containing pancreatin and bile salts. While 4 h in simulated stomach conditions had nearly no effect on the isolates survival, the subsequent 24 h exposure to simulated gut conditions lead to a reduction in each bacterial population (FIG. 6 ). In particular, cell survival was dramatically decreased in isolates F192 and F1157, similarly to what was observed to the standard strain B. subtilis 168 (FIG. 6 ). Isolates ABP1 and ABP2, which showed higher sporulation efficiency, and consequently higher cell number at time 0, were the best fit to survive in the gut.

In an embodiment, the remaining four isolates, namely ABP1, ABP20, ABP27, ABP2, were characterized for their antimicrobial activity against several fish pathogenic strains, namely P. damselae, V. harveyi, T. maritimum, A. bivalvium, and S. aureus. As illustrated in FIG. 7A, all isolates showed some extent of antimicrobial activity. Strain ABP1 was successful in inhibiting the growth of S. aureus, T. maritimum and to a lower extent V. harveyi. ABP20 was only active against Ph. damselae. ABP27 inhibited the growth of S. aureus and of Ph. damselae while ABP2 was active against Ph. damselae, V. harveyi and T. maritimum. The control B. subtilis 168 could also effectively inhibit the growth of S. aureus, Ph. damselae and T. maritimum, but this last inhibitory activity was lost when using its cell-free supernatant (FIG. 7B) as opposing to the killing activity observed with the cell-free supernatant of ABP2, clearly indicating that this strain produces an extracellular inhibition molecule(s) capable of inhibiting T. maritimum growth (FIG. 7B).

In an embodiment, and in an attempt to infer the germination capacity of these strains inside the animal gut, spores of the same four isolates, ABP1, ABP20, ABP27 and ABP2, were subject to different germinants, namely L-alanine and a mixture of KCl, glucose, fructose and L-asparagine (AGFK). For the conditions tested, isolates ABP20 and ABP27 were unable to germinate (FIG. 9 ), leading to the selection of isolates ABP1 and ABP2 as the best PRO strains.

In an embodiment, the 4,068,058 bp genome of ABP1 was found to consist on 4,304 open reading frames (ORFs) with 4,184 genes identified (30 rRNAs genes and 86 tRNA genes).

In an embodiment, isolate ABP2 contained a slightly bigger genome, with 4,308,180 bp. A total of 4,643 genes (from 4,759 ORFs) were identified, including 28 rRNAs genes and 82 tRNA genes.

In an embodiment, the G+C content of ABP1 and ABP2 genomes was estimated to be 43.9% and 43.4% respectively.

In an embodiment, an exhaustive comparative analysis against the reference B. subtilis str. 168 [14] using Geneious R7 v7.1.7 software (Biomatters, Auckland, New Zealand) revealed the absence of more than 200 genes from ABP1 and ABP2 genomes. These are mostly associated with prophage like regions, namely Prophage3, SPB and the Skin element, or with mobile genetic elements such as the integrative and conjugative element ICEBs1. As previously described for other gut isolates including B. subtilis str. BSP1 [17], several negative regulators of sporulation (e.g. rapE, rapK) are also absent, resulting in a higher sporulation efficiency of these isolates when compared to the B. subtilis str. 168, with the advantage that this behaviour can have at the industrial and gut levels. Interestingly, both isolates lack the sdpABCIR operon of sporulation delaying proteins, which might result in even earlier trigger of sporulation.

In an embodiment, ABP1 and ABP2 genomes also accommodate new genes, some of which coding for NSPs-active hydrolases. For instance, additional genes that might be involved in xylose and mannose metabolism are found in ABP1, while ABP2 contains one myo-inositol catabolic operon, that might contribute to the cycling of inositol phosphates in the marine environment or to their bioavailability (from PF-diets) inside the fish-gut.

In an embodiment, by sequencing the 16S rRNA gene, all isolates could be assigned to a genus, being Bacillus the most prevalent (>60%). Affiliation to a species based on a single molecular marker (16S rRNA) was limited, as expected. This was the case for isolates belonging to the B. cereus group (B. cereus, B. anthracis, B. thuringiensis, B. mycoides, B. pseudomycoides, B. weihenstephanensis, and B. cytotoxicus) or to the B. subtilis-B. licheniformis clade (B. subtilis, B. vallismortis, B. mojavensis, B. atrophaeus, B. amyloliquefaciens, B. licheniformis, B. sonorensis, and B. tequilensis), whose 16S rRNA gene sequences obtained do not differ enough to distinguish them.

Although several Bacillus spp. are quite common in the gut of different animals, including the ones with high-fiber feeding habits, such as soil invertebrates or the giant panda [19], few studies have focused on their carbohydrolytic potential. For example, predominant B. subtilis strains from the gut microbial community of the giant panda, seem to have the capacity to growth in a higher fiber environment [20], opening the possibility that also in fish, Bacillus spp. may have a decisive role in shaping their host digestive capacity towards the efficient utilization of PF-diets. In fact, two recent studies, although limited to cellulase and xylanase activities, reported the isolation of carbohydrate-active Bacillus spp. from the gut of different fish species. The 160 isolates tested in the present disclosure showed different, and in some cases potent, hydrolytic capacities when using as sole carbon source selected carbohydrates including xylose, galactose, arabinose, or mannose. This observation was further sustained by the presence of genes coding for specific extracellular CAZymes that can help fish in obtaining the otherwise unavailable energy trapped in PF. The absence of amplification for these specific genes in some isolates, despite showing broad carbohydrolytic activities, is not surprising considering that some studies suggests that new or substantially different CAZymes involved the metabolization pathways are yet to be found in the Bacilli group of organisms. Furthermore, the lack of PCR amplification of these genes, observed with some isolates, may also be caused by mismatches of the primer pairs, due to the difficulty to design gene-specific primers regarding genomic regions poorly conserved.

In an embodiment, PRO approval within EU for incorporation into animal feed, including aquafeeds, is subject to strict and exhaustive exigencies following EFSA guidelines on quality, safety, and efficacy of the candidate(s) bacterial strain(s) [21]. Besides the obligation of strain deposition in an internationally recognised culture collection, candidate PRO isolates must be tested for the presence of any acquired antibiotic resistance genes [11, 16, 22]. PRO, which are given to animals in massive amounts, should not contribute to the escalation of antimicrobial resistance by acting as vehicles of transferable genetic determinants. Unfortunately, these rules do not apply worldwide, and very recently antimicrobial resistant strains were found in PRO products used in Vietnamese shrimp culture or in Chinese human commercial products, with all the risks those findings pose to the aquaculture production sector and to public health [23]. Although EFSA guidelines only require the absence of acquired (transmittable) resistance genes, allowing the use of bacterial strains whose antibiotic resistance is chromosomally encoded, the option of eliminating all the strains showing any antimicrobial resistance to the different classes of antibiotics tested. Adding to that criterion, strains showing strong hemolytic activity, indicative of virulence potential in several pathogenic bacterial species, including sporeforming ones, were also not further tested. These tests allowed to select a group of 11 PRO candidates that qualify with the minimal biosafety issues to be approved by EFSA.

In an embodiment, to demonstrate efficacy, EFSA requires three in vivo studies showing statistically-significant effects on each target animal species [21]. To conduct such follow-up in vivo studies in European sea bass growth and digestibility trials, it was necessary, for practical reasons, to narrow the group of interesting and potential PRO candidates. These were subjected to a series of consecutive tests to analyze some desired characteristics on a future PRO product. First the sporulation yield, an important parameter in industrial and economical terms, was determined by comparison with the well-studied standard laboratory strain B. subtilis 168 [14]. Six isolates demonstrated high yield spore formation, which anticipates a good suitability for cost-effective spores' production in industrial scale. Additionally, higher sporulation levels might also act as a form of propagation inside the animal gut, maximizing these strains beneficial effect [10, 17]. Second, exposure of purified spores to sequential simulated gastric and gut conditions, revealed the four isolates best equipped to survive passage through the gastrointestinal tract, important to guarantee their in vivo efficacy. In particular, isolates ABP1 and ABP2, which also showed higher sporulation efficiency, seem to be the best suited to reach, at higher numbers, the gut where their PRO action can take place. To take advantage of these isolates as PRO, upon passage through the stomach and anterior gut, spores must germinate to originate new vegetative cells that can produce the enzymes/molecules thought to benefit their host. In nature, spore germination is believed to occur in response to specific nutrients. For example, B. subtilis spores are known to germinate in response to L-alanine, L-valine and L-asparagine but not in response to their D-enantiomers. Taken this, and although the mechanisms of germination of spores of different Bacilli (independently of their specific species) are thought to be essentially the same, it cannot be ruled out that some of the isolates might respond efficiently to other germination molecules that might be abundant in vivo (inside the animal gut), explaining the germination failure of isolates ABP20 and ABP27 under the conditions assayed. Finally, and besides their carbohydrolytic potential, these PRO might also benefit the fish host by minimizing colonization with pathogenic species, known to be especially problematic in marine aquacultures. This is the case of T. maritimum whose growth was efficiently inhibited in vitro, when exposed to both cells and cell-free culture medium of isolate ABP2.

In an embodiment, sequencing ABP1 and ABP2 genomes allowed a comprehensive screening of their genomic potential to better meet the EFSA criteria for PRO. Both genomes accommodate new genes, some of which coding for NSPases (NSP-active hydrolases). For example, additional genes that might be involved in xylose (e.g. ABP10666, ABP10667), mannose (e.g. ABP10654, ABP10671) and sucrose (e.g. ABP10829, ABP10830) metabolism are found in ABP1, while ABP2 contains one myo-inositol catabolic operon (ABP24564 to ABP24567), that might contribute to the cycling of inositol phosphates in the marine environment or to their bioavailability (from PF-diets) inside the fish-gut.

In an embodiment, dissecting these genomes permitted to detail and further document their biotechnological value as PRO and/or as sources of carbohydrases or antimicrobial molecules. For instance, determining the number and type of CAZymes present in each genome provides deeper understanding on their carbohydrolytic potential also allows identification of genomic features responsible for adaptation to life within the gut that may support the role of Bacillus spp. as PRO [10, 12-13, 17-18]. The growing applications of spores in biomedicine and biotechnology (as oral vaccines, PRO or display systems) [12-13, 18], and the fact that there are approximately 30 PRO strains approved as feed additives in EU, but only one for aquaculture (Bactocell®, which is not a sporeformer formulation), underscore the importance of this disclosure.

Sequences

This disclosure relates to 2 PRO strains, ABP1 and ABP2, which genome comprises at least one polynucleotide encoding a protein which is involved in PRO behavior, and which polynucleotide is substantially identical to a polynucleotide sequence according to ABP10666, ABP10667, ABP10654, ABP10671, ABP10829, ABP10830 for ABP1 and ABP24564 to ABP24567 for ABP2.

In an embodiment, the polynucleotides as listed in Table 6 were isolated from Bacillus subtilis strain ABP1 or ABP2, and are absent or divergent in/from B. subtilis 168 [14], and at least in 5 out of 11 sequenced Bacillus isolates including:

TABLE 6 Gene Name Lenght (aa) SED ID NR/Protein ABP10118 202 1 ABP10119 215 2 ABP10120 286 3 ABP10121 153 4 ABP10181 604 5 ABP10182 851 6 ABP10654 316 7 ABP10655 880 8 ABP10656 37 9 ABP10657 254 10 ABP10658 422 11 ABP10659 74 12 ABP10660 771 13 ABP10661 425 14 ABP10662 710 15 ABP10663 280 16 ABP10664 623 17 ABP10665 389 18 ABP10666 163 19 ABP10667 178 20 ABP10668 237 21 ABP10669 355 22 ABP10670 65 23 ABP10671 257 24 ABP10672 130 25 ABP10673 275 26 ABP10674 527 27 ABP10675 294 28 ABP10676 509 29 ABP10677 79 30 ABP10678 61 31 ABP10825 106 32 ABP10826 111 33 ABP10827 194 34 ABP10828 520 35 ABP10829 516 36 ABP10830 473 37 ABP10831 451 38 ABP10832 227 39 ABP10833 151 40 ABP10834 161 41 ABP10835 63 42 ABP10836 489 43 ABP10837 152 44 ABP10838 234 45 ABP10839 227 46 ABP10840 598 47 ABP10841 381 48 ABP10842 278 49 ABP10843 384 50 ABP10844 367 51 ABP10845 344 52 ABP10846 358 53 ABP10847 344 54 ABP10848 482 55 ABP10849 202 56 ABP10850 216 57 ABP10851 388 58 ABP10852 322 59 ABP10853 72 60 ABP10854 39 61 ABP10855 437 62 ABP10856 563 63 ABP10857 240 64 ABP10858 332 65 ABP10859 421 66 ABP10860 418 67 ABP10886 52 68 ABP10887 1015 69 ABP10888 66 70 ABP10889 982 71 ABP10890 715 72 ABP10891 56 73 ABP10892 84 74 ABP10981 427 75 ABP10982 300 76 ABP10983 390 77 ABP10984 467 78 ABP10985 392 79 ABP10986 594 80 ABP10987 446 81 ABP10988 335 82 ABP10989 248 83 ABP11306 51 84 ABP11307 272 85 ABP11308 504 86 ABP11309 341 87 ABP11310 464 88 ABP11311 404 89 ABP11312 269 90 ABP11821 388 91 ABP11822 130 92 ABP11823 162 93 ABP11824 669 94 ABP11825 112 95 ABP11826 306 96 ABP11827 335 97 ABP11828 284 98 ABP11889 298 99 ABP11890 308 100 ABP11891 52 101 ABP12521 153 102 ABP12522 63 103 ABP12523 92 104 ABP12651 250 105 ABP12652 58 106 ABP12653 43 107 ABP13703 49 108 ABP13704 185 109 ABP13705 44 110 ABP13706 303 111 ABP13707 82 112 ABP13708 243 113 ABP13709 260 114 ABP13710 48 115 ABP13711 339 116 ABP13712 78 117 ABP13713 382 118 ABP13714 141 119 ABP13715 49 120 ABP13716 224 121 ABP13717 58 122 ABP13718 50 123 ABP13719 192 124 ABP13720 209 125 ABP13721 273 126 ABP22957 419 127 ABP22958 299 128 ABP22959 187 129 ABP22960 102 130 ABP22961 573 131 ABP22962 84 132 ABP22963 58 133 ABP22964 222 134 ABP23145 87 135 ABP23146 273 136 ABP23147 52 137 ABP23148 81 138 ABP23149 306 139 ABP23150 60 140 ABP23151 62 141 ABP23223 973 142 ABP23238 376 143 ABP23224 200 144 ABP23225 623 145 ABP23226 65 146 ABP23227 378 147 ABP23228 107 148 ABP23229 130 149 ABP23230 51 150 ABP23231 156 151 ABP23232 670 152 ABP23233 112 153 ABP23234 306 154 ABP23235 273 155 ABP23236 47 156 ABP23237 285 157 ABP23502 37 158 ABP24563 41 159 ABP24564 484 160 ABP24565 388 161 ABP24566 309 162 ABP24567 339 163 ABP24568 41 164 ABP24598 52 165 ABP24599 111 166 ABP24600 48 167 ABP24601 384 168 ABP24602 189 169 ABP24603 674 170 ABP24604 389 171 ABP24605 170 172 ABP24606 43 173 ABP20078 155 174 ABP20079 56 175 ABP20080 196 176 ABP20081 93 177 ABP20082 43 178 ABP20083 109 179 ABP20084 144 180 ABP20085 51 181 ABP20086 182 182 ABP20087 49 183 ABP20088 53 184 ABP20089 73 185 ABP20090 67 186 ABP20091 216 187 ABP20092 117 188 ABP20093 66 189 ABP20094 279 190 ABP20095 40 191 ABP20096 101 192 ABP20119 72 193 ABP20120 503 194 ABP20121 269 195 ABP20122 172 196 ABP20123 165 197 ABP20226 227 198 ABP20227 2296 199 ABP20228 253 200 ABP20229 880 201 ABP20230 285 202 ABP20231 744 203 ABP20232 355 204 ABP20233 83 205 ABP20234 379 206 ABP20235 58 207

Sequence Listing SEQ. ID SEQ. No. Name Amino acids sequence (one letter code) SEQ. ID. ABP10118 MNLTGESKNFDDYLLELNEVDYSNPIICALANELFNPLQTEIEKVKIAYEFVRDEISHTWDTQSKRVTCNASE NO. 1. VLSFKEGICYAKSNLLAALLRSEGIPTGFCYQRLMLFNTPDKGYCIHALNAVFFHSLNKWIRLDSRGNKIGID AQFSLDKERLAFPIRQEFDEIDYPLIYVRPHPKTIAVLKEHKDAIEMYKYHLPERI SEQ. ID. ABP10119 MIWLVGLDWSIQWGTVFTVAGTLTAAFLGQVFSHRYSQKREEIKQKKESFQNLYSPVVFKILNYLELEREK NO. 2. QNIMFIKGLDETEFTERYQDDELYNPSIEFKEILEIVGLNLKYGSLELIREYQETLSIAKRMEAFEGHCGTHLYF CGVFISDYINLSKDLGVYSQTMETSTEGSLLLSRLETLIPQLVVLECLWNFYLGFFMQYLVLIKKINIL SEQ. ID. ABP10120 MELKNKIKRVAIYLRKSRNKEGEETEETLAKHRKRLLDIAHKNNWQYEIFQEVGSSMDEMRPECQRMINKL NO. 3. TDGIFDAVLSVNLARVTRDDAETPKFMNLLRQDDILFVTDSERVYDLEVQEDWQALKFTGFVNNWEYENI KAQLRKGKKDSAKMGRWSNGKPNYGYIYNRLERKLEIDEEKAKAVKLAFQMTIDGIGADNIAVKLNKLGY RTNKGKFFHGQSIVRMIRSEIYKGWIVANRLKGRNKTNGKIRPQDQWIVVKDAVKPCIIDEDTWDKANKA GHLIK SEQ. ID. ABP10121 MYSYKLIDNEKVREKLEELIDEKREIHLKLTDNHLDKHLGITYDLLDVNDDGSYSGFFRTTPYIRRSDLILPGESI NO. 4. GIKLPSYFLIMINYLSRLEEQDCFPELELKITYNDTNFKTWETKFIIKVDQISKIEISSFYKLQTSLVYEFISKNKK SEQ. ID. ABP10181 MAVVTTIKHPMISGYVKGFVDKYEISRRKAKNEHNIFEMFINDLILSSYNNDPNASYEDMETGTAFGIDGV NO. 5. AIFINDKLVEGVEDVDYICNSTRKIEVKFLFTQTKTSEKFDRSEVRDFLQGVNRFFNFEFCEITELKNSWETAK YIYDLSTKFKNDPALKMYYTALAPKKISVKDEDIDLHLKSEILTGLEVLKQRYIFDEDNISLNFIGLKEIRELHQK ENNLTEIKFNLDKQPVPYPKDSTGIIKSAYFGLIKLEDLLDILSEAVDGERILRKGIFEDNIRDYLGANEKFDVNL DMKNGLTGTNAHLFGLLNNGITIIADQVHIISTEASLVNYQIVNGCQTSNVIFESLKDIIEKNIYIPIRLIGTEDE DTKNAIIKATNSQTALKPEQLLALRDEQKSLEEYYRAKRNQNKFLLYYERRTEQYRNEDIQKTKIINIPFQIKA TSAMFLDLPHEVSGQYGKVEQKTRGKLFTDSSLLNPYYVSGLTWYRVEAFIRNNEEGKKHRRARWHIMM VIKYLISDLKNPSKIIDKNAEKISEKVEKVMLNDAKSLEIIENALSLIKEFIINEGILDISEDRKFFERKETTTGL IEMLKNRLKTLS SEQ. ID. ABP10182 MEHSNKLNIVYKSIQQMKESYGKLLKVEFHIHTPASHDYRLLPGKLFKNMKLTEVFDVALNEGLYSKEFLERI NO. 6. QKEDFAIFEKQVIEDINRDFHVSFSNFKEILGYQLIAHSLYKNNIHAAVISDHNTINGFKKLQAVLVDYYKSRI KGNTQRKSIKLFLGIEISCSDYYHLVGIFDEHKYTDLKNFVSKYIHSEEEGTYISCLDMVNRITENGGIPYIAHIN TSDFLGTNLYKRSLFGFSGLKILGLTNIDSKERISNRIKKYQESSKGDFCFIHEGDSHELNQLGKKNTWIKFNN LSFKSLKKAFKNYQFCIYIDKPIYNDRFLKGIYIEPGEKGFLGDKEQPEKPFIVDFSRDLNCIIGGRGVGKSTILSI LETAFTLEVTNINQLEYISRHNLIYIVFNYKNMDYILNFIPQITESGYSGNNYFLRKAFSETTETESGTRRLSQN WINLYRVSQVESSNGYKFQELNYNETTTIIESVYKKSYSINNIVELSNTGRISEFIRDIVLNGERLNGSKIVLSKL NKLHKNNYRKYLRENIQSVLVNIKKREENVKMAIEEFNRLNNKLIQIVYSPKLKDPTFYLKELELRYDPIFDRE KGKRVLNTYLTWDDIDEFVYEATKKFGYLEFLELILNKEHKQIENELSLNNFISGTITGEYENVSIKNMVRVYN KIEERIFRNIEKVTNSFKLLFEIIDEFSLKFNINSKETIRTEKVVMKDIDELSLGQKVVAILTLIFNYGEHSVDSTPL VIDQPEDNLDNLYIYQNLVKSLRKIKNKRQVIIATHSATIVTNADAEQVIILESDNKRGWLSKKGYPDDEVVL KHIVSILEGGRESFIHKKETYMTVLDI SEQ. ID. ABP10654 MTQSPIFLTPVFKEKIWGGTALRDRFGYSIPSETTGECWAISAHPKGPSTVANGPYKGKTLIELWEEHREVF NO. 7. GGVEGDRFPLLTKLLDVKEDTSIKVHPDDYYAGENEEGELGKTECWYIIDCKENAEIIYGHTARSKTELVTMI NSGDWEGLLRRIKIKPGDFYYVPSGTLHALCKGALVLETQQNSDATYRVYDYDRLDSNGSPRELHFAKAVN AATVPHVDGYIDESTESRKGITIKTFVQGEYFSVYKWDINGEAEMAQDESFLICSVIEGSGLLMYEDKTCLLK KGDHFILPAQMPDFTIKGTCTLIVSHI SEQ. ID. ABP10655 MKKRLIAPMLLSAASLAFFAMSGSAQAAAYTDYSLYKVEPSNTFSTESQASQAVAKLEKDTGWDASYQAS NO. 8. GTTTTYQISASGIHSESEAKAILSGLAKQTSITGTSSPVGSKQPYVTISSGAISGEKQANTILAKLKQETGVAGA VKAYGAAQPYMNVMTSDIADETKVKALIQSLAKQTGIKSSYQPITHTVSVTTIQSGTIVGDSRAAQIKNAFQ KESGLQASLKETVKGQAYYTFTTAAISGEANAKTLLQQLKQSTGITGSYKSINQKTTVESYNVQSAYFKGLNT VKDAISQIKKNTGVSGSYQQVGKSTSYTVNMKGITKQQLQKIDTFFKKKKWHYTSSSVKKTTTSAAYQITTA KILGEQQANKAAAFFAQKKVKATKTTAGTTAENQYQLISEETSDQSKVTKGLNILKKNQLSASAKSVKKQIA DTFKITTESLLDQTKVNQALTFFKSNHISAASQKTGQTAASSYQITTEAIISQEEIDRVLTFFKQNKIAVTTSKT GQTAYTQYKIVTAQLSSKTALNNGLTYLKSQGLTPSYTTKSNTLYKISVNEQFTGNDTAAAASSKLKQLYGW ASSIVKVKNGPQIMKTNYNLSLRDMVQKQMTVSPQTDGAAYVSLTYINTATSTVTADALNIRSTPEVSPTN VIGQFKKGDKVKIIGQTNGWAKINLGWRNASSDEVVQYVDPNNFSRDSKYYFQFLKLSQTAGLNATEVN QKVLAGKGILTGKAKAFIDAANKYGINELYLISHALLETGNGTSDLANGLTYNGKTVYNMYGIGAYDSNPNY YGAKYAYEQGWFTPEAAIIGGAKFIGSSYIHNTAYNQDTLYKMRWSATATHQYATDIGWAYKQVNRMYS LYSLLDGYTLYFDVPEFK SEQ. ID. ABP10656 MYYLEIMIKMLKEIRKEPKKFDIIFVSSPPFLLLLSG NO. 9. SEQ. ID. ABP10657 MKGVKVFHHPIIVESFRILEKLLYKKADHIVINSEGFLHYLNEHSPLVKEKVTFIPNSAREKELLISSNDAKTALK NO. 10. IIYVGNIGLAQNVHIIRNLAEKLHEHQIEFLIVGYGVEKKELLNYIREKNLMNVKIVNPMTRKECLELMSGCDI GIVTLKDSTVFETVLPGRIIDYITCGIPIVGSIAGYSKTIIEQEGVGLVTSNSSSEEMLANIMKIYNDPGLLKKM QKNCHKLIRENFMWETNIEKLINVIEDTR SEQ. ID. ABP10658 MRKKVCMFVWNHFTNDARVLRECTALSDKYYDVDLICIHDPNNPDLDLIQKYNDHFTVYRVKRSPLLFYIQ NO. 11. FIYKLFKNKWSILFFLLIWICLLRMFPLLTIGFSLFAVIVLKTKLKTMLVRGSIIMRMILKGYSKKYDIYHSNDLN TLPQGFICSKFRFKKRKLIYDSHEVQTSRTGYDSPFYSKMEAYLIRKIDIIMIVENHTRAAYNKELYGFYPKVLH NYPFLLEETKEQIDIHHMLGLPKNEKILLYQGGIQVGRGLDKLIKAMPFINEGTLLFIGDGRIKKDLENMVNN MELQHRVRFLPKVPLSELPKYTRSAYLGFQVLNNVCFNHYSASSNKLFEYIMAGVPVIGCDFPEIKKVIQGE KVGLVVDSHDHLSIAKGVNTLLENADLHYEFHKNCDKAKRKYNWETEKSQLLSLYN SEQ. ID. ABP10659 MQIKKNQKNQELADKYNDLKIKYHKSLEVQEDLITLCQELIREKEYIEARYNNLKESKLGRLTVWMWKRRR NO. 12. RNK SEQ. ID. ABP10660 MKQSKDIKTLLSKQLEKVRREKEILIGLKEKEVSITGFDDFFFDTPMRILAEYNKQTLEVDAEKVYLSLFERTTN NO. 13. FSIPSNKEIYKLTGDRIIIDPFITLSGSVKGQIYIAFYKNNELYSTKIFEAPFDKISADVPENTTSYRFALRLEGKGY LQLNKLKIKQVFKEQIASKNIGVNRSITISKASKIQQFIDSIEAETQNYKNEKKELRIAAILDEFSYECFKHDAEIL RLSNTDWDNEILEFNPHFVFVESCWQGNQGHWQYEVANLHKNKHRTALKKLTEYCKSKNIKTVFWDKE GYENFEFFKTAASYFDYVMTADENTVKKFKETSSINNVGILPFAAQPRIHNPINKNLHHLGGIAFAGSYYNN KHESRKRDIEEIIKPALDFGIDIYDRYYNVPAAKKVNNTWPEEYQRHIVGSLNYSQMNVAYKNYNMFVNV NSVQNSKHMFARRVFELLASKTMVISGPSKGVQEYFGDLVPVACSKEETVNILKTFLYNPVYREMYEKKGH RLVLNSHTYKNRLQEICDHIGIDINLLEKPRISIISSTQRTEYMENLYNNARHQTYQNLELIIILNKNSMDAEE WKQKFSSLHFPVTILQVDENVSLGHCLNKAVQRSTGEIIAKFDDDDYYAPHYLEDMLHSMEYSGADIVGKS AHYVYLEERELLILKTVGSGAERYSDFISGATLVFKKEVFVSLGGFSDKNRGEDSDFLKRAKENGNIIYSNDS WNFCLVRRANRNSHTWNITADDLLRNSTVHSMCKDYKKPITI SEQ. ID. ABP10661 MKVCVIGLGYIGLPTSVMFAKYGVDVIGVDVQPHVVDSLNNGEAHLEEPGLQEFLDEALANGNFKAQLVP NO. 14. EPADAFIIAVPTPNNINDNMSCDLTYVLQAVDNIIPYIRKGSTIIVESTIAPRSIEDYVQPLLEQNGFTIGEDIYL VHCPERVMPGNIFHELANNMRIVGGITPSCSEAGEKVYRTFVKSKIVKTDAKTAEMSKLMENTYRDVNIAL ANELTKICNDLHINALDVIEMANMHPRVNIHSPGPGVGGHCLAVDPYFIVAKAPETADLISRSRSINSSMPI YIVEKVREIMEMVNGRTITIGGLAYKGDIDDLRESPALEILEMLKSEKKYEVRAYDPYVNHSENAQNLTEAL GGSDLFLILTDHSLFKTINDEDTNRMSNKVIFDTRNIVRNVPEDCECINLGSIHNFLNNAVLNV SEQ. ID. ABP10662 MRKYLCLFSFVILFFLTLSFYGERVLAYTDTSTYKVTIKDEFTSEDKVKGISNKINNETGWDANYKLTGNTTRA NO. 15. FKIITGGFYGEDKVKDVLNDFEQNTGINGSYSENGNVQTIYQITTGGFTGESKVKQVLDILQSQTGVKGTYT STGEKQYYYRIVSGGFQSEQRIKEVLSKFENETSIKGSYEPIGNSKITYTVLSGGFSTEDNVKKAAAETKSQTGI EASYEKIPDSESYRLVISNITESELTGIESFFGKKNWWYVKKEVKNQSYRLISEPILDDQIIDKGLSFFESNKW WASKQKTDQLGENKFRITTEKISDETKLLKALNFFESNKWWAVSQKTTIKGYRITSEVINSEAVLNKGLDFFK SKNLWATYSNLSKDTYIINLNEEFTGIENATSAVNKLSNVYGLNAEVVKIKDGPQIMNTNYNLTLSDMISKQ MNANPQTDSAAYVSLSYINTSTSTVTADYLNVRSTPEVKSDNIIGQVQKSDKVTIISKEGNWAKINMGWR KASREEVTYYINPENFSISSKYYFQFLKLSQYAGLTATEVNNKILKGKGILEGKGESFIKAAESNNINELYLIAHS LLETGNGSSELANGVMYNGKKVYNMYGIGAYDGDAVTKGAQYAYNQGWFTPEAAILGGAKFIGSSYIHN ATYHQDTLYKMRWEPTVSHQYATDIGWAYKQVNRMYSLYTLLDNYTLYYDIPKYK SEQ. ID. ABP10663 MEINQLRKETIKFIDLKEYKIRIEEPYLLCVTTEDGVPFEFLINIRLNQNKLLILSSGAYDNVKLKPPIFQRYTW NO. 16. MTEFNHSVVYFNDPTLYINQKLSIGWGQGTKNHFYLATITNVIRELAYKIKVNTKDIFFYGSSAGGFMSLILA SFLRANAIVNNPQTDVCTFYQSHVDRLFETLYPNEDKHEVIKQFRYRLNVCAFFQKLKQVPKIFYYQNYACS FDVETQLIPFLNSIKSEKTLAHLTADKEIELHLYYDAELGHNPLNKQKTMEIIHKAMFGS SEQ. ID. ABP10664 MRYKVKLARKIKNRLFRSKKKTQKENAAVIVHPADNRVFSLFDKTKRIEENQQVPVRKISEFSWNGSILKIA NO. 17. GYMYIKGLPLQKEDQVRKRLLLVNNGVLFTAVSLRDVPVDKLSIDTSNVPGAYKWAGFSQQINFSKLMND KPLPQGEYKLFLEIEAVDDQNVKHQEVHTVGNVSNFLSNDVYATKMEFHSAKKLMKFNLIVNYDEGEKTI NLSCNKLQEIDPSLLELDTGKEANRFLRKLNTSLFHFAYDVFRLLPIKSNKIVFASDSRLDMTGNFEFVYEELL KREENFDFKFFLKSSIRDRKSLSELMSMAYHFATSKIIFIDDFYPIIYPLKIRKNADLVQLWHAVGAFKTFGYSR IGLPGGPSPHSKNHRNYTKVIVSSENIRKHYAEGFGVDIENVIATGVPRTDFFFDEAKKAFVKERLYTEYPFLK DKKVILFAPTFRGNGQQSAHYPFEVLDFDRLYRELKDEYIFLFKIHPFVRNDANIPYQYSDFFYDFSSFREINE LLLVTDILITDYSSVCFEYALLNKPMIFFSYDVDDYIRKRDFYYDYFDFIPGPLAKTSEQMISIIKEEKYNFEQIDS FVHYFFDDLDGKASERVVDQIVFPQEEEPSEDKVLKR SEQ. ID. ABP10665 MKTFLTRIVKGVFGTAYKLLSALLPVQHNKIVIASYREDHLSDNFKGVYEKLKQDPSLRITLLFRKMDKGLIGR NO. 18. VAYLLHLFSSLYHLATCRVLLLDDYYFPLYVVPKRKETVAIQLWHACGAFKKFGYSIVNKPFGPSSDYLKIVPV HSNYDYAIVSAPAAVPHFAEAFQMEQKQILPLGIPRTDYFYHKEHIRTVLDEFHRVYPELKHKKKLLYAPTFR GSGHHQEGDAIPLDLLQLKSALSHKDYVVILHLHPYMRKHAHTEEDDFVLDLTDSYSLYDLMAISDGLITDY SSVIFEYSLLKRPMYFYCPDLEDYLEERDFYYPFESFVPGPISKDVPSLVHDIESDHEADTKRIEDFSQAFITHQ DGKSSGRVADFISSFLTSGAD SEQ. ID. ABP10666 MTLLLKKKYPDSKVFIFGKTPYKLDHFSFVDAAYQINDIPEDVRIDHAFECVGGRGSESAIEQIIAHVHPEAC NO. 19. VALLGVSEYPVEIETRMVLEKGITLIGSSRSGREDFARTVDFLAQYPEVVDYLETLVGGRFPVRSIEEITNAFE ADLTSSWGKTVIEWEI SEQ. ID. ABP10667 MINQTYRLVSARQFEVTYKDKVVHSDKVVVRPTHLSICAADQRYYTGSRGKEAMDKKLPMALIHEGIGKV NO. 20. MFDPTGTFKVGTRVVMVPNTPVEEHEVIAENYLRSSRFRSSGYDGFMQDYMFMAPDRLVELPDSINPHV AAFTELITIAVHALSRFERMAHKKRDTFGVWGTEISDLS SEQ. ID. ABP10668 MIYAEILAGGKGSRMGNVNMPKQFLPLNKRPIIIHTIEKFLLNDRFDKILIVSPKEWINHTKDILKKFIGQDDR NO. 21. LIVVEGGSDRNESIMSGIRYIEKEFGIQDDDVIITHDSVRPFLTHRIIDENIDAVLQYGAVDTVISAIDTIIASED QEFISDIPVRDNMYQGQTPQSFRISKLVELYNKLSDEQKAVLTDACKICSLAGEKVKLVRGEVFNIKVTTPYD LKVANAILQERISQ SEQ. ID. ABP10669 MTLLVSFPDNARAILKEYQMGHYSFPIHVLLTQHAKSLETEFPELTVSVINEKHPLHIYKAVFSMLSSKAVIV NO. 22. DNYFVLTTVLTCRPDIECIQVWHANGAFKRFGLKDINTQNRSRADVRRFRKVYASFDRIVVGSEHMADIFK EFFDIKGDKFLRFGVPLTDAYYEVQENSNDLKNKYHLPADKKIILYAPTFRDHQFESFSLPFSEKQLQHDLKG EYLLAVKLHPVMKQSAELPGDSAWIKDVSDLPLADLLKMSDLLISDYSSVPFEFALLDKPILFYTYDMEAYNR TRGLIRNYSEVIPGVPCCDSRALLDQLKVMDNLQSEFERFSREWNLYSRGNASKQLLSYINEKSI SEQ. ID. ABP10670 MTSRFDPKQQCADDFDEQIVKKRKPGFQSVISSKRLPRIVGRHSERFMHFITYHSSFKAHYRWRD NO. 23. SEQ. ID. ABP10671 MQTKPINQLDFVDGELTSFVSHLETSFLDQNKGAFIVTANPEIGFEAMQNPRYEAVLSSADFILPDGIGVVL NO. 24. VSKLIGKPLQSRIAGYDLFTSLLEKADQKKKRVFFYGAAKHVIAQTIERIERDYPGIEIAGYSDGYVKNQREVA DKIAATNPDMVFVALGYPNQEFFIHKYRHLFPQAVSVGLGGSFDVFSGNVKRAPSFFIRFHLEWMYRLITN PARWRRMLSIPKYVTAVLKHERTSAKPQYTGQVKDQSRHL SEQ. ID. ABP10672 MKKVITYGTFDLFHYGHMKLLERARCLGDYLIVGLSTDDFNLQKQKKSHHSYEHRKLILETIDFVNLVIPEKS NO. 25. WEQKITDIKKYGVDTFVIGDDWKGKFDYLNEYCKVIYLPRTEGISSTKIKKEISDLS SEQ. ID. ABP10673 MNALVRIVKEQVTSFPLILRLASYETKSQYQMNYLGVLWQFLNPLIQMLAYWFVFGMGIRNSKPVLTGAG NO. 26. EVPFIVWMLAGLIPWFFISPTILDGSNSVFKRINMVAKMNFPISSLPSVVIASNLFSYFVMMGIYVIVLFASG VYPSMHWIQYIYYLICMIAFMFSFSLFNSTISVLVRDYQFLLQAVTRLLFFLLPIFWNISEQLGKNHPNLLPVL KLNPIFYLIEGFRNSFLDGKWFFQDMKYTLYFWLFTFLLLLVGSILHMKFRDKFVDFL SEQ. ID. ABP10674 MKLKVSFRNVSKQYHLYKKQSDKIKGLFFPAKDNGFFAVRNVSFDVYEGETIGFVGINGSGKSTMSNLLAKI NO. 27. IPPTSGEIEMNGQPSLIAIAAGLNNQLTGRDNVRLKCLMMGLTNKEIDDMYDSIVEFAEIGDFINQPVKNY SSGMKSRLGFAISVHIDPDILIIDEALSVGDQTFYQKCVDRINEFKKQGKTIFFVSHSIGQIEKMCDRVAWM HYGELRMFDETKTVVKEYKAFIDWFNKLSKKEKETYKKEQTEERKKEDPEAFARFRQKKKKPKSLANAVQIA ILSILTVFMAGTMFFNAPLRTIASFGAIPQNEVKNHHGNAKGKSEERLTAVNKQGFIANEKAAAYKDQGLK QKADVTLPFGTEVTVAAKGKQAAKIKFDGHSYYVKKSAVAANMKHAELHAAAFTSYVSQNAASSYEYFLK FLGDSRTSIQSKLNGYTEGDTADGRKTLDFDYEKISYVLENDKATELIFHNISPITPASLSLSDSDVLYDSSKKR FLVNTADQVFAVDNEEHTLTLMLK SEQ. ID. ABP10675 MKLKKVRKAIIPAAGLGTRFLPATKAMPKEMLPIVDKPTIQYIIEEAVEAGIEDIIIVTGKSKRAIEDHFDYSPE NO. 28. LERNLEEKGKTELLEKVKKASNLADIHYIRQKEPKGLGHAVWCARNFIGDEPFAVLLGDDIVQAETPGLRQL MDEYEKTLSSIIGVQQVPEEETHRYGIIDPLTSEGRRYQVKNFVEKPPKGTAPSNLAILGRYVFTPEIFMYLEE QQVGAGGEIQLTDAIQKLNEIQRVFAYDFEGKRYDVGEKLGFITTTLEFAMQDKELRDQLVPFMEGLLNKE EI SEQ. ID. ABP10676 MKTVFMVVYTIDVNKGGMTTAMLNRSKMLVHNGYKSDLVTFDYNPYYENITSELRQIGKLDPDVNILNV NO. 29. NDYYRDLNTEGNVDPSYYEDEAKTEQEGYFIQDSEYDTKQYIRYFKQGSYVKYKKWTEDGYLSHIDFFNEN RQRIKREEFHKNKYKHREISFDPSNNKMNYEKYYTPDGFCYLIRWYNSETEKQQQVFLFNRNSNKVLMFK NNAEFHTYWLNEIAAAENEKPIFICDGPGSSGKVRGMKKELAHRIYMVHINHFETPYTYGSKVKQDHIDFL SNIDKLDALVVLTNDQKKDIEKQFGEHGNIFIIPNSMPYTDLPDIKKDNKKVSMFVRYHKQKAIDEAIKAFV RVIKKVPDARLEIFGHGAEKSRLECILIIELNLQQNVFIKGYAKNVREEMGSSLITLLTSNYEAFGLSITESFMN GTPVISYDCNYGPRDVISDGIDGYIVPQKDQKALANQIIKLLNNPDLAKEMGLKGREKVLTEYTNEVVLNK WLQLFNVLEKK SEQ. ID. ABP10677 MYDFLNVPQPDYSWIEHPIEEAGLTYIKVPEKPVYRYYGKYVKYQRFSSSVNWLYQVILMTAQAKVQKRRV NO. 30. RKTRTQRI SEQ. ID. ABP10678 MFLTYTNGEGYEHYQYLINELSLIIFEGIFGKISIILSGGAWHFIQNNKASALSFVNHFLS NO. 31. SEQ. ID. ABP10825 MAWFLLVIAGIEEIIAAIAMKYIDGTRKKWPIIVMTVGFGLSFYCLSQAMIVLPAGVAYAVWTGIGSIGVSA NO. 32. VGFIWFKERFQLSQVISLCLILAGVIGLRLTSSS SEQ. ID. ABP10826 MNWVLVFIAGLLEVVWASSLKHADSLLDWIIIFILIAVSFILLIRSYQKIPMAAAYTVFVGIGTVGTYLTGIVLG NO. 33. ESFSAAQMFFLALLLAGILGMKLFTKESKSQPGGEQ SEQ. ID. ABP10827 MPKQTSGKYEKILQAAIEVISEKGLDKASISDIVKKAGTAQGTFYLYFSSKNALIPAIAENLLTHTLDQIKGRLH NO. 34. GDEDFWTVLDILIDETFLITERHKDIIVLCYSGLAIDHSMEKWETIYQPYYSWLEKIINKAIANLEVTEEINSKW TARTIINLVENTAERFYIGFEQDENVEVYKKEIFSFLKRSLGTA SEQ. ID. ABP10828 MSKQGNFQKSMSLFDLILIGMGAIFGSAWLFAVSNVASKAGPSGAFSWILGGAIILLIGLVYAELGAALPRT NO. 35. GGIIRYPVYSHGHLVGYLISFVTIVAYTSLISIEVTAVRQYVAYWFPGLTIKGSDSPTISGWILQFALLCLFFLLN YWSVKTFAKANFIISIFKYIVPITIIIVLIFHFQPENLSVQGFAPFGFTGIQAAISTGGVMFAYLGLHPIVSVAGE VQNPKRNIPIALIICIIVSTIIYTVLQVTFIGAIPTETLKHGWPAIGREFSLPFKDIAVMLGLGWLATLVILDAILS PGGNGNIFMNTTSRLVYAWARNGTLFGIFSKVNKDTGTPRASLWLSFALSIFWTLPFPSWNALVNVCSVA LILSYAIAPISSAALRVNAKDLNRPFYLKGMSIIGPLSFIFTAFIVYWSGWKTVSWLLGSQLVMFLIYLCFSKYT PKEDVSLAQQLKSAWWLIGFYIMMLIFSYIGSFGHGLGIISNPVDLILVAIGSLAIYYWAKYTGLPKAAIDYDK SEQ. ID. ABP10829 MNYIKAGKWLTVFLTFLGILLFIDLFPKEEHDQKTKSKQKPDYRAAYHFTTPDKWKNDPQKPIYFDGKYHYF NO. 36. YLYNRDYPKGNGTEWRHAVSEDLVHWTDEGVAIPKYTNPDGDIWTGSVVVDKENTAGFGKNALVAIVT QPSAKDKKQEQYLWYSTDKGKSFKFYSGNPVMPNPGTDDFRDPKVIWDDQDNKWVMVMAEGSKIGFY ESDNLKDWHYTSGFFPEQAGMVECPDLYMMRASDGANKWVLGASANGKPWGKPNTYAYWTGSFDG KEFKADQTEAQWLDYGFDWYGGVTFEDSKSTDPLEKRYALAWMNNWDYANNTPTMKNGFNGTDSVI RELRLKEQDGTYSLVSQPIEALEQLTVSTEEIEDQDVNGSKTLSITGDTYQLDTDLSWSELKNAGVRLRESED QKRHIDVGIFAEGGYSYVNRAATNQPDKSNTYVESKAPYDVSKRKVHLKILVDKTTIEVFVGDGKTIFSNEV FPKPEDKGITLFSDGGTASFKNITVKHFDSIHK SEQ. ID. ABP10830 MNIKKFAKQATVLTFTTALLAGGATQAFAKETNQKPYKETYGISHITRHDMLQIPEQQKNEKYQVPEFDSS NO. 37. TIKNISSAKGLDVWDSWPLQNADGTVANYHGYHIVFALAGDPKNADDTSIYMFYQKVGETSIDSWKNAG RVFKDSDKFDANDSILKDQTQEWSGSATYTSDGKIRLFYTDFSGKHYGKQTLTTAQVNVSASDSSLNINGV EDYKSIFDGDGKTYQNVQQFIDEGNYSSGDNHTLRDPHYVEDKGHKYLVFEANTGTEDGYQGEESLFNKA YYGKSTSFFRQESQKLLQSDKKRTAELANGALGMIELNDDYTLKKVMKPLIASNTVTDEIERANVFKMNGK WYLFTDSRGSKMTIDGITSNDIYMLGYVSNSLTGPYKPLNKTGLVLKMDLDPNDVTFTYSHFAVPQAKGN NVVITSYMTNRGFYADKQSTFAPSFLLNIKGKKTSVVKDSILEQGQLTVNK SEQ. ID. ABP10831 MKQNKRKNLQTLFETLGEKHQFNGTVLAAEGGDILYHHSFGYAEMTEKRPLKTNSLFELASLSKPFTALGIIL NO. 38. LEEKGILGYEDKVDRWLPGFPYQGVTIRHLLNHTSGLPDYMGWFFANWDPHKIAVNQDIVDMLMNEGL SGYFEPNEGWMYSNTGYVLLAVIIEKASGMSYADFMKTSIFLPAGMNETRVYNRRLSPERIDHYAYGYVY DVHSETYVLPDELEETNYVVYLDGIQGDGTVNSVTSDLFRFDQALYQDDFISKASKESAFSPVRLNNGETID YGFGWVLQNSPEKGRIVSHSGGWPGYSTLMIRYIDHRKTLIYLSNKEEDTEYEQAILKAAEHILFGQPYEVP ERPADKKKKAIDTAIYSRYVGSYLLQDGTAAQVTAENERLYLEIAGQLRLELFPSSETRFFLRALSVEVEFTLG VDAAKSFILYEDGSEEEAVRTK SEQ. ID. ABP10832 MIGILAGMGPKSTSPFIDKVIDYCQKLYGASNDIDYPHMMIYSCPTPFYADRPIDHDEMKKAIIDGAVKLEK NO. 39. TGVDFIALPCNTAHVYYEEIQQALSVPMLHIVEETIKEIPHLAKKAVVLGTEPTIQSAIYQKVLKGNGQEVIHK DHWQQAVNQLIAAIKQPNHMQHTQALWQTLYEEISQHADIIISACTDLNAVLDHIQSEIPIIDSSACLAKST VSTYLAYQS SEQ. ID. ABP10833 MKKPVLKPFASLEIKVDPPITIGETSLGLRRFIPIRSGTITGEVKGRILPGGADSQMIRANGRTDLSARYVIETA NO. 40. DHELIYIENNGIRQVSEPFRKQAAAGEIIEPEHVYFRTVPTFETGSEVYQWLHDRLFIGSAERTPDYVLLDIYE VQ SEQ. ID. ABP10834 MENFIGSHMIYTYENGWEYEIYIKNDHTIDYRIHSGMVAGRWVRDQEVNIVKLTEGVYKVSWTEPTGTDV NO. 41. SLNFMPNEKRMHGIIFFPKWVHEHPEITVCYQNDHIDLMKESREKYETYPKYVVPEFAEITFLKNEGVDNE EVISKAPYEGMTDDIRAGRL SEQ. ID. ABP10835 MGKTGYIGAAIVVAACIIILSAVVCLRDTVYYQPMRWTGIILFFAGIVMVPAYSAKRKPGKEK NO. 42. SEQ. ID. ABP10836 MTHQIVTTQYGKVKGTTENGVHKWKGIPYAKPPLGQWRFKAPEPPEVWEDVLDATAYGPICPQPSDLLS NO. 43. LSYTELPRQSEDCLYVNVFAPDTPSQNLPVMVWIHGGAFYLGAGSEPLYDGSKLAAQGEVIVVTLNYRLGP FGFLHLSSFDEAYSDNLGLLDQAAALKWVRENISAFGGDPDNVTVFGESAGGMSIAALLAMPAAKGLFQK AIMESGASRTMTKEQAASTSAAFLQVLGINEGQLDKLHTVSAEDLLKAADQLRIAEKENIFQLFFQPALDPK TLPEEPEKAIAEGAASGIPLLIGTTRDEGYLFFTPDSDVHSQETLDAALEYLLGKPLAEKVADLYPRSLESQIH MMTDLLFWRPAVAYASAQSHYAPVWMYRFDWHPKKPPYNKAFHALELPFVFGNLDGLERMAKAEITD EVKQLSHTIQSAWITFAKTGNPSTEAVNWPAYHEETRETLILDSEITIENDPESEKRQKLFPSKGE SEQ. ID. ABP10837 MIGRIIRLYRKRKGYSINQLAVESGVSKSYLSKIERGVHTNPSVQFLKKVSATLEVELTELFDAETMMYEKISG NO. 44. GEEEWRVHLVQAVQAGMEKEELFTFTNRLKKEQPETASYRNRKLTESNIEEWKALMAEAREIGLSVHEVK SFLKTMGR SEQ. ID. ABP10838 MNENMSFKELYAIVRHRFVLILLITIGVTLMMGFVQFKVISPTYQASTQVLVHESDGEENSNLSDIQRNLQY NO. 45. SSTFQSIMKSTALMEEVKAELHLSESASSLKGKVITSSENESEIINVAVQDHDPAKAAEIANTLVNKFEKEVD ERMNVQGVHILSEAKASESPMIKPARLRNMVMAFGAAVMGGITLAFFLHFLDDTCKSARQLSERTGLPCL GSVPDVHKGRNRGIKHFGE SEQ. ID. ABP10839 MIFRKKKARRGLAQISVLHNKSVVAEQYRTIRTNIEFSSVQTNLRSILVTSSVPGEGKSFSAANLAAVFAQQ NO. 46. QEKKVLLVDADLRKPTINQTFQVDNVTGLTNVLVGNASLSETVQKTPIDNLYVLTSGPTPPNPAELLSSKA MGDLISEIYEQFSLVIFDSPPLLAVADAQILANQTDGSVLVVLSGKTKTDTVLKAKDALEQSNAKLLGALLNK KKMKKSEHYSY SEQ. ID. ABP10840 MIIALDTYLVLNSVIAGYQFLKDSYQFYDSGALLLTAVSLLLSYHVCAFLFNQYKQVWTYTGLGELIVLLKGIT NO. 47. LSAAVTGIIQYAVYHTMFFRLLTACWVLQLLSIGGTRILSRVLNESIRKKRCASSRALIIGAGSGGTLMVRQLL SKDEPDIIPVAFIDDDQTKHKLEIMGLPVIGGKESIMPAVQKLKINFIIIAIPSLRTHELQVLYKECVRTGVSIKI MPHFDEMLLGTRTAGQIRDVKAEDLLGRKPVTLDTSEISNRIKGKTVLVTGAGGSIGSEICRQISAFQPKEIIL LGHGENSIHSIYTELNGRFGKHIVFHTEIADVQDRDKMFTLMKKYEPHVVYHAAAHKHVPLMEHNPEEAV KNNIIGTKNVAEAADMSGTETFVLISSDKAVNPANVMGATKRFAEMIIMNLGKVSRTKFVAVRFGNVLGS RGSVIPIFKKQIEKGGPVTVTHPAMTRYFMTIPEASRLVIQAGALAKGRQIFVLDMGEPVKIVDLAKNLIHLS GYTTEQVPIEFTGIRPGEKMYEELLNKNEVHAEQIFPKIHIGKAVDGDWPVLMRFIEDFHELSEADLRARLF AAINTSDKMTAASVH SEQ. ID. ABP10841 MTKKILFCATVDYHFKAFHLPYFKWFKQRGWEVHVAANGQTKLPYVDEKFSIPIRRSPFDPQNLAVYRQLK NO. 48. KVIDTYEYDIVHCHTPVGGVLARLAARQARRHGTKVLYTAHGFHFCKGAPMKNWLLYYPVEKWLSAYTD CLITINEEDYKRAKGLQRPGGRTQKIHGIGVNTERFRPVSPIEQQRLREKHGFREDDFILVYPAELNLNKNQK QLIEAAALLKEKIPSLRLVFAGEGAMEQTYQMLAEKLGASANVCFYGFCSDIHELIQLADVSVASSIREGLG MNVLEGMAAEKPAIATDNRGHREIIRDGENGFLIKIGDSAAFARRIEQLYHKPEICRKLGQEGRKTALRFSE ARTVEEMADIYSAYMDMDTKEKSV SEQ. ID. ABP10842 MNSGPKVSVIMGIYNCERTLAESIESILSQSYKNWELILCDDASTDGTLRIAKQYAAHYSDRIKLIQNKTNKR NO. 49. LAASLNHCLSHATGDYIARQDGDDLSFPRRLEKQVAFLEKHRHYQVVGTGMLVFDEFGVRGTRILPSVPEP GIMAKGTPFCHGTIMMRASAYRTLKGYRSVRRTRRMEDIDLWLRFFEEGFRGYNLQEALYKVREDSDAFK RRSFTYSIDNAILVYQACRRLKLPLSDYIYIAKPLIRAFMPAAVMNRYHKKRVMNQKEGLVKHE SEQ. ID. ABP10843 MNSSQKRVLHVLSGMNRGGAETMVMNLYRKMDKSKVQFDFLTYRNDPCAYDEEILSLGGRLFYVPSIGQ NO. 50. SNPLTFVRNVRNAIKENGPFSAVHAHTDFQTGFIALAARLAGVPVRVCHSHNTSWKTGFNWKDRLQLLVF RRLILANATALCACGEDAGRFLFGQSNMERERVHLLPNGIDLELFAPNGQAADEEKAARGIAADRLIIGHV ARFHEVKNHAFLLKLAAHLKERGIRFQLVLAGDGPLRGEIEEEARQQNLLSDVLFLGTEERIHELMRTFDVF VMPSLYEGLPVVLVEAQASGLPCIISDSITEKVDAGLGLVTRLSLSEPISVWAETIARAAAAGRPKREFIKETL AQLGYDAQQNVGALLNVYNISTEKDHNR SEQ. ID. ABP10844 MIVYAVNMGIVFIWSWFAKMCGGRDDSLATGYRPNKLLIWIPLASLVLVSGLRYRVGTDFQTYTLLYELAG NO. 51. DYQNVWQIFGFGTAKTATDPGFTALLWLMNFITEDPQIMYFTVAVVTYSFIMKTLADYGRPFELSVFLFLG TFHYYASFNGIRQYMVAAVLFWAIRYIISGNWKRYFLIVLVSSLFHSSALIMIPVYFIVRRKAWSPAIFGLSAL FLGMTFLYQKFISVFVVVLENSSYSHYEKWLMTNTNGMNVIKIAVLVLPLFLAFCYKERLRSLWPQIDIVVN LCLLGFLFGLLATKDVIFARFNIYFGLYQMILVPYFVRIFDEKSNALIYIAIVVCYFLYSYLLMPVDSSVLPYRTIF SR SEQ. ID. ABP10845 METPAVSLLVAVYNTETYIRTCLESLRNQTMDNIEIIIVNDGSADASPDIAEEYAKMDNRFKVIHQENQGLG NO. 52. AVRNKGIEAARGEFIAFIDSDDWIEPDYCEQMLRAAGDETDLVICNYAAEFEDTGKTMDSDIAQTYQDQP KEHYIKALFEGKVRGFSWNKLYRRSMIDAHRLSFPLRGELEHVEDQFFSFRAHFFARSVSYVKTPLYHYRIHL SSIVQRYQKKLFESGLALYEANAAFLQENNKLEEYRKELDTFIVLHSSICMLNEWKTSGSRRLFEKLRNVGVI CADPVFQESLSKTGTAPFDAKRSCLLLMAKYRMIPFVAMASAVYQRVIEYKMRNRG SEQ. ID. ABP10846 MSLQSLKINFAEWLLLKVKYPSQYWLGAADQPIKAAAHQKKIILTLLPSHDNLGDHAIAYASKAFLEQEYPD NO. 53. FDIVEVDMKDIYKSAKSLIRSRHPEDMVFIIGGGNMGDLYRYEEWTRRFIIKTFHDYRVVQLPATAHFSDTK KGRKELKRAQKIYNAHPGLLLMARDETTYQFMKQHFHEKTILKQPDMVLYLDRSKPPAEREGVYMCLRED QESVLQEDQRNRVKAALFEEFGEIKSFTTTIGRRVSRDTREQELEALWSKLQSAEAVVTDRLHGMIFCALTG TPCVVIRSFDHKVMEGYQWLKDIPFMKLIEHPEPERVTAAVNELLTKETPRAGFPRDVYFKGLRDKISGEA Q SEQ. ID. ABP10847 MTPLVSIIVPMYNVEPFIEECIDSLLCQTLSDIEIIILVNDGTPDRSGEIAEDYAKRDARIRVIHQANGGLSSAR NO. 54. NTGIKGARGTYIGFVDGDDYVSSAMFQRLTEEAEQNQLDIVGCGFYKQSSDRRTYVPPQLEANRVLTKPE MTEQLKHAHETRFIWYVWRYLYRRELFERANLLFDEDIRFAEDSPFNLSAFCEAERVKMLDEGLYIYRENPN SLTEIPYKPAMDEHLQKQYQAKIAFYNHYGLAGACKEDLNVYICRHQLPMLLANACASQNSPKDIKKKIRQI LSYDMVRQAVRHTPIQHEKLLRGERLVLALCKWRLTFLIKLFFEQRGTMKGSAKQA SEQ. ID. ABP10848 MTPFIVKTLGVEAFGFVHLTQNVINYFSIITVALSSVVVRFFSVAAHRGEREKANAYISNYLAASVLISLLLLLP NO. 55. LAGSAFFIDRVMNVPQALLADVRLSILIGSVLFILTFLMAGFGAAPFYANRLYITSSIQAVQMLIRVLSVLLLFA CFAPKIWQIQLAALAGAVMASVLSFYFFKKLIPWFSFRMKDLSFRTSKELFQAGAWSSVNQIGVLLFLQIDL LTANLMLGASASGKYAAIIQFPLLLRSLAGTVASLFAPIMTSYYSKGDMDGLMNYANKAVRLNGVLLALPA ALLGGLAGPFLTIWLGPSFSSIAPLLFIHAGYLVVSLAFMPLFYIWTAFNQQKTPAIVTLLLGAVNVVLAVTLS GPAHLGLYGITLAGAISLILKNAIFTPLYVSRITGYKKHVFFKGIIGPLSAAVFAWTVCKAIQFIVKIDSWPSLIA AGVTVSFFYAVFAFMLVCTKEERQLVLKRFRKTKGAVNL SEQ. ID. ABP10849 MILKRLFDLTAAIFLLCCTSVIILFTIAVVRLKIGSPVFFKQVRPGLHGKPFTLYKFRTMTDERDGEGNLLPDEV NO. 56. RLTKTGRLIRKLSIDELPQLLNVLKGDLSLVGPRPLLMDYLPLYTEKQARRHEVKPGITGWAQINGRNAISW EKKFELDVWYVDNRSFILDLKILCLTVRKVLVSEGIQQTNHVTAERFTGSGDVSS SEQ. ID. ABP10850 MKNVAIVGDGGHGKVIRELINARSDTRLAAVLDDKFKTFEGGKEWYTGPPEAVTELRRLIPDVLFLIAVGN NO. 57. NSVRKQLAERLGLRKDDFITLIHPSAIVSRSAVIGEGTVIMAGAIIQADARIGAHCIINTGAVAEHDNQISDYV HLSPRVTLSGAVSVQEGAHVGTGASAIPQITIGAWSIVGAGSAVIRPIPDRVTAAGAPARIISSIQTSNKG SEQ. ID. ABP10851 MHKKIYLSPPHMSGREQHYISEAFRSNWIAPLGPLVNSFEEQLAERVGVKAAAAVSSGTAAIHLALRLLEVK NO. 58. EGDSVFCQSFTFVATANPILYEKAVPVFIDSEPDTWNMSPTALERALEEAKRNGTLPKAVIAVNLYGQSAK MDEIVSLCDAYGVPVIEDAAESLGTVYKGKQSGTFGRFGIFSFNGNKIITTSGGGMLVSNDEAAIEKARFLA SQAREPAVHYQHSQIGHNYRLSNILAGVGIAQLEVLDERVEKRRTIFTRYKNVLGHIAGVRFMPEYAAGVS NRWLTTLTLDNGLSPYDVVQCLAEENIEARPLWKPLHTQQLFDPALFYSHEDTGSVCEDLFKRGICLPSGSN MTEDEQDRVIEVLLHLFQTAEVKKWTASIR SEQ. ID. ABP10852 MDSKHSMISLKQKLSGLLDVIPKQSEIIYADYPLYGNVGDLFIMKGTEAFFKEHGIRVRKRWNPDNFPVGR NO. 59. KLDPNLIIVCQGGGNFGDLYPYYQGFREKIVQTYPNHKIVILPQSIYFQNKDNLKRTAEIFSKHANLHIMTRE KASYATAQAYFSKNHIQLLPDMAHQLFPVIPTQQPSNQKLRFIRTDHEANQALQEHTETESYDWRTVLSAS DRRTIAFLQTLNVLNKKAGNPLPIAYIWGKYSDYIVQKAIRFFSRYESVETSRLHGHILSALLQKENTVIDNSY GKNANYFHTWMEGVPGTRLIQHASKKENLPAHM SEQ. ID. ABP10853 MSELFSVPYFIENLKQHIEMNQSEDKIHAMNSYYRSVVSTLVQDQLTKNAVVLKRIQHLDEAYNKVKRGES NO. 60. K SEQ. ID. ABP10854 MLTPLSSLYMIEITPYTFMKKELPKKCLNFFPSLILLRI NO. 61. SEQ. ID. ABP10855 MMDMKLQQVQVLKPQLTQELRQAITLLGYHSAELAEYIDELSLENPLIERKETDTPPLSYHKTNKNRMNA NO. 62. QEAGLQLSNPQKTLQDALKQQSLDMNLTNTEKKIFNYLIHSLDSNGYLEEDVEEAARRLSVSAKETEAVLAK LQSLEPAGIGARSLQECILLQLQRLPNRNEQAEMLVSAHFDAFAQKKWKALSVETGIPLHTIQDISDDIAAL HPRPGLLFARPEQDVYIEPDIFITVKNGHIAAELNTRSFPEIDLHPQYRTLLSSGSCQDTVSYLSAKYQEWRW LSRALRQRKQTITRIINELITRQKDFFLKGRSAMKPLTLREVADCLSLHESTVSRAIKGKTIQTPYGLFEMKLFF SAKAEASGEGDASNYAVKMHLEDLINQEDKTKPLSDQKLVDLLYEQHGIQISRRTVAKYRDQMKIPSSAAR KRYK SEQ. ID. ABP10856 MQWTQAYTPIGGNLLLSALAALVPIIFFFWALAIKRMKGYTAGLATLGIALIIAVLVYRMPAEKALMSATQG NO. 63. AVYGLLPIGWIIVTSVFLYKITVKTGQFDIIRSSVLSITDDRRLQALLIAFSFGAFLEGAAGFGAPVAISAALLVG LGFNPLYAAGICLIANTAPVAFGAIGIPITAVEGPTGIPAMEISQMVGRQLPFLSVFIPLYLIIIMSGFRKALEV WPAILVSGVSFAVVQYLSSNFLGPELPDVLSALVSMAALAVFLKWWKPKTTFRFAGEQESAASIETARTNP AAPAYSGGQIFKAWSPFLLLTAMISVWGIPSVKSALTGHYEGSAVFLKWLNAVGEKLTFAPGVPFLNNQIV NADGTPIEAVYKLEVLGSAGTAILIAAVLSKFITAISWKDWGTVFKETVQELKLPILTIASVVGFAYVTNSSGM STTLGMTLALTGSMFTFFSPVLGWLGVFITGSDTSANLLFGNLQKVTALSVGMDPVLSVAANSSGGVTGK MISPQSIAVACAAVGLAGKESDLFRFTIKHSLFLLLLVCIITFLQHHVFSWMIP SEQ. ID. ABP10857 MKYKQIKTKKIYEEVADALLDMIKNGELKPGDKLDSVQALAESFQVSRSAVREALSALKAMGLVEMKQGE NO. 64. GTYLKEFELNQISQPLSAALLMKKEDVKQLLEVRKLLEIGVASLAAEKRTEADLERIQDALKEMGSIEADDEL GEKADFAFHLALADASQNELLKHLMNHVSSLLLETMRETRKIWLFSKKTSVQRLYEEHERIYNAVAAGNGV QAEAAMLAHLTNVEDVLSGYFEENVQ SEQ. ID. ABP10858 MATIKDIAQEAGFSISTVSRVLNNDESLSVPDETREKIYEAAEKLNYRKKTVRPLVKHIAFLYWLTDKEELEDV NO. 65. YFKTMRLEVEKLAKAFNVDMTTYKIADGIESIPEHTEGFIAVGTFSDEELAFLRNLTENGVFIDSTPDPDHFD SVRPDLAQMTKKTVNILTEKGHKSIGFIGGTYKNPNTNQDEMDIREQTFRSYMREKAMLDERYIFCHRGFS VENGYRLMSAAIDILGDQLPTAFMIAADPIAVGCLQALNEKGIAIPNRVSIVSINNISFAKYVSPPLTTFHIDI HELCKNAVQLLLEQVQDKRRTVKTLYVGAELIVRKSMNEG SEQ. ID. ABP10859 MKMAKKCSVFMLCAAVSLSLAACGPKESSSAKSSSKGSELVVWEDKEKSIGIKDAVAAFEKEHDVKVKVVE NO. 66. KPYAKQIEDLRMDGPAGTGPDVLTMPGDQIGTAVTEGLLKELHVKKDVQSLYTDASIQSQMVDQKLYGL PKAVETTVLFYNKDLISEKELPKTLEEWYDYSKKTANGSKFGFLALFDQIYYAESVMSGYGGYIFGKAKDGSY NPSDIGINNEGAVKGAALIQKFYKDGLFPAGIIGEQGINVLESLFTEGKAAAIISGPWNVEAFSKAGINYGITK LPKLENGKNMSSFIGVKSYNVSAFSKNEELAQELAVFLANEKNSKTRYEETKEVPAVKSLANDPAIMKSGAA RAVTEQSRFSEPTPNIPEMNEIWTPADSALQTVATGKADPKQALDQAAETAKGQIKAKHSGK SEQ. ID. ABP10860 MQHRQVALLLSIIPGLGQFYNKQWIKGIVFLFLGASFFAVFGDLLNMGFWGIFTLGTEVPRDNSVFLLAEGI NO. 67. IAVIVTCFGLAVYYVNLRDAFQSGKQRDENKPLSSLKEQYQHIISEGYPYVVSGPSLFILIFAVIFPILFSFALAF TNYDLYHSPPAKLIDWVGFQTFANIFTVDIWRSTFFDVLAWTVVWTLAASTLQVSLGIFLAIIVNQKDLRFK RFFRTILILPWAVPGFVTILIFAGLFNDSFGAMNHDILAFFGIDPLPWMTDANWSRLALILMQGWLGFPYIF LVSTGVLQSIPDDLYEAATIDGASVFSKLRYITLPMVFIAMAPIIITQFTFNFNNFNIIYLFNGGGPAVTGSTA GGTDILVSWIYKLTMQSSQYSLAAALTILLSVFVISIALWQFRQTKSFKEEA SEQ. ID. ABP10886 MRKDKLVSTVFKNNAIEIYTIIILKNPDTLVRIKEIQLFHTKKSLAASAAKL NO. 68. SEQ. ID. ABP10887 MFPEVNDKDELQKIFLNVSGKTIHSLIRDDTNIEQNTNIIDIDRVLDHKKSDFLVRNSEEFLEHNPFFHFFSPF NO. 69. LSCKIEEFIVKVRIEDAVDNEDEFVKKVIKHILDLMFEKAFRVLVLEVNIARLEGKLEGTTPEERLNHFLAVSLN DESFLKSVYKEYEVLTSLLCVTIDDYFTYVMEIIKNTKREISSLNSKFNSDNDLGAITNITTGLGDTHQKGKSVS TIYFKSGKKIIYKPRDLTLEQGFQEVLYWLDGKNIPGILNFKRVQIHTVNDSGWMEHIDYKSCFNKNEANDF YTRSGNLLCLLYLLNAVDFHHENLIAHGSFPVLVDLESLFHARLKVDQIDKKSAFVTATELVDNSVQSISLLPT KISKRVGDKDISLDIGGLGAYKEQLSPHKSLVIENAGTDTIKILRKNTFIKPQLNNPSIKTGSYLYSENYTGQIK DGFESLYSWVMLNKDEFWDKISQTFKETNSRFIFRPTYLYTQLLRISSHPDFMRDTYRRKIILHRIGIDYIQEY KDILNSEYKDLLTGDVPFFRSSIEHEHLIDSRGGKIHNILEEPPIKTVKQKIFNLSKEDLKRQIDFIEMSYISNEKR LKEVTDIKFSKAANLNKIKSENWIDEATQIGEFIVENSVCGINKKQKDRMWIGPSLEGIEEDIWNANVLGFD IYNGNSGIALFLGYLGEILNRQDFKQAAIETMRPIQKFISEIKEDHPYLIGAFQGISGYFYTLNKLSNLFEDSELR KTTLENISVLSKLGKFDKVYDLIGGSLGSLAVMLSIIPNITEENNKKEILKISHIHCDHILSVAKNFEEQISWPGK FSAAYSGFSHGNSGFIAYLYKFFKLTNDEQLLEVIQRALRFERRLYSEDHNNWYTTENKDKLANGWCHGAP GILLSKLILKDNGFEDEYIEKEISTAIDSSIHNGIGNNPTYCHGDLGVLSILNYASDLTNNINLKNRCLRTYQDLF ENVLAMKWRKRDLVCTRSYSLMIGLSGIGYSMIKNYAPEIVPNFLWLE SEQ. ID. ABP10888 MKKDMVKNASGFIEEDELISLANGENATGGGTPVTAIITALTGTTFTVTLSAASCPTSACTNLCNK NO. 70. SEQ. ID. ABP10889 MDISYENNNFIRDAVINFSSPTNEVEKLRIKNKDYFGNFYTFFLDFYQQRLFNTLENASKENNLKLNKQKIISS NO. 71. ALEAFSQELIQLCIRTLIVDINDRKEKGLLEGKDSKLRYKNYNNLIFKSEYVAEILNKYPVLTYLISSRISNKILYLK EVLENLRKNRQDIYRELRIEFDEVSNIYFSSGDTHNGGKNVLIIETNQGKIVYKPHSLSPDILFNSIVDYVNNS DKILKKIYKIRTLNYKDYGYQEFIDYKECETSEKLNFYFYRVGVSLSIFHIIGCDDLHHENLIAHGEYPVVIDLETL IKNNSIYKPRNNNLIDNFHEDINYSVLGTMLLPLNLQTSIFDFDLGGISNDENQTSEIWKSYIIDFEGTDEIQL TKKSVIMNSTQNRATYNGKAADPKNYIEEILKGFTDCYNFVLENISGFHDLVKKVGSSNLEVRQVLRATSIYA RFLEASTHPNYLSSFEERKKLFKKINIAEGVTDKFSKKNLYELESLMCNDVPYFSTMYNSLDLICNKSTSIVNFF RESLLDVVLNKTKSISKASLKKQQYYIRMSLTTTIKDSWKKTNKHNKKYRPKLFGNNNKNYLECATEIGDLFL ETAIWNNDRSKCTWVAPIISENNKVKLGPLNFDLYEGGGVILFLALLGKENGKKEYFDLALAGMRGIEELFL SDDKMDDRLSLFTGIGSLSYIYYHLYTHTNDYKYYEKFKKYIKKINEMNISGDIALDIVGGVSSLIVFLLNLYKET KLDILNSVCCKLGNTLYQCLENDKHNYLTGLSHGYSGFTWALCYLGHITKEEKYTTLGKELLKIENKFFDLHTS NWKDLRVGEGNSDPVYWCHGAGGIALSRAFLKDLLKNKENVVDKEIDKEVDRDLSSAICKLLSDGFKKTTD HSLCHGSFGNIDILLKLSEFLNDIDLQEVAFKEAQNAINYIRDKGFIPGLQDHFDLNTFMLGLGGVGYSLLRL HNPVNPSLLAMEVRSYNE SEQ. ID. ABP10890 MIVKKKKRIPIVKQLQQTECGLCCCAMLIRFYNSNETLFELRSFLEAGRDGLTIKQLKNLLVHKGFKADIYKST NO. 72. IPGLKKINVPFIAYWNNEHFIVVEKTKKNFYYIIDPANGRRKLTEEEFRKGFSSYILYAVPSENFTPNKRKDKN VWFGVLKNITNYKLLFSIIVFLSLISYLLTLYVPILVQKLIDTSIEHNNLNSISNIVWITFLISILYGMFVLFRGLKM ISLNIFLSKNLVVDTFAHLLKLPFKFFDLRSPGDLLFRLNSMNGFRELLSTQLISGLIDLGAVVFILAYMFFKSIP LTLITILIFAINTIFMFLTRPAVAQAIDDEVAEQSKSQAIQIESIFSIAAIKISGMENEIFSTWNNSFNDVIKRFKK RSILQNIVNTVTQVFQTIAPLVILILELLLFFDNKFTMGEVIAYHSLSVTFFGLTTSLFGTYTQFILATSYLERVKD ITETECEKNFENAVNLKLRGNVKLENVSFSYTKHSPKVLKNISLEIREGQKIAIVGSSGSGKSTLSKLIMGLYDP TEGQICFDSIPLEKLDKKQLYKQMGIVPQDITLFNSSILKNITLNNKNTSIEKVRKVAKAAQIDKEIESMPMKY NTPISEMGMNLSGGQRQRIVLARALLNDPKILILDEATSSLDLVNETLISKYLSEMGCTRVVIAHRLSTIMDS DFIIVLDKGEVVEIGKHEELIALEGVYSNLYRSQMKR SEQ. ID. ABP10891 MKNYKGDGAVFLVIGFCLGLFMGVVFDILPYGLSLGILIGSLIDFYFYARYKNNKK NO. 73. SEQ. ID. ABP10892 MSMSRKETPDDNAFIESFHSSLKSKTLYLNSIERTSTIIVERNVKDYIYYNNIPYSNETKQPITDKLSAIGCLKG NO. 74. VLIPVSKTG SEQ. ID. ABP10981 MIDVIRVSGGYGRKDVLQDISFAVKPGEFLGILGPNGSGKTTLLKMLSGSITPRSGEVLLECRSVGSYKTKEL NO. 75. ARKVAALPQKTEQAFSFTVEETVQFGRYAYQSGLFRQLTGEDHDIVKRVMKQTDILRFAKKSIHELSGGEQ QRVYVAQALAQEPRYLLLDEPTSFLDLSFQKSLLDLIKQETVASKLAVIGVFHDVNIASLYCDRLLLLKDGKAE VLDRPEAALCADRIERVYHTDITALDHPERANPQFTIKAKTIPEKAEPLFLKERIEQYLPRGITFSADRPMRVL SSEEGFAWRRKLVFDSGNNSGWPHDLSTVEQEALFIQHDCKLTACHIVSESNDLCIIGMKDAKGRFIMWV VVSGCLHDGQFVKVISATAKAAAQHRVFCSDVLIAATHSGRLPDQTILLTQIQDQTAACVKALKN SEQ. ID. ABP10982 MKVEGIIPAILTPITKEQDFHPGVAEKLVNHLIDSGVHGIFALGTNGEFHLFSQEEKLQIAETVVKAVNKRVP NO. 76. VFIGAGENSTEATISLSNQMADIGADVLSIITPYFVAPSQKELYQHFRTISENVALPVLLYNIPSRTGVSLEPET VERLAALPNIIGIKDSSGSFDNIKAYLERTKDQSFSVLAGTDSLILDTLKAGGTGAVAATANVLPQTVVSIYES YKQGNIEESEQYQKQLDPLRATFSLGSLPAPLKKATELAGIDVGPPKHPIAELSGEGLQKVKKMLEGYGIETK LVKEQ SEQ. ID. ABP10983 MKTLYHFQTAARIEAGAHSLNFLGDHLDQTSGWNQIRSVFILTQPSIVSLGYADQIKEVLAEKGISSEINTDI NO. 77. QPEPTEQNIEEVFQLFSAGSHDAILGIGGGSVLDAAKILSVLKTNKKPISELVGTNLVEKPGVPLVLIPTTSGT GSEVTPNAIVTFPEKELKIGMVSPYLLPSLVILDPVLTIGLPKAITAATGMDAFTHALESYISNKANPFSDMFA LESMRLISSSIQEAYHHGDKLEAREKMLIGAMYGGMALTSAGTAAVHAMAYPLGGKYKMSHGVANSML LPHVTAFNADHVTDRLSDVAGVIGIEQKGSKASQAERVIQKIEEWTADLNIPQNLKAFGVSKEDVPTLAEA AADVKRLMDNNPKPMSVAEIEAVYLKLLEV SEQ. ID. ABP10984 MDVLSGSVITFILAVIVVYILFTTWLTMRFRSKSSAEFNNAAKTLPAIVVGILLMSEFIGTKSTIGTAESAYTHG NO. 78. LAASWSIVTVSIAFFIFSYFLVGKFYKTGQYTISGIISDKFGRSTKLVVSTIMIVALLLVNLGNYLSGSAAISSILG LPLMTCAIITAIVSTFYFTFGGMKGVAWVTILHSLVKYVGVLITLGVALYLTKGWEPMTQQLPEHFFTWDG SIGWGTIGAWFIGNMGAIFATQFIIQAITSSKSEKEAKRSTLYAALLCLPLAIAIGVIGVAARHLYPDIDAIYAF PVFMQQMNPVLSAIVATSLVASIFVGVSTVALATTTLIMDDFYVPKAKPTPEQRMKVTRYASIIIGFIPLLGV ALAPELLTLSFFTRALRTSIAVVAAMGFYLPYFNSNRGATIGLVLSGMATTVWYLLDNPFGIDNMYIAIIVPF VVLVLDRLISSPAKKESNVKEEF SEQ. ID. ABP10985 MKQSEVSLLIDGRIRKNETDEARKDAFLPTDCPQNHAANLLELDNGDLLCVWFGGTQEGIADISIYMSRLA NO. 79. KGSSEWTQIEKLSDDPSRSEQNPVLFQEPSGRLWLMYTAQMSGNQDTAIIRYRTSDDRGHTWSGIDTLFG EAGTFIRQPLVVLDNGDWLLPVFYCITLADVKWTGNRDISAVKISSDKGKTWEEVKVPSSMGCVHMNIEK LHDGTLLALFRSRFADSIYASRSIDNGRTWSEPEPTELPNNNSSIQFTALQDGTLALVYNHMKANETTERRA SLYDEIEDEDDTRTGVDTEARPAFWGAPRAPMTLALSHDGGVTWPVKRNIEVGDGYAMTNNSKDKLNR EFSYPSIKQGKDGDLHIAFTYYRQAIKYVRVPQMWASADQE SEQ. ID. ABP10986 MKIKVLGIAPYKGLGDLLTELAKEEQDIQFQLEVGDLRSGVAIAEQAVSQGIDIMMSRGGTASLIQKHVRIP NO. 80. VVDIPVSGYDLLRALTLIKDYQGKAAVVGFENITQGVRTISELFGIEVDLYTIKEEMEVWDLLRDIQQQGTQI VLGDVITDKAAKELGMQSMLITSGRESVKEAFHTAKQMYRLFKEASEEQRMFRDMIDQEEKGMLVIDDN SRVRFVNKMVKKWMKEGLLEPIAPAAAVNEWWDELAFAVQSIREGKLSGYFQLETGEVVWHMKGSFLS KGELLIAIEQSSSSRDDRNHPVWSFAAPVHSLHPFSSFTQQSSSMRDTVQQAQAFSQTHKPILLYGEEGTG KSDLALAIHQMSPRRQHTFMTIHCSKVKETSLLKALPAVQNGTIFLRYVEHLPLEVQHDLALQWMKPDQQ IRWLASSSADLCEEMKAGRFDPDLYSCLQGLTLYVPSLSERVEDMEDMSRLFIAEFNSVYGTQVVGLAPEV MDAFRNRTFRENVRQFKRVLEELALTVKSGYITLAEAAPQLDRLSNEKKEESLKGYTEGTLEDIERRIIQAVL QEENMNQSKAAKRLNINRTTLWRKLKE SEQ. ID. ABP10987 MTNIRCKKGANISRKILIVADDLTGANDTGVQFVKAGMSAAVLFDRSGANPGDIKEDVMILDTDTRGVSP NO. 81. SEAYKEVSSASHPFARLESHLFLKKIDSTLRGNIGIEIKALMDLGRFDVAVIAPAFPDARRITVDGMHYVNGL PVHETEAAVDPKTPVAESRIADLLFGQTNIQPKTIGTKQLHKPDEQIQQDLRAWKTQGHEWFVCDAETNE DLRRIVQVFMNSGQSVLWVGAAGLAGALAQHVRKRALQTGKRNEPVMIVSGSASNTTNRQLAYVREQR DLLDVRINPLNVLNGCEAWEHKRAIDQVVVHQGKDVLLYTDAKPETVQRIIAFGRKQGLDRQAVGEKLSL FLGAVTSEIVKLTGLKRLVLTGGDTARAICNELGADGIQLLGEIEAGIPLGKLLNADIYAVTKAGAYGQTDSVL RAVEVLRNVEEEDRWQNQSLR SEQ. ID. ABP10988 MAKPIIALTMGDAAGVGPEIIIKAFEQTNLHENGTLFVIGDYSILNRAKTFIGSDVDIVKINEPEEAADVKPG NO. 82. VIPCLDLQLLTDELRVGEVSAEAGNAAFRYLEKAIALANENQIDGICTAPLNKEALHKAGHMYPGHTEILAEL TQTKDYAMMLAAPNLKVVHVTTHVGLLDAIHLIDAKRVYTTIQLAHDTLIRAGIPQPKIAVCGINPHAGEN GLFGHGEEEEKIVPAVERAQSEGIQAFGPLPADTLFFRAVRGDFDMVVAMYHDQGHGPIKVLGLEAGVNI TVGLPIIRTSVDHGTAFDIAGTGKADPASLEEAVRQAIMLSGTRNRHA SEQ. ID. ABP10989 MEFYKKTAIITGASRGIGRAIAETLADKGANVVINGTNEELLKSMCTELNTERKCASYVAGDASLPETASLLI NO. 83. AEAKQQFGQIDILVNNAGINLRKTTVDTSLEEWKRVIDLNLTGIFLMCQAVIPEMTAQGGGKIVNMSSTTS KTPHHNASPAYGASKAGINYLTMHLAKELAAHRIHVNAVCPGPIETDMSKQWSEEYRAAVVERIPLKMIG SPEHVANIVAFLASDKSDFMTGETININGGTYMN SEQ. ID. ABP11306 MSPPNEAPIIPLDCGSLVTFQFSSISGMNWFVCQTHSLMELAFYYLRDRIP NO. 84. SEQ. ID. ABP11307 MKKLIENTENPRTTQSIKKDLEGLGLNKGMTVLVHSSLSSIGWVNGGAIAVIQALMDIVTEEGNIVMPSQS NO. 85. VDLSDPSEWHYPSVPEKWWDTIRESMPAYNAQYTPTTGMGKIVEVFRSYPEVKRSCHPNYSFIAWGKDK NKILNKQSLNFGLGEQSPLGNLYMDNSYVLLLGTDFDSNTCFHLAEYRIPFQKVVIKGAPVLINGKTVWKKY KDLEFREDLFEEIGKSFEIESDMKSGKVGSANCRLFSLKEAVDFAEKWFIEYDCKMNSRG SEQ. ID. ABP11308 MSNYRDYILKGKDVAVFEIDTDPISLDPAKCDDYIGQIISQAMFEPLFIRDIETEQWVCGAAENFEVSSDGLT NO. 86. YIFNLRKDRFWSDGISVVAQDFVFAFQRLFHPKINSPIGQILSFIKNGEEILNGVLPVTELGVEALGPRKLKISL TECLPFLPSILGSPNTSPFPYRTEQVSWTDERLNITNGAYVLKEYKSGQFVRLERNPFYPNSSSNHVKDVLFV INRELDYSLQNYEKGNIDVTCNTYFPFEEIKRFKQRDDFYMFPSGILFFLQFGNRNDLFKKKQARQALYYIVN KSQIAQTLHGGIIPWDHFASIGVSEKLFDDQSNYCYHPEKAVKLWKQEERENQALSILYADFFPNGEICHSI KSEMEKHLGITLTLEGCSFEDFVIRHEQREYDLCLALLSPLYNDPFNYFQYFLSELSEEDEDEFIDILQKALGDE KENHCTYYKKANDYLLEKLPSIPLFNGQSIFLKNPFLKGYKIFKDGSISIQNLSWGTEEKPKL SEQ. ID. ABP11309 MYKLADRIQIVSLHNGRIFLIDDEITELEGSPQHTEKALKLLEKGCMEEELNRIMPLEDTQKLLEFLKEEELLRE NO. 87. NWENEYLDTIVEKQLYYLDDFSIDSNQLQSNLKSAKVVILGVGGVGSVLIQHLIGAGIENFILIDNDVVNIHN LNRQFLYTQEDFGKPKVKAAENFMRKVNPSVKVTSYQTTIDSIKSLDFLASHSIDIFINAADYPKHLDKIVDE YCFERKIPWVGSGVGRHQGFWGPLFVPGKTCCLNCFIAEEEKEMKEIEKIIRERSNSIIQASFAPTNTIVSAFL AMDVIHFLAQINQIHSYLTRCQIDFTTLKLNRFTIDEPKLCNCGGE SEQ. ID. ABP11310 MLSKNYSFSLSISHLKSKSDNHQRVQEIFGVTDTQLNNRLIFKNITFLMHDVTYITGFSGSGKSTLVNLIKKDF NO. 88. PDAVIPTPPAKQDIPIIDLLDLELQESMKILGWVGLGEAYLYLTPYSALSEGQKTRFLLAMALSRNPSIIIVDEF LSNLDRITAKVVAYSFQKICRKQEIHLIVASAHNDLIEALAPDILIDLDLNGTHRITNRPIEKPFVPDISGVQVES GTIKDYEELKRFHYFGDEDLFVDNEFETEIFTIRLKEKCIGVSVMKSPYPKDWEEIDYFKDINDRIRCLVRLIIH PSFRTIGLSKLLMRPKFLDVPYIETRSALGLYMPIYLSGGYSRTELPDNKLSPLRQKLWNNLSFMGLSDVHLL RDDIYCENFVQNLSGKQKEALRYLALNVYVEMMVNNYIYFRSISKMIPLLPKEMDELKEMFLDVSDEIPVTV LLQETSLFKMQGFVVQHKQ SEQ. ID. ABP11311 MPLFSTNKNVSFIYLTSCFGNGFFERGIWMLFLIEKGFSLFQIGLLQAFVNGTMFLFEIPGGMLADRYGRKV NO. 89. SLLIGRFMIMSYLLIIMIADSFESLALSFCLLGLGMTFISGSEESLLVDSVKEQTGENNFSRFLGRYMAIITVALS LAMMIGGFLKEISWSLVFAVSFIFQMVAFFGCFFLKETKYKKGSQRESFTLIFKDTFNFLKTNNTSRTLIFGIA LFTGIGSIFYMFAQELFNQLGIKVYLISIFFGLESFLAAILADRAYILEKKFSSRGVMMVCVYLCGISFLLIYINFN WLILSFFIISAFYNLFTTISYSVINQDIPSKQRATLLSIISFISSLVMFISIPIFGYLSDKFGTAYLLSFTGVISMVLVA LSILSFYKNRKDSVEKHKLLKVQEK SEQ. ID. ABP11312 MEKKLSHHPIDRRVDLTYDEFMKEYGLPGKPVIISNAINNWEAKKLWTLDFFREKYGHIIVPIFESGKRYELY NO. 90. ETTLGEYIDYILKEEQEDGIFNLADWEFSRDCPELREHYQVPNYFQSWLEDAPISLLPALRWIYINQKNTGSG LHIDYGHTASWNAVISGKKKWILLNQNESENIYNGAVDAFNPDFKKFPLYTHSQTFYGEQSEGDIMYIPSG WWHQVHNEELTIAVTENFINETNYKNCLWPLVSNIVEYQLEISKTPEKVQKV SEQ. ID. ABP11821 MGGGLYGHRNIEDERLKEWIKTWKAENYIHFFCNYYGVGMNAEFNDSLAKQVELVIQESSSITVSKDRYLF NO. 91. DEVMKYMTPEMFYCYFRYDSSTAYCGNYYEVLIEFADELTKKKLIKGYDYVQTGGITLEKNGEVIGHIGQMS DLFWQTFYDQYIVEDYGAIEHARNNGKDITLQIWNDKVFENTEQFYKFIEQILFECNVNLGFGFKMSRFEN ESKLKGHTSNTKLCLSNIELEETPLRYFNFANYTKIPRHKYLAYYQVIEFFFTRAVRKARFPQPNELLIVKYIATN SITELEVVTWLDDIKSRGKHYTKPSEKYPALFPLEATEIVESVAKRIYLIRCSLVHSKEAPNDVNFIPNLNDEIID KEISLIKYVAEKVLYKWSNAPE SEQ. ID. ABP11822 MLESTYLQITDVIGKIIPADWSKIVLYAEILDGSREVYFFFQTPENDEYIYSHDIPEQFQVSKKIYTELLIDLQEL NO. 92. FKQLHNEFKENNPEAWTNLTLNLESNGTFSIDYNYDDVLSSELDDLQRRDVWKC SEQ. ID. ABP11823 MENELNALYRSIAETVNEMIPEPWEKFLFYAQVSETGGGTYFFYNSQNEPNHFKYSLEIPFEFDIDENEFDQ NO. 93. YEMELFKLSEKMRDVFKDHDQELFYSFTLSLERSGKLTVNFDYTDWFKTDYSFSDQUIWKFKYLGEEPKDP SLQKLIKKYLEEYPENPI SEQ. ID. ABP11824 MKVFEAKTLLSEATDRAKEYKELRTQMVNLRKALKSVADLSDSEFSGKGASNIKAFYHDHVGVTDQWIDYI NO. 94. DMKIAFFNSIAGAAEDKALSDAYIEESFLEHELANANKKSKSIMSEQKKAMKDILNDIDDILPLDLFSTETFKD ELADANDKRKKTLEKLDALDEDLKTEYALSEPNEQFIKSDFQKLQEATGKGKNATPIHYNAKAYRESDIHKK KGDIETRTEAYLKIKKEEAKEREIEKLKERLKNYDYADADEFYEMAKTIGYENLTAEQQRYFTQIENTRELEAG FKGVAVGLYDSGKDAVVGLWDMVTDPGGTVEAITGAMAHPIKTYEAISAAIEESYQKDMVNGDTYSRAR WVSYAVGTVVTSIVGTKGVGAVSKTGTAAKVTTKVKTAASKSATAQKAITVSKQTVDHIKQKVNTGIEVSK KHVKTKLNQIGDLTLADILPYHPRHDLVPAGVPYNAVNGVTLKEGLQKFAKVILPKPYGTSSSGRRTPAPHV PPVTVKYGEHYAKWSRKKVLKPNVEYKTKEGYTYNTDNYGRITKVEADLQLGEAKRNQYAQSNAGKPQD RLPDDDGGHLIGSQFRGSGELDNLVAQNSQINRSGGEWYKMETEWAAALKEEPPRKVSVRIRPKYLGDSL RPDSFEVIYRIEGKGLFKKFIKNQAGG SEQ. ID. ABP11825 MDKDFLIIKIKDIQKGDTLTNRACGNWDMKLSRAKECKRAIVVRSGVILNVYKIVDAWESDEPAKITKTNN NO. 95. RVRFQLAECRDYSYLIGGTLKTKTQNPVSSLSLETLMELVK SEQ. ID. ABP11826 MYLYKVNNQNQIEDIREKPFKKEKEIQDLCEANLQQMLGLGFVKSEFRISNFRIDTLAFDAETKSFVIIEYKN NO. 96. TKNFSVVDQGYAYLAAMLNHKADFILEYNENHDLPLKRDDVDWSQSKVIFISPVFTVYQKQSIHFKDLPIEL WEVKRYENDLIQLNQMKADGVSESIKTISQQSETIQEVSKEIKVFSEEDHLADKPFDIIELYQQLKEFIFNLDD HISIKPTKLYIAFTSNKRNFTDILLLKSGLKLWVNMKKGELHDPEERMRDVSETGHWGNGDYEIFIKDEENIE YIMGLIKQSYEKNK SEQ. ID. ABP11827 MKKRFILLGLFASVFMLAVYISFQNKNTHPVQSPVIHPEEDRIFFIYSNLFIKESVLLSTSTGERFNRRTFKVAD NO. 97. VPYIQMKSYKSTDLVLLAEHEPFYYTLEKDAIKEHPLSDPFAFWHEGKDVSVKAYNVDTTGNEIRINDKKMK KEYTLTLPSLVTMGASDENYIYIIQSMAIYVIDRKTEEMIETLSLASYADQFADSKEFIVASSEHELTVIEKGTW KATYIAYPEDLEYADTVYYDKESGSFYVTYEDKKGEANLLEYGKEFSFHTYSLNFPYMEAKFKGNLLYIVAQE EHKKGIGGYVGVFDIHSKKMLYQFDLPEEQVKVQDFVVVD SEQ. ID. ABP11828 MGGSYLSDLCSMYQKDKFFTGFVPDELLTYACELFPLSEKETVTALLNCSMGNKAKSFVMFTSKGLYWKRF NO. 98. GEQEGCVTWEAFTDIQSIKSTDDYEIWFEGEEVFDVGFSSYPADLLAELLRMIQQFLSENGSDLLTEAWRD HVSVSASELKEISTLFQNSHDKMFGLTNGLLVGNEISEKREVRLRKRLHIPKDQEMISFWSTFPVKQTDGITL TDKGIYFSDPFLRLFYPWHVFKETPVMLKDQELIVGKENVIQLLENLMPAEDVFAFIEQVKRRISAVTS SEQ. ID. ABP11889 MLRKKGQETKDYKTQQVESWGLRLIGKNEKIEKKSNISIAILDSGIDSNHEDLKGVVKKEYNALEPSKGVIED NO. 99. KFGHGTAVAGIIASNDNKIGTLGIAPYADIYSVKVLDDKGRGSVESIVKGIEWSIDNNVDIVNISVGLKKSDQ KLKRVIDEANEKGVIVVAAAGNNYGLNADYPARYQNVISVGAINKKMKRAKYSARGKIDFVAPGEDILTTS PKDNYINVSGTSMATPFVSGVIANIIMQEPVKYSKTKSRFTSIYKTLKKYSTPYLSEKSDMKSLGNGLISLKKE TNNEKIN SEQ. ID. ABP11890 MKKSIKFIAISLIFAIIVSIIPEKNVASAGAETPVEITNEDLQRALVENGDIVDPDSVEIVKNNEDTIKAEVDVQT NO. 100. DDFGIDQDLDGSDSESLIDEDLDESSSETVTAEVDKEDATAIVTSVEKDEDGKDIEKKYEVDIEEADGDDIVA TFKDLDTNQVYDVNTKEAQASFAFLVPIAVVVGGALVEHLVAASLAIVIAGVTYTVATKVRSKLKKKKKYYY YAATLNKNKTNMYIGPALSKKQAVSRLRKGDVWSVSKSKAKNVAQTAGGGRKPVGPEIHNKKDGKIKKG TYYYHYHTYNRKGGHSFY SEQ. ID. ABP11891 MWESIQNGKRVNKIFESKDGNYISNFTVQGNVEKIEKELVFIRGILEKEKNN NO. 101. SEQ. ID. ABP12521 MKLIYPYGADKIYLGNPVELFRDQDTGDYIIPKNATDIPPELNGEGMWRPMFNEEKQTWIETADQAYKKS NO. 102. LLEDVPSESNPTNDQLSALGKQLTEEKLARIQADQAQKALGMQLTEEVIARKEAEALSQSLGKQIAALKLDL LNLKGGMTSES SEQ. ID. ABP12522 MSLNFWVYALFYKWATTSMVREAMMFHDCSVDDLKEGVSEKYVTLAQFKEITDQTYEETMKAN NO. 103. SEQ. ID. ABP12523 MSELSEVPDMNLLEKEITEIKTEQKTLEQRVSVLERSSDRQDQQIMTLNEKLNKIEENTTWIKRTITGAIITAV NO. 104. STGIIGGAIAIMYSLLQH SEQ. ID. ABP12651 MKLEQQEINILHSDSGPYGIAISPEGKVWFTQHKANKISCLDRTGQIQEYIVPTPDAGVMCLTVSSEGDIWF NO. 105. TENRANKIGKLTAKRQFIEYPLPHQHSAPYGITEGPDGDIWFTEMNGNRIGKLTSEGKIHEYELPNEGSYPS FITLGSDHSLWFTENQNNAIGKITESGELTEFPIPTPAAGPVGITKGHDDALWFVEIVGNKIGKITVSGDITEY DIPTPNARPHAIAAGVKSDLWFTEWGGIKSEG SEQ. ID. ABP12652 MVYRMGGNKIGRLTSDQTIEEYTINTPHAEPHGIGCDNDGTVWFALECNKIGKLKLTK NO. 106. SEQ. ID. ABP12653 MKVKEKRIVVNKFPSQPDEEDCRNLTLLGWGSGGFFLFLHTFR NO. 107. SEQ. ID. ABP13703 MKQRKRIIQKDRRKLLKYFNAKFTAEERAMESLFCEKTSQSSSNVLLND NO. 108. SEQ. ID. ABP13704 MKTKSEPKVILEPAKESDLPEFQKKLQEAFAIAVIETFGDCEDGPIPSDNDVQESFNAPGAVVYHILQDGKN NO. 109. VGGAVVRINSQTNHNSLDLFYVSPEYHSQGIGLSAWKAIEAQYPDTVLWETVTPYFEKRNINFYVNKCGFH IVEFYNEHHSDPHIHRNGRVDDKPLPDNDDFFRFVKIMKKKD SEQ. ID. ABP13705 MPLTLIWRNFEFSEKFLGTYADNVLKVLQEAQEELEDEFKIIVE NO. 110. SEQ. ID. ABP13706 MSLEEQLQSKEEELTKLVSTFAAKEGTNETSISGLEFIRSAKPLMPVHTMHEPALCIVLQGRKVISIIGEDFFY NO. 111. GKGEYLVVAVDLPVIGEILKASEREPYLCLRLNFNLMQIAEVSKEYQQHSTNHNAAGRGIFVDQTDGVILDA LIRLVKLLHTPEDTEILAPLIIKEILYRIMQGKHGHTVKSLVAKGSKLSEVAAALDYLRNHFSQEIKIDALAKKV NLSPSALYHHFKQVTMMTPIQYQRALRLHEARRLIFGKDMRVADAAFQVGYESPSYFNREYRKMFGKPP GKDRKENLNLYYV SEQ. ID. ABP13707 MEKNNHSYGGLWVTKDRYIRHELLSNGRYVEARGNVECAYTGNYQITGDRIEYQDDAGFTADGDFINGIL NO. 112. YHAGMVLHRDRS SEQ. ID. ABP13708 MSIKNKVVLVTGGSSGIGAATVDLLAENGATVIAAARRTDRLETLVTTLQQKGYHADYKQLDVTDFGQMQ NO. 113. QTVQEVTDAYGKIDVIVNNAGVMPLSKLDSLKIAEWNRMIDVNIRGVLHGIGAVLPVMKEQNSGHIVNIA SIGAYEVTPTAAVYCATKYAVRAITEGLRQEATHNIRTTLIAPGVTESELADHITDKQASEAMIEYRRQALPA SAIAHAILYAISQPIEIDVSELIVRPTLSL SEQ. ID. ABP13709 MRRIDFGLTFLICTLIMLFNEIWKLLGNRPEAFKYGSIIYQVIAVFSSIITNVAIGVAGAISFYYIAQLIDKKKNRE NO. 114. LYTDLRKHLLFMFYNHLKLLTRLDQFREVNNRERRVADFYDIFDIPVFYDNFKKINSKEEVTRFKKNLYDYFA TQSEQQIKVFTEAFEKDIKKLKEKSNIRFFKESKDLIDTVCIIYDDDFSMISSIYLSNFEDTQNKSNYIEELVKDY YDFLNATVILYEELEEFLESMDKNRWVVFIKMLD SEQ. ID. ABP13710 MENAQEIYELVKEMSKTVKEIDETTKRIENTTKRIAKGYELITEELAE NO. 115. SEQ. ID. ABP13711 MTYRVGSMFAGIGGTCLGFIQAGAEIVWANEIDANACITYRNYFGDTYLQEGDITQIDKSTIPELDILIGGFP NO. 116. CQAFSIAGYRKGFEDDRGNVFFQILEVLEAQRNVYGRLPQAIMLENVKNLFTHDKGNTFRVIKEALEAYGY TVKAEVLNSMEYGNVPQNRERIYIVGFQDENQAEMFRFPEPIPLTNQLNDVVDRTRRYDERYYYDETSQY YEMLREAMVSTDTTYQLRRIYVRENRSNVCPTLTANMGTGGHNVPLVLDYENNIRKLTPEECLLLQGFPA DYHYPEGMANSHKYKQAGNSVTVPVIRRIATNIINVLNGETNANDEQEHQYAITQ SEQ. ID. ABP13712 MIPFLGNRIQNAREARGLKPSQVADKVKVTRSTYSLYESENRTPSLETFIRIAETLNVSADYLLGLKEEMTSL NO. 117. NEEEN SEQ. ID. ABP13713 MFFTNQPASNRTTYKQMLSSTGSLSNLFSESDSPYLVSRNVENAFCEALGAENLGRSDCSADASKDRVGIG NO. 118. IKTFLHGNGHTLQKVAEFNRDSDLYRGKSPKELINIVATLRNERIEFTKRTYGIDTMIYHCVTRKPGKILIFEEP MDLVQISSITNIKVSNNRNTITFEDGLHEYSFNVTKSTLYKRFITDEPIEEIDVEILENPYQELAKLFGFEIAPIQ VPEVSSPIENFEYVILPLFSDRGNKRHVPEKSGLNQWNAAGRPRNANEIYIPIPMWIHRKFPEFFPARDKPF QLRLPDKSLLSAKVCQDNSKALMSNPNSALGEWLLRQVMNLGERELLTYEMLERLSIDSVIVYKHSEQHYSI DFREIGSYDEFENENN SEQ. ID. ABP13714 MTDTFSKEQRRKNMQAIKSRSKLEDKVTKELWNRGIRFRKNVKGLFGKPDIAIKKHKIVIFIDSCFWHACEK NO. 119. HGNKPKSNTEYWEKKLQRNKERDREVNKYYEEKGWNIKRIWEHELKEDFDETINRIIAFIEAVKHEQRK SEQ. ID. ABP13715 MLKIKKLDFMPFFNRMICFVDVKNPDEADKKALAKDILENNKDQYQGYD NO. 120. SEQ. ID. ABP13716 MKFIELDPALQIKVRQLEANAEEHQDKSHPDVRALWLELQKEDSICGALSEKDGSYKVCLRAPVEERNRCS NO. 121. LHGGKTLKGEQMTPAQKLNMMKNLRPRVVEHCWYAEESNFLASLTESEIKYMSFLEKSVKDQYHVNDGL EELLLEDILQSAIIHMRMVNRGVFEKGSRHTARPLQEVLKTIKELGWTCKEKGGKVQFVSVRNDFMASIFG NNTEEEEEDKKLN SEQ. ID. ABP13717 MSLKEKLAELNKRAGKLEGSLKKASKKASSEADRLKKKRQEREYYDAYEKKFPIDKNF NO. 122. SEQ. ID. ABP13718 MKKDWFSQRLELINKEQKLNEEFNLWKLQQITKRMKEVTKKLDELETERV NO. 123. SEQ. ID. ABP13719 MGLFNKKSEMVKFEEELNVVQGSIREVEAELRDFDTSKKGIELELKLGADSSLTKRLKKVSEKVAETEKCLAE NO. 124. LRQREGEINAEKRTAYLNELADKDLASIDKGRRATVIKYELQALMRVVDERDGRWGYSKPENLLKEYGIEIG HIPAEHLRREEFDSFWKTRKNDAEKRIQNECQEAIETLKKYLGGFDK SEQ. ID. ABP13720 MESKVNMLRILEFYMGETGNFKKLVVIQEIYRNNPSKMKGCELSFLKDNKFVAKGFFEAETIMVRNSFHSY NO. 125. NSELPELKEHHFKKMEKRDQDSHYPVSETTVLYLSGYVFAEFKFHKIANDKKIGDKVYLPIKLDDKQKPDSN EFCKLLVLEEYRDGTFELPELPKRAEMFTCWVRLELAPDSKNDSGVKVSEREFNKARMGEIKGNIA SEQ. ID. ABP13721 MSEDVKKYFTTGEFSKLCRVKKQTLFHYDEIGLFSPEIKKENGYRYYSYHQFEIFQVISLFKELGVPLKEIKCLIK NO. 126. GKTPDKILHVLKEKSIEIDKKINELKQLQTILQTKVTLTEQALETDFSSISFEYLNEETFMLSRKTLNLPERKYVA AISELIHEVQQYELDEGYPIGGIFAREQILEKDFYNYSYFYIKVKDGAENINYHVRPKGLYAVGYEIGGKTEEA YRRIIEFIERNGMQIGENAYEEYMLDEMVVDGYENTYAKILLQVKEV SEQ. ID. ABP22957 MREKKLGPVLLSGLIVGPILGSGIILLPPIIYGKTGDYAILAWFIMMIISFLFASLFGKLSVLFPNESGVAHTVEL NO. 127. AFGQHIKQLTSVFFIIAGSVGPVAVLMTASQYLKALFKSNGWSLETYGIILMMICLFVLLSNISSVGKVSFMF STVSTVVLLSGGISSIPFMRDKAFIKTPFHLDDFGYSILLLFWALVGWEIIGNYSLDVKNRKRTIPQAIVISSVVI TTVCIVVAAAYQWIDLHHTHTLTIILIPLLGTSFASPTMAFITTILCMSTYLLVTGGVSRLIASENKKITLISYRSK TNIPIGAISILTLVHAIVFILLFINIINVEQIVGMANAFFISNAICGILSAYKLLPGKFSKSLSLMLIISFLIILSFSSIWI LLMIALITTFYLIRHFIWIRQLKKSATNSQDKLRF SEQ. ID. ABP22958 MEIRHLKTFITIVEKGGFTKAAEYLGYAQSTITSHIKDIEQEIGGPLFNRFGKKMLLTEVGEYLLPYANEMIRIS NO. 128. EKVKQIQSNDEPMGNLVIGAPESLTVYRLPPIIHEFKKLFPKVKITLKSSTCWELKDDLRNGKVDLAFLLEYEQ EEADLYIEKLITEPMILVFPKQHKLQNTPFDDFYFSSDEVILYTEHGCSYRTYFEEYMKHQGLVSENTFEFWS VEAIKQCVMCGLGISLLPLITVQKELKENKLSGLIMDETRIITQVAYHKKRWNSLAMAEFINIVKKHAELWK RTQTL SEQ. ID. ABP22959 MNPLLLDVPLQLETERLILRAPHQTGDGKIVNQAIRDSFSELKAWLPFAQELPTVEETEINLRNAHINFLKRE NO. 129. SFRFLIFDKDSNDFIGITSLQRIDWNIPKCEIGYWVNTKYSGNGYMTEAVKKLANFGLHNIKFRRIEIRCDST NLKSRAIPEKLGFVFEGTLRNDDLSADGSKLTDTCFYSIVK SEQ. ID. ABP22960 MVDQLWAYFLNLIEEAIETGKSETYFPDQPLLLKMKSISNDMLLFEIDQKQKVLLPKLDFFESLLKNAKSFFE NO. 130. TMNFVLEGNCDYEYELNKIDELQTKIKCM SEQ. ID. ABP22961 MKVFEAKSLLSEAENRAKDYKELKNQMIKLRKAFKAVADLDDSEFSGKGANNIKAFYHDHVGVTDQWIDL NO. 131. IEMKIAFLTSISGVLEDASLSDAYIEESFLEHELTNAYKKSKSIMSEQKKAMKDILNDIDDILTLDLFSTETFKDE LSSAENKRKKTVDKIGDVDENLKTEYAITEPNEQFIKADFQKLQESTGKGKNATPLHYNAKAYRESDIHKKK GDIEKQSEAYLKIKKEEANKCEIKDLKKQLVKVTDPDEYLKIAKKIGYENLEPEQQVYFRQLEELQQKAEIGKG IAMGMYEAGKDTVMGLYQLARHPIESLSGTVNAALHPIDTYKIIAKDIEDTFQREMINGDSHSRAKWVSYV GSTVVLAIVGPKGIDKVSKVAKAGSKVAALKTLEVSKTGIKKGIEYVKIPSVFEQQFAMAGGSGTFPFNVLD GENYKNSALEIFKNSSTVQGLKKAKPHEVVNELKTFQSRKYTFGGQSFLIDKRGMKHILERHHPNLWDGSI KSQQSFLNKEMTVNDVADAIESIMKQNREELTKKGTKFSYQIRGSYEGQQYVVGFQKGRVGQFYPEK SEQ. ID. ABP22962 MVQEVMVMKKDFGDSISNKVYEYRVLARLSQQELAKKVGVSKQTIFVMEKGNYVPTLLLAFRIAEFFKVD NO. 132. VNEIFTYEKGNDQK SEQ. ID. ABP22963 MNNKKNIFDIVMYIIFGVLSLFLVAKTDYGTGVLVFVAILYLAVIAYKIKQVFSNSDS NO. 133. SEQ. ID. ABP22964 MRKKRVITCVMAASLTLGSLLPAGYASAKEDSKTTPSYEELALHYKMKSEKISSNGKLVEIEYVSGNETHKV NO. 134. QMNGNNHTVKVDGIEQKGLNFEYDENVAKRTNYENNNLKSNEFTTQAAKPKKGYHYVGTLSGHTKAAK NALSVTMSLVGIVPGLGWGSKAATILFSYWAKEQIPDAYYKYDLYEKGAMTDSWYQYATVQFLKIKLIKRK WANLGQVLLQK SEQ. ID. ABP23145 MKNFDKGTVVRTVLLLIALINQTMLMFGKSPLDITDVQVNQLADALYTAGSLIFTIGTTLAAWFKNNYVTA NO. 135. KGHKQKAILKQNNLTK SEQ. ID. ABP23146 MTIAVKKNLVSEAKYALKCPNPMTAEYITIHNTYNDASAANEVSYMIGNTSSTSFHFAVDDKEVRQGIPTD NO. 136. RNAWHTGDGTNGPGNRKSIGVEICYSKSGGAKYYAAEKLAIKFVAQLLKERGWGIDRVRKHQDWSGKYC PHRILSEGRWNEVKAAIDAELKALGGKSSSKKTTSSKAVKKPSSSKKKSSFNLPSGIFKVKSPLMHSAAVEQI QTALAALHFYPDKKAKNFGIDSYYGPKTADAVRRFQLMNGLKADGIYGPATKAKLEALLK SEQ. ID. ABP23147 MKRKQTFIFSMILLSVASIGLRSFWTNPFTTGVMIFVLALTIYAIIKDLRRR NO. 137. SEQ. ID. ABP23148 MEYHLKSRQEVEDFIRHEVLTTKEAAELLGVNRQRVSQLISSGKLNPIKKLSGISLFLRTDLEEKKKELEAGRK NO. 138. KYRPYDE SEQ. ID. ABP23149 MDEGTYNIDIVGFHGTSLESAQKIITEQNFTSGDIRNDHWLGQGAYFFREDPEQAKIWAKNKIKGSETAVI NO. 139. KTIVSLDNNSFLNLDTRSGLNYFNRYIKTEVKRKILEEKAEIELTTDDHSKIKHIYRCFFCNELPTNIKAIQRTFF VQSTLNEDETFKKMDVFVQGVQVCIRDLSVIDFTKTGINNVINMHTFRRRKKTKQKENYRKDVMKMRRE FNNPELIKDAENLGIKITLNSSEPGVFANVNGERYRINIDDLFSECDDDLYYHEDFKLDDFSITRDSNQHKVEI IKEEKNFYKNELVEAA SEQ. ID. ABP23150 MKSFFQFDDYNIIDVNYKFNNNFEGDEAVLSPIFDFELEFEDETKDEADLILGIELGIRI NO. 140. SEQ. ID. ABP23151 MTDFERKVYQIIVNMHLYGKNPTLDDLKRKTGKSKEDIRTAVKSLLMEGELKWDKQQKKWII NO. 141. SEQ. ID. ABP23223 MTDSWQNGFIEKINRNGNNGGLRKPQYGALSAIRAHWTISSKPATIVLPTGTGKTETMLATILSEQIESVLII NO. 142. VPSNLLRDQTFEKAKSFGILPDLKMVGKNILYPNTVLYKTRIKDETEVWEWFSEANVIVSTVNAVNGLSTSIL NKLVEKVDVLMIDEAHHIAAGGWSSLREKFLNKRILQFTATPFRADGKKIDGDIIYNYSLSLAQKDGYFKPID FYPIEEFNEELGDIQIAEKAVELLNKDLEDKYMHQLLVRANSKKRAEELYNKIYSIYKKFNPVLIISGQSKKNKE NLKKLREGIAKIVVCVDMFGEGIDIPNLKIAAIHDKYKSLPITLQFIGRFARSKSGIGNARIVTNIANDDLKDAL QSLYSQDADWNQLLSMHSSDAIQTEISHRKFINQFYSNDNINIDISQIKMRISTRVFYLGGVHWNRKGWR SVLNVDKTEFFINEESSVMILIESIESQVDWSDQKDISKYNYDVFIIYVDKKNKLIFINETNASKGNQLIKYMFS EANQISGERVFRVLDGINQLMIGTLGLKEQPSGRISFRMFAGTNIKDGINQVARASTTKSNLFATGYKDNN KISIGCSYKGKVWMRWVDSVVFWRKWCQKIGSQILDSSINTDYILENSLQSEEITEYPRGIPYKIQMPVEFE LSNSELKAFYIPNEDKEIPFYLCEFNNPRLDGKQLLFELWINERKYTFSQTLKERGFVINRILGKDIKIKKSRNM ITVEEYLQDNLPQVTFFNEDGSLSIVEGNLVVNKKPLAEVLFPKEKLHIVDWKKLKVDITIESQGLTKLNNSIQ YASIKNIVPVDSLIIFDDDNSGEIADIVCISTNEEHRKITVQLYHCKYSHGTNPGARLLDLYEVCGQAERSITW NDSMVELLKRMRFRENKRINENKTSRFEKGNLSDLKTIENQIRSGFETEMKISIVQPGVSISNISQQMNQLL LATDTYLKETYGIDLNCYFSK SEQ. ID. ABP23238 MSQAIPSSRVGVKINEWYKMIRQFSVPDAEILKAEVEQDIQQMEEDQDLLIYYSLMCFRHQLMLDYLEPG NO. 143. KTYGNRPTVTELLETIETPQKKLTGLLKYYSLFFRGMYEFDQKEYVEAIGYYREAEKELPFVSDDIEKAEFHFK VAEAYYHMKQTHVSMYHILQALDIYQNHPLYSIRTIQSLFVIAGNYDDFKHYDKALPHLEAALELAMDIQN DRFIAISLLNIANSYDRSGDDQMAVEHFQKAAKVSREKVPDLLPKVLFGLCWTLCKAGQTQKAFQFIEEGL DHITARSHKFYKELFLFLQAVYKETVDERKIHDLLSYFEKKNLHAYIEACARSAAAVFESSCHFEQAAAFYRKV LKAQEDILKGECLYAY SEQ. ID. ABP23224 MSKIPPEKYYEACITYHLVNYFEFTLEKKIYPFSISQIEEKKEGYDFGYKMSEKSFFIQYKRPYKVIPKDTYHWKI NO. 144. EIEQLKTINRKANNINTYYALPSFGDSMGWYEALDNTFFVNSRSLEYQIKQINRGRNIKTTFISPEKILLDKFY RISCNIVGDLHSVAVSQKNINSKIGNITNYIKGLNEDVKSSTWLYILEED SEQ. ID. ABP23225 MKYENVEVLGSYSVREGGSINFSMGKNLELGTEINTYIHELFHMHLTNYSSLGFLLLLFEKECNLSLEYQDEL NO. 145. HYNQIKELSTIIFNRTVDVQEVYANNQELLWLENNINSEFKEKSFKLKPKKYQEYCNKLNIITNDMRLNNEEK RYWIDRVCFYALNIQIFSDKFIEALKSRQKLSEYLSRNHPNKRLDEALVKYSKNEKFDGVVEIRIQDILSKIKKIN IIKYFNEILSQLEPNATNFKIGDYLCENDIKKFIELNQKRMDERVKLFDFYNLDVIKVDDISNHLNFGIFAIKNY ESTINKENFYYITEALINLTPSYISEEVSYDFLNNPKIKVIGIPSQEFDIAKMKPNYIEVKDTPIVVLIDSYNTAKKI LKVLLNGELYVGDLYEQTVKNFSTILFFRERTEPKIIYIFPTLKKMSIRLVKELGIEDILVYSKDTRFKKILSIFNCE VEMLKFIKWIFSFIMKSSCIFTSIGDPATKMSFNLTRSLFDDVMKIKIPNYYIHWAALPTKKTIGEPFYSLMEF ENGENIGSFKATNQNTIIFFLNKNDAVNYRKKIFTTDSMAHKLEVVGIDRHYWNIIEKYILETGINICICTDVN NNIGKIMKLKEVDNIITQFSKV SEQ. ID. ABP23226 MKFKLTLCAVIALIGVSFISSSLGNEVNVASRNMTSKAANDSTNSLADKAIFDKEMTIAENGTLG NO. 146. SEQ. ID. ABP23227 MRSLGTISSPHVGMKINEWNRHIQKFNVTDAEMLKAEIERDIDIMEEDQDLLIYYQUAFRHQLMIDYVIPT NO. 147. EGNQMELSEYLKRIEGSNRKMEKLVEYYYYFFQGMYEFKEGNFLSAITFYQKAENTIPYISDEIERAEFYFKM AEVFYHMKQTHVSMHYSSQAYNIYKTHDLYSVRRIQCHFVIAGNYDDLESHEKALPHLEQALKGARLLESK NKRIYGQALFNIGNCYLKMGELTKAAKYMEKSIFQFKKSNFNNLTQAYHDLALIYFLQHKQEQAMDCFRK GVRFACKFDDDLFKIMFEGLQTLFIKKGEASILLNVFNKLETSQGYPYMEELALLAAKFYTEIGQMDDSVICF KKMVHARKQIQRGDCLYEI SEQ. ID. ABP23228 MTVREELIKRNPTPIMKNILKRYEEAKEFIQHSTKEQFEEDLSRVKNKLDTLTRAYLESANDYMNPMLREMY NO. 148. KTEKLLKEYDETASVVITAIQSSKVEIVLPSQNQI SEQ. ID. ABP23229 MDLFEECIEALKDPKEILSDELTEQYFETLNNKFPITSWARIDWDKVPQKESIETYDDLYNWLKFQGIVDTTI NO. 149. NLLWNPSDVPVVRTTLENALEVLDDVLAVGSDTFMYSDHGFVIEFFHDGEVTIGRSE SEQ. ID. ABP23230 MAQLFTAGLFLFQIGLAIMETEKGLLYKKSAEQFNNLLLLNEIRLTYTLKF NO. 150. SEQ. ID. ABP23231 METEKMGQLYQQIAEQLNEMIPSEWTKIVLYAEILDDSSEVYFFFNTPQSEEYIYSHDIPKQFDVSKKIYVSL NO. 151. LIELQELFEELREEFKANNQDTWTNLTLKLENTGKFSIDYDYTDVIASDLNGTQRQVVWEYKNLGILPEDKE DKDFVINYFSL SEQ. ID. ABP23232 MVMKVFEAKTLLSEATDRAKEYKELRTQMVNLRKALKGVADLSDSEFSGKGASNIKAFYHDHVGVADQW NO. 152. IDYIDMKIAFFNSIAGAAEDKGLSDAYIEESFLEHELANANKKSKSIMSEQKKAMKDILNDIDDILPLDLFSTET FKDELADANDKRKKTLEKLDALDEDLKTEYALSEPNEQFIKSDFQKLQEATGKGKNATPIHYNAKAYRESDI HKKKGDIEKRTEAYLKIKKEEAKEREIEKLKERLKNYDYADADEFYEMAKTIGYENLTAEQQRYFTQIENTREL EAGFKGVAVGLYDSGKDAVVGLWDMVTDPGGTVEAITGAMAHPIKTYEAISAAIEESYQKDMVNGDTYS RARWVSYAVGTVVTSIVGTKGVGAVSKTGTAAKVTTKVKTAASKSATAQKAITVSKQTVDHIKQKVNTGIE VSKKHVKTKLNQIGDLTLADILPYHPRHDLVPAGVPYNAVNGVTLKEGLQKFAKVILPKPYGTSSSGRRTPA PHVPPVTVKYGEHFARWSRKKVLKPNIIYKTKEGYTYTTDNYGRITSVKADLQLGEAKRNQYAQTNAGKPQ DRKPDDDGGHLIATQFKGSGQFDNIVPMNSQINRSGGKWYEMEQEWAKALKEEPPKRVNVNIESIYKGD SLRPTKFIIEYTIGNKTKFVTIKNQAGG SEQ. ID. ABP23233 MDKDFLIIKIKDIQKGDTLTNRACGNWDMKLSRAKECKRAIVVRSGVILNVYKIVDAWESDEPAKITKTNN NO. 153. RVRFQLAECRDYSYLIGGTLKTKTQNPVSSLSLETLMELVK SEQ. ID. ABP23234 MYLYKVNNQNQIEDIREKPFKKEKEIQDLCEANLQQMLGLGFVKSEFRISNFRIDTLAFDAETKSFVIIEYKN NO. 154. TKNFSVVDQGYAYLAAMLNHKADFILEYNENHDLPLKRDDVDWSQSKVIFISPVFTVYQKQSIHFKDLPIEL WEIKRYENDLIQLNQMKADGVSESIKTISRQSETIQEVSKEIKVFSEEDHLADKPFDIIELYQQLKEFIFNLDD HISIKPTKLYIAFTSSKRNFVDILLLKSGLKVWVNMKKGELHDPEEKMRDVSETGHWGNGDYEIFIKDDEHI EYIMGLIKQSYEKNK SEQ. ID. ABP23235 MKKRFILLGLFASVFMLAVYISFQNKNTHPVQSPVIHPEEDRIFFIYSNPFIKESTLLSTSTGERFNRRTFKVAD NO. 155. VPFIQTKSYKSTDIVLLAEHEPFYYTLKKDVIKEHPLSDPFAFWYEGKDVSVKAYNVDTTGNEIRINDKKMKK EYTLTLPSLVTMGASDENYIYIIQSMSIYVIDRKTEEMIETLSLASYADQFADSKEFIVASSEHELTVIEKETWK ATYIAYPEDLEYADTVYYDKESGSFYVTYEDKEGEANLLEYGKEFFIHIV SEQ. ID. ABP23236 MYIVAQEEHKQGIGGYVGVFDIHSKKMLYQFDLPEEQVKVQDFVVVD NO. 156. SEQ. ID. ABP23237 MGGLYLSDLCSMYQKDKFFTGFVPEELLTYAYELFPSSEKETVTALLNCSMGSKAKSFVMFTSKGLYWKRF NO. 157. GEQEGCVTWEAFTDIQSIKSTDDYEIWFDGVEVFDVGFSSYPADLLAELLRIIQQSLSENGLDLLTEPRIDHV SVSASELREISILFQNKHDKMFGLTNGLLVGNEISEKREVRLRKRLHIPKDQEMISFWSTFPVKQTDGITLTD KGIYFSDPFLRLFYPWHVFKETPVMLKDQELIVGKKNVIQLLENLMPAKDVFAFLEQVKRRISAVTSS SEQ. ID. ABP23502 MFVLLLYPKQSLLIHYSSKAEKGRTLFILFLASTLNI NO. 158. SEQ. ID. ABP24563 MFNGKHLKVKACFKSNAFLIIIKESVYIFISPLPDDAFRTP NO. 159. SEQ. ID. ABP24564 MDQREKMDTAGGNTSCKHKKFFRKITIISTFGGLLFGYDTGVINGALPFMAQRDQLDLTPFTEGLITSSLLF NO. 160. GAAFGSLAGGRLADRIGRRKTILNLAFLFFIATIGCSFAPNTSVMIICRSLLGLAVGAASVTVPAFLAEMSPAE QRGKTITQNDLMIILGQLLAFTCNAVIGTSMGEYAHVWRFMLILATLPAIFLWFGMLIVPESPRWLASKGK VGEAFRVLKHVREENCAKAELTEIKASINRETEINRATLKDLSVPWIRRLVGLGIGIAVVQQITGVNSIMFYG TQILQKAGFARDAALVANIGNGVISVIACTFGIWIVGKVGRRPLLLTGLAGTTASILLIAICSITLQGTPVLPFIV IGLTITFLAFQQSAVSVVTWLMISEIFPLRLRGLGMGISVFFLWMMNFLIGLTFPVLLDQLGMSSTFFVFVV LGASAILYVKKYLPETKGRTLEELENDFRSNQGVRKASSGKGEINM SEQ. ID. ABP24565 MINGEKKVDRPIRWAMVGGGRGSQIGYIHRSAALRDHHFQLVAGAFDINPERGKDFGMNLHVTPERCYL NO. 161. DFQQMFEEEAKREDGIEAVSIATPNGTHYEICKAALNVGLHVVCEKPLCFTFEEAKELENLAKKKNRVVGIT YGYSGHQMIEQARQMIANGELGDIRIINMQFAHGFHSDPVEMNNPSTKWRVDPKFAGPSYVLGDLGTH PLFLSEIMIPELKINKLLCTRQSFVKSRAPLEDNAYTIMEYDNGAVGTVWSSCVNAGSMHGQKIRVIGSKAS IEWWDEQPNQLRFEIQGKPVQILERGMGYLYPEALQDDRIGGGHPEGLFEAWSNLYSRFAVAMEAADR GKELEHMWYPGIEAGVGGVRWVENCVRSADKGAVWVDYQ SEQ. ID. ABP24566 MSIHIAGAPCCWGVDDPKNPYLPPWERVLQEASQAGYKGIELGPYGYIPMDIERVQAELLKNNLSIIAGTIF NO. 162. DDLVSESHLGNLLEQVDEICSLITKLPFSFQDKEERFRFSPPYLVLIDWGHDERDYKAGRPDQAKRLSKKEW NRMMSHIRTIAERAWKQYGVRAVIHPHAGGYIEFEDEIQQLLKDIPYDIAGLCLDTGHLYYSKMDPEQWL RDYADRVDYIHFKDIDEHVYQQVMGEHIRFFDACAKGVMCPIGQGIIDYEAIYKLLKDIHYHGYITIEQERD PRNSDTSLRDVSQSLAYLKNVGY SEQ. ID. ABP24567 MEKEVFSKMKTTIYDVAEKAGVSISTVSKVINHQPVGMKSKQKVLDAMQELNYKPSVLASALTGKRTSTIG NO. 163. FLLPDIANPLIAEMARRVEDRAHEYGFNVVICSTDFKSEKEERYVSLLRQKRVDGFILAGGFRNKQVIHELIS DNIPVILLSESQPYSSLTTVTVDNFLGGYELTAYLISLGHSRIAVIAEDNASSRERIRGYSQALQESDLDIHEDLI VVTDSTAESAQSLASSLLQSSNPPTAMICCNDILAIGALLAAREEHVLVPEELSITGFDNTLISKSSDPPLTTVE VPVQSMCSQAVDLLIDEIEGKASEKQKILVLPKLIVRKSTSRFH SEQ. ID. ABP24568 MSLVKNGDSIKVVFVFQKNEQIEEVELNSAQLSALLHSKQV NO. 164. SEQ. ID. ABP24598 MDINDASEHLIQLKQDLIDRSKIEMINKLKRWAFSFLKHLNFEIQTFNYGFV NO. 165. SEQ. ID. ABP24599 MKKRLIGFLVLVPALIMSGIILIEANKKAPVEVLESAWDEFGLFSFQIGKTDPSITIGMDHTKSEAKLREYLEH NO. 166. NLSREAKEKYKIYIFKDDIDKLEKEHREYLKANNPNK SEQ. ID. ABP24600 MRFTAGGNLSTMDSQVLDVIKKAYNLGMVNKDNMLLRNEAINAYRNSI NO. 167. SEQ. ID. ABP24601 MLPEYRKKTPEEILEEIERLKRGRLKVYIGSAPGVGKTYRMLQEAHELKAEGLDVVIGLIETHNRKETEDLIGD NO. 168. LEIVPKKNIDYKGRLLEEMDTEAIIKRAPDLVLIDELAHTNVPFSQRNKRYMDVEEILKSGINVLSAVNIQHLE SLHDIVQQITGVQVRERIPDSFLHMAHEIILVDVTPEILRKRLSEGKIYHPSKIEQALNNFFTASNLGALRELSL REVANDVDERVEKANEKNGKNKPSGINEKIMVCVQHGSNAERLIRRGWRIANRLKTELIILHVTNEVSMK RSTENRKKIQDWKRLAIQFNARFIIEQIKKRHIAKAITDVAKEHDVTQIILGQSARSRWEEIRKGSIVNMIMR YTTGVDIHIVSDQQPRRK SEQ. ID. ABP24602 MLKIIRLALLMIIICGILYPLLMTGLAQAIFPDQANGSILKNKDGQIVGSELIGQQFTKSNYFQGRISSIKYNAV NO. 169. GSGSNNYGPTNQEMLERTKSFIRVLEEGNPDLKTKELPIDLITNSGSGLDPDISVKAAKFQVNRVSNATGVS ESTLNKLIDNTIDGRSLGIFGEPRVNVLKLNMKVQEIISKGN SEQ. ID. ABP24603 MNKSNENSEMIKEAITQSFIKLNPLSMMKNPVMFVVEVGTFLVLLMLIMPSAFHSEEGYVYNLIVFLILLFTI NO. 170. LFANFAEALAEGRGKAQADSLKKTKKDTVARRINKNGTVTDISSADLKKGDIVLVETGDFIPGDGEIIEGLASI DESAITGESAPVIKEAGGDFSSVTGGTKVVSDSIKVRITADPGESFLDKMISLVEGAKRQKTPNEIALTILLVTL TIIFLLVVVTLLPIANYVGVHIELSTLIALLVCLIPTTIGALLSAIGIAGMDRVTQFNVLAMSGKAVEVAGDINTII LDKTGTITFGNRLAAEFIPVSSTTQEELMQAAVITSLFDETPEGRSVLELAKNNGASWEASAYESAEIIPFTAE ERMSGLIKDGHHYRKGAVDSIKAFVQEMGGPLPLDLQSKSEEVARQGGTPLAVSYNNRILGLIYLKDTVKP GMRERFDELRKMGIKTIMCTGDNPLTASTIAKEAGVDDFIAEAKPEDKIRVIREEQEKGKLVAMTGDGTN DAPALAQADVGLAMNSGTIAAKEAANMVDLDSDPTKIIEVVAIGKQLLMTRGSLTTFSIANDIAKYFAIIPA MFTVAIPGMQVLNIMRLHSPTTAILSALIFNAIIIPLLIPLAMKGVKYVPMSASKLLSRNILIYGLGGIVVPFIGI KLIDILVSVFMS SEQ. ID. ABP24604 MKGHTRLLIPMSIILTIILVSLKVPQTLSPSIEVTTLEGVKQVISIGPVASLESIKHLGTNGGGFFGANSAHPFE NO. 171. NPSPLTNVIEILSMWCIPASLTYTYGRFAKKQKQGWVIFGAMFILFIAFLSLIYVSESHGNPALTALGLDPSQ GSMEGKEVRFGIAQSALFSSVTTAATTGTVNNMHDTLTPLGQITPLSLMMLNTVFGGDGVGLVNMLMY AIIGVFICGLMVGRTPEFLGRKIEPKEMKLITVALLAHPLIILAPTALAFLADIGKGSISNPGFHGVSQVLYEFA SSAANNGSGFEGLADNTPFWNISTGLVMLVGRYISIIALLAVAGSLVQKQPVPETIGTFKTDNLLFIGILVGV VLIVGALTFFPVIALGPIAEYLSIR SEQ. ID. ABP24605 MGILQIIVVIMLMLFMIKPLGTYIYHVFSNEPNKTDKIFNPIEKIIYKICGMKNRLSMTWKQYAGSLLLTNMV NO. 172. FIAVGYVILRFQYILPLNPNGENMNSMLSFNTIISFMTNTNLQHYSGETGLSYFSQMAVIMMMMFTSAA TGIAAAIAFIRGITSKGKTIGNFLKIL SEQ. ID. ABP24606 MNNNLGGITLDDVCMLAVIAVIFAVFWAFVKWCDFTIGGGEKQ NO. 173. SEQ. ID. ABP20078 MPKQQTAELKPFFHNKTVLVTGGTGSIGSQIVKRLLMLTPKQVIVFSKDDSKQYVMSQKYAEDKRLLFVLG NO. 174. DVRDHRRVNQVMKGVDIVFHAAALKQVPTCEDHPFEAIQTNLIGGQNVVEAALSHRVQHVINISTDKAV FKDTDYKLIKKKGLF SEQ. ID. ABP20079 MPYEEYEELKKKTIKVIQRKNYSIRIIDQKFENDNLDQLYKEVARLLFERALKSSE NO. 175. SEQ. ID. ABP20080 MGANNQGKVFEANIEKSAADQKLFFYRIKDVNPMFLKRGAAVSKNKYDCFLHFNGYLFPFELKSTKDKSIA NO. 176. FREKIIKPQQIKYLKEATQYPNIIPGFLFQFREPENKVYFVHIDEFLKYKNIAEKQLKHTYKNKVNKASIPIAICE EIGTEVRWMKKKVNYTYYLNKLCVELIKKEQSRDKPLHTYNTPVKTGVR SEQ. ID. ABP20081 MYVLKSLLKEVYIVKKQWKPVDSRLNELMHEYSVSIEDLVERTGLPKQRINDYVSGFKSNMNIGTAMTFAD NO. 177. AIGCSIEELYVWNFKERRQLIK SEQ. ID. ABP20082 MKTVKEAIDEKDLQRAHRNLINLADNNEELMQEIRWIKKGTTL NO. 178. SEQ. ID. ABP20083 MNLKNIDENRYKKTYSVQPNDIFFVVRKNGNQTPYLIYKDKNKMLKLINLQSGASNYCADTIDSLVGIYIKE NO. 179. NQESPANKVNPIKEYFFAKSHETSIRVHNTFNYNPIK SEQ. ID. ABP20084 MKTIKLYELVSEGKKPIIKFNDNVYEWIEESVDTMMMGKIIGASIEYEDSVRFLIDLNPFEAYNRSVARHDW NO. 180. RDDEGNCVLTWFDTSFYPKNGIEAIYLPINGRTEIAFDFTEEDSLLNEYAKVPQEISYVEWLENEVKQLISK SEQ. ID. ABP20085 MIVTAWILLIMFGLFALSDLNLTEDETKHIKFFMLMKFFSVFIAAIAAGVI NO. 181. SEQ. ID. ABP20086 MKNTEFKKTSFLEEYKRGDEMRRDFIIHEGYTAIEEIIKEVNQRGSLNEADIYYGTPKPQLSFSDVELGYMLT NO. 182. SMMEYATNHVGNPVDEECEFENKLAYFEYKDEIVQIFEVYGQGTESWFSKPSDDTIDKLNNTAYGVYLIQF DDFINYTKNKDSESEKLSPSSTILNDITGGYTVGRGSK SEQ. ID. ABP20087 MLELDEYILKSEMDFADPEEIRSCIISFVSSLQQYIDLCKEELNEEYRV NO. 183. SEQ. ID. ABP20088 MVELAKEENMLFFDHYPTEYGGWQTGNRDVWGIWGQRYLLKKVSDGCCEYVSR NO. 184. SEQ. ID. ABP20089 MYGEDVEVTLDGNIKVKVFVFCLPTTCKEEKEKRALLTLKNLIDKRLKNEDLKYLDVQSDFVLIPKMIENGEF NO. 185. SEQ. ID. ABP20090 MRVSSEALKIVIVQHLERDNDLMSEGKIIVLPCRDEKTAKEFEDFYRKKFPSTQLMSIEIVDSNIYG NO. 186. SEQ. ID. ABP20091 METKKYVRIIRNASKYGDMTGQIFPLFGTWEDSYKIDGSDGVVYVRKKDVEVIVTENRRPKVDERVLITEVL NO. 187. LSSGHYKIGDIYTVLSVVDIYGTITVKEHSNCVISREYEVIVDEVKKEEADGMENVNQTVINNANTVFEKKDD KYFGYKSRFGDIVIGGAYSYRFVVQYAKTNQDVVVIPGDENTVTTPVCTTLEERLWQPEKAVKSSPRNLHY SEQ. ID. ABP20092 MEVGDKIHNTNEQITALEKKKYQIETTLLEKQRDLLKLETQQNKEKLELLFELSEVLTQLQDEEWVSCMIALR NO. 188. IIRRNKRKYLNLFELVNEKAYINKDKFKVLHDEFFDLKQQLNEI SEQ. ID. ABP20093 MIYKTFLPYADKVYLTIVDSAQREADSYFPMLDDRWKLTDKRHNKADEKNKYNYSFITFENNYRQK NO. 189. SEQ. ID. ABP20094 MTQFDKQYNSIIKDIINNGISNEEFDVRTKWDSDGTPAHTLSVMSKQMRFDNSEVPILTTKKVAWKTAIKE NO. 190. LLWIWQLKSNDVNDLNKMGVHIWDQWKQEDGTIGHAYGFQLGKKNRNLNGEKVDQVDYLLHQLKNN PSSRRHITMLWNPDELDAMALTPCVYETQWYVKHGKLHLEVRARSNDMALGNPFNVFQYNVLQRMIA QVTGYELGEYIFNIGDCHVYTRHIDNLKIQMEREQFEAPELWINPEVKDFYDFTIDDFKLINYKHGDKLFFEV AV SEQ. ID. ABP20095 MFKVLDVLDGEKTKQNTYIYWLFVCGNFLFVVFYLADVFL NO. 191. SEQ. ID. ABP20096 MLKDKNKITKSIEKINKLEEGLALFEEGDEEYLSVLVKIQGLYDEIADTALECFKEMTTKIRKTGQKRIGKGIDQ NO. 192. LPYTIKENIADQVNELKGSFLDESKY SEQ. ID. ABP20119 MDSYPESLKKETEEIKERVRNGNIKEDRIKEIAETTVEFLKSEEKRHKYFSEVAAAMADNLSEFFKSYLKGE NO. 193. SEQ. ID. ABP20120 MKKLRVMSLFSGIGAFEAALRNIGVEYELVGFSEIDKYAIKSYCAIHNVDEQLNYGDVSKIDKKKLPEFDLLV NO. 194. GGSPCQSFSVAGYRKGFEDTRGTLFFQYIDTLKEKQPRYFVFENVKGLINHDKGNTLNIMAESFSEVGYRID LELLNSKFFNVPQNRERIYIIGVREDLIENDEWVVEKGRNDVLSKGKKRLKELNIKSFNFKWSAQDIVGRRLR EILEEYVDEKYYLSEEKTSKLIEQIEKPKEKDVVFVGGINVGKRWLNNGKTYSRNFKQGNRVYDSNGIATTLT SQSVGGLGGQTSLYKVEDPIMIGHIDLKGHDAIKRVYSPDGVSPTLTTMGGGHREPKIAVEYVGNINPSGK GMNDQVYNSNGLSPTLTTNKGEGVKISVPNPEIRPVLTPEREEKRQNGRRFKEDDEPAFTVNTIDRHGVAI GEYPKYRIRKLTPLECWRLQAFDEEDFEKALSVGISNSQLYKQAGNSITVTVLESIFKELIHTYVNEESE SEQ. ID. ABP20121 MDINGKDLNKIHNIDCVQFMRENMGDCSIDLTVTSPPYDDLRKYNGYSFNFEATARELYRVTKDGGVVV WVIGDKTHNGSESGTSFKQALYFKEIGFNLHDTMIYEKDSISFPDKNRYYQIFEYMFVFSKGKPKTINLISDR NO. 195. KNKWYNGKKHIKGHYRKMDGEKVRHNKQNLLKEFGVRFNIWRIPNGHQKSTLDKVAFEHPAIFPERLAE DHILSWSNEGDIVLDPFMGSGTTAKMAALNNRKYIGTEISKEYCDIANERLRNYIGTI SEQ. ID. ABP20122 MKKVIAIDMDQVLADLLSDWVAYINTHDDPFLKEEEILCWDIKKYTNTNNNVYRHLDYDLFRNLDVIEGSQ NO. 196. RVVKELMKKYEVYVVTTATNHPESLKAKLEWLTEHFSFIPHSNVVLCGNKSIIKADIMIDDGIHNLESFEGM KILFDAPHNRNDNRFIRVMNWEEIERKLL SEQ. ID. ABP20123 MALIILEGPDCCFKSTVAAKLSKAMKYPIIKGSSFELATSGNQKLFEHFNRLADEDSVIIDRFVYSNLVYAKKF NO. 197. KDYSILTEQQLRIIEDKIKLKAKVVYLHADPSVIKERLSIRGDEYIEGKDIDSILELYREVMSNAGLHTYSWDTG QWSSDEIAKDTIFLVE SEQ. ID. ABP20226 MGYKLMAYGGYFLFCLFFLLMDGWRGMGICLIIAGLALLALEPYKIKAQKNIDKLKENAETLKHYESGFNPD NO. 198. NFFNTYKTKIAFKESDSLVKIYQLNRNEHIEEYTIPFSNIIESEITLDNQIISKVSKSGIVAGGLLAGGIGAALGGL SASSIQNEMVKSVTLKITVEDLGKPIHYIDFLPTQEVEGYNTQGYKKDSNIIQQALKNAEYWHGVMDVIIKK ASKVAQ SEQ. ID. ABP20227 MSQNLKIILTPQADTSSKTVEQLNQQIKSLEKKLNSLKLNTNIDSTTLKALQEFSSAVDAYQKNLKSYNQTVR NO. 199. ETSTVIKNADGSVEKLTQQYKKNGEILQRETKIINNRNTALKQETQEVNKLTQATEKLGQVQKKTVQRNLQ GQPTKIVQKNRQGFDDIVYTTDPKTNSTSSKTTTNYDQQRRAIEQLKQDLEKLRQQGIVTDTTISSLGRKIN TAQSAQQIEALQNRIRMLDDKSAAVAKNNELKKTIELYQRQAQVNVQNLNTRYGSSMGSSNRQAVQDY LNAVNSLNVSTGSNNIRSQIQSLNMQFRELASSAQAAANQASSFGAELTQTFKSMSTYLISGSLFYGAISGL KEMVSQAVEIDTLMTNIRRVMNEPDYKYNELLQESIDLGDTLSNKITDILQMTGDFGRMGFDESELSTLTK TAQVLQNVSDLTPDDTVNTLTAAMLNFNIAANDSISIADKLNEVDNNYAVTTLDLANSIRKAGSTASTFGV ELNDLIGYTTAIASTTRESGNIVGNSLKTIFARIGNNQSSIKALDEIGISVKTASGEAKSASDLISEVAGKWDTL TDAQKQNTSIGVAGIYQLSRFNAMMNNFSIAQNAAKTAANSTGSAWSEQQKYADSLQARVNKLQNNFT EFAIAASDAFISDGLIEFTQAAGSLLNASTGVIKSVGFLPPLLAAVSTATLLLSKNTRTLATTLILGTRAMGQET LATAGLEAGMTRAAVASRVLKTALRGLLVSTLVGGAFAALGWALESLISSFAEAKKAKDDFEQSQQTNVEA ITTNKDSTDKLIQQYKELQKVKESRSLTSDEEQEYLQVTQQLAQTFPSLVKGYDSQGNAILKTNKELEKAIEN TKEYLALKKQETRDSAKKTFEDASKEIKKSKDELKQYKQIADYNDKGRPKWDLIADDDDYKVAADKAKQS MLKAQSDIESGNAKVKDSVLSIANAYSSIDISNTLKASISDVVNKLNLKDNLDPEELEKFSSSLGKLQEKMQK ALDSGDEKAFDNAKKDIQSLLETYSKSDSSIDVFKMSFDKAQKNIKDGDKSLSSVKSEVGDLGETLAEAGNE AEDFGKKLKEALDANSVDDIKAAIKEMSDAMQFDSVQDALNGDIFNNTKDQVAPLNDLLEKMAEGKSISA NEANTLIQKDKELAKAISIENGVVKINRDEVIKQRKVKLDAYNDMVTYSNKLMKTEVNNAIKTLNADTLRID SLRKLRKERKLDMSEAELSDLEVKSINNVADAKKELKKLEEKMLQPGGYSNSQIEAMQSVKSALESYISASEE AASTQEMNKQALVEAGTSLENWTDQQEKANEETKTSMYVVDKYKEALEKVNAEIDKYNKQVNDYPKYS QKYRDAIKKEIKALQQKKKLMQEQAKLLKDQIKSGNIAQYGIVTTTSSPGGTSTSTGGSYSGKYSSYINSAAS KYNVDPALIAAVIQQESGFNAKARSGVGAMGLMQLMPATAKSLGVNNAYDPYQNVMGGTKYLAQQLE KFGGNVEKALAAYNAGPGNVIKYGGIPPFKETQNYVKKIMANYSKSLSSATSSIASYYTNNSAFRVSSKYGQ QESGLRSSPHKGTDFAAKAGTAIKSLQSGKVQIAGYSKTAGNWVVIKQDDGTVAKYMHMLNTPSVKTGQ SVKAGQTIGKVGSTGNSTGNHLHLQIEQNGKTIDPEKYMQGIGTSISDASQAEAERQQGIAQAKSDLLSLQ GDIDSVNDQIQELQYELVQSKLDEFDKRIGDFDIRIAKDESMANRYTSDSKEFRKYTSDQKKAVAEQAKIQQ QKVNWIQKEIKTNKALNSAQRAQLQEELKQAKLDLISVQDQVRELQKQLVQSKVDETLKSIEKSSSKTQGKI KDVDNKISMTEEDEDKVKYYSKQIKLIQQQQKEAKKYIKQLEEQKKAAKGFPDIQEQITEEIENWKDKQKDF NLELYNTKKSIKDIYKSLADEVVSIYKEMYEKMRDIELEAHQKATQDKIDEIDKEDEEAKYQKELKEKNQAIQ ETKDKISKLSMDDSSEAKSQVKDLEKQLQEQQEALDEYIKDRSNTKRKEALQDQLDKDEESINNKYDDLVN DERAFKKLEDKLMDGKITDIAKQLNEFTKFINENMKSIGKSISNNLIDKLKDAASALNTVTTGNTTGKKVSSF ASGGYTGTGLGAGKLAFLHDKELILNKTDTENMLEAVKQVRQTSTDNSVKTTSKWGQPGKISDVLSKSISL VTPAMNAAVASQTSLTKGLIPTLKNFSTPTVTPSTPQGNTSNNQNSFTINVTEASNAKETASLVYKQLANG LKNTGLNFNIT SEQ. ID. ABP20228 MIRQSQYFLFDNEKSIDYGVENVNTESGLVEESFLGSRSVNETYVKGRSEPYTEGVKREAKQFPLNFYVGEN NO. 200. YDEKKIRAIKRWLDVDDYKPLAFSENLDIVYYAMPVDTSDLVHNAARHGYVRLTMKCNSPYAYSRNTSTHS FDISSGMKTIELHNKGDVAIYPTVEILKIGDGDVKIENLSDYTDPFIFSNLKDREIVKVNGDKEIIESSLYGNERY DDFNDNYIRLDYGKNRLKVTGKCKLRLTFRFKYR SEQ. ID. ABP20229 MITIRKDTEIKNIRLSLAKPDKTKIANIDEVLNPTVTLNHGSSVHELSFSIPLKATYDGVIKRNHVVDLLKPWYL NO. 201. IKTEFYGLAIWFIITKRTKSFSSEMDTVQVECRSLQHELSRISVLKYEETSKNLQEVVTDCLKNTSWTVGYIDT LFNVKRRQFDVSSTNKLDFLYSICEKFDAVPVFDTVKETVSFYKESDISKYKGLKLNPRQYMISMDDSDDAD ELVTRLYATGKDGISINSVNPTGQSYIDDFSYFLFPFQRDEQRNVISHSAYMPDELCHAILDYNDLVNSEGN AFNKLLTQKNEAETGLTELNNELYTLDLEVQKLLDRIEVAKKAGDDTSQLKAQLAVKQKAVALKKNQIATIE STISQISASISKLKEKLSFENNFSENQQKLLSRFISTTEWSNDSIYDENELYDDANEELESRNTPPVNVTLDIVN FFNCISEKHNWDRFSLGDIVRVQQSDLNTDIKAILSAITIDFEQSNISVTVTNGKRVQSDFEKVIKTVYRTNKI STELNKRKIEWDKVTENFNIRNDRISVQPAPPVIASDGTAITHKVNDNGSVDITIQWNYVDSNEDKYNIDG FEVYLHGSDDNEEYTFGSVQASENLQNVKYDRRTATFTGLPSNMYYTIGVQAYRRVDADIDINQILLSDIVK SNHPSENPYLPTPSIEVKGSLSGKVNGLYTISTESKPEEPETGTIWIDPKTNKQELFNGEEWIVSSAGSADSL NGFTASLTTSPNSIPVRDQSGVISGSIDGNAEMLGGRAASDYALTENIPVPPKFAKGVYTGDGTLSKQIPLA FTPDLVKITPISPEDSQLVIESQLGGYAYQVTSTGLSLIGGDLSYGALGNNLFITGSDSNCRGNKLNVKYIWE AYQQN SEQ. ID. ABP20230 MGSLPTKLTEVIKLADFAELYNDPILSKKRIGSVEDPYLTYSETLTVYNGRALLTEIPNREFRVEVIGDKKEWR NO. 202. EIEDGELEDNYFKVDYLMGVVFFNASNEGKSLTFNYSGEGASFFPASRIWIKRQGNMVIETLQGLIDDAED TIIRMNERIAECERVTKRCIEITNWCRQATSDYEYVVENTRKIYLPMVYTYQDLMDTYPNPQIGWVVTIRDT GIEYRWDGFDWINISISDQFDGYNVVSSYIEPYNIRTVWLRTNSPPSKKRVKPSKDAPDGSMVWIRKG SEQ. ID. ABP20231 MSDNLIPVNTMGYYDEETKQWVPIDAVALKSENYRFTADDISQKFNKIGDIDAIKATGNTLSEKIINEFNYR NO. 203. GINISWLGAKGDGTTDDSSVFSSIESTYQDKVFDLAGKTYVVNSFPNKNKYLNGYFIIDGNKYFSGYVSSFQ TGNSNIIIGNNAAKNFRPGDQYKGIAGHNIIAIGENALSNASEYTKNTTAIGAGALFNNKYGVYNLAIGLQS QYYVTGVQGDAFKGTRNTSVGDNSMRFNKDGYSNVAMGRNALQTNEKSLWNTALGAAAMSGYAPLN LDSKTIINNSPQTAGYQVAVGTNSLYWSNGIGNVGVGVNAGREIKNSQRNVAMGYYAMSQLDSDVSFE GKQRFFPSIQAGYTWIGQDITLTHIGHTFIVGQNLSLALDGGEKFSTTVKSITVDTFTVSTTQIAQNEISGMA QVSEYYTTTGTYVWKDNNIQVSMGNHPFQNGYKVLMSVGGREAIYFTVANSTSSGFTVSTDIIGDESGAV KITEYSDTTPMAVNYDNTAIGVKAAWKMKKGSFNTAIGGLSLENNKGDYNTALGYMALKNNTTGNQNT ALGYGALRFTTGGDEMKDISNSTGVGFNSRVSGSNQIQLGDGNSTPYSFNALQNRSDLRDKADI RDTVLG LDFINKVRPVDYKWDIRDEYVEIKEDGTVITHERDGSKKKNRYHHGVIAQEIQKVIEAEGIDFGGFQHHELS GGEDVMSIGYTEFIAPLIKAVQELSAKVEEQAKEIAALKKA SEQ. ID. ABP20232 MTIQARQMLVSPGKYPIKGRYAMTAEYITFHNTANDASANNEISYMRNNNETVSYHFAVDDKEVVQGLP NO. 204. TNRSAFHCGDGEYGTGNRKSIGVEVCYSKSGGERYRKAEALAIKFIAQLLKERGWGVERVKKHQEWSGKY CPHRVLDEGRWNEVKAAIAAELKSLGGKSTTPTKTSTKPTTSSPSSSSAASGSLKSKVDGLRFYSKPSWEDK NVVGTVNKGIGFPTVVEKVKVGSAYQYKVKNSKGATYYITASDKYVDVTGSVKASSPTPKTTSTSSSSSSIKS VGKIKIVGVSSAAIVMDKPDRNSSKNIGTVKLGSTVSISGSVKGKNNSKGYWEVIYNGKRGYISGQFGSKI SEQ. ID. ABP20233 MTKINWKVRLKKKTFLVAIFSATLLFVQAIASAFGYDLTVFGDNLTEKFNALLTFLTAMGIIVDPTTQGISDSE NO. 205. QAMDYDSPR SEQ. ID. ABP20234 MLEQMISSSKVGVKINEWYKYIRLFSVPDSEILKAEVEEEIRHMKEDQDLFLYYSLMCFRHQLMLDYLEPKT NO. 206. LNEERPKVSDLLEKIESSQTDLKGILEYYFNFFRGMYEFEQYEYLNAISFYKQAERKLSLVADEIERAEFHYKVA EIYYHMKQTHMSMHHIVQAIDSYKAHENYTVRVIQCSFVIGLNYLDMDYPEKAIPHFKDALDKAREIDMS RLIGSSLYNLGLCSFAEEAYEKASEYFKEGIRVYQDNGYEHSNRILDILLMLTKTTFKMRNHSEGISWCAHGL SLSKNLNDEIMAKMFEFIHALYVDNDNEKLNSILNYLELKSMLSDVEDLASDAAKYYNEKEDHKVAVAYYEK VLYARKQIQRGDCLYET SEQ. ID. ABP20235 MKLKHASVFILAIVLIGFVSTYLTNTQKDVQEARRGHTASIGFTDGHSYEIASRGHTS NO. 207.

The term “comprising” whenever used in this document is intended to indicate the presence of stated features, integers, steps, components, but not to preclude the presence or addition of one or more other features, integers, steps, components or groups thereof.

The disclosure should not be seen in any way restricted to the embodiments described and a person with ordinary skill in the art will foresee many possibilities to modifications thereof.

The above described embodiments are combinable.

The following claims further set out particular embodiments of the disclosure.

REFERENCES

-   1. Fetissov S O. Role of the gut microbiota in host appetite     control: bacterial growth to animal feeding behaviour. Nat Rev     Endocrinol. 2016. doi: 10.1038/nrendo.2016.150. PubMed PMID:     27616451. -   2. Baumler A J, Sperandio V. Interactions between the microbiota and     pathogenic bacteria in the gut. Nature. 2016; 535. doi:     10.1038/nature18849. -   3. Ganguly S, Prasad, A. Microflora in fish digestive tract plays     significant role in digestion and metabolism. Reviews in Fish     Biology and Fisheries. 2012; 22:11-6. -   4. Ray A K, Ghosh, K., Ringo, E. Enzyme-producing bacteria isolated     from fish gut: a review. Aquaculture Nutrition. 2012; 18:465-92.     doi: 10.1111/j.1365-2095.2012.00943.x. -   5. FAO. The state of world fisheries and aquaculture: Opportunities     and challenges. Food and agriculture Organization of the United     Nations. Rome, Italy. 2014. 243 p. -   6. Krogdahl A, Penn, M., Thorsen, J., Refstie, S., Bakke, A. M.     Important antinutrients in plant feedstuffs for aquaculture: an     update on recent findings regarding responses in salmonids.     Aquaculture Research. 2010; 41:333-44. -   7. Sinha A K, Kumar, V., Makkar, H. P. S., De Boeck, G., Becker, K.     Non-starch polysaccharides and their role in fish nutrition—A     review. Food Chemistry. 2011; 127:1409-26. -   8. Joint FAO/WHO Working Group Report on Guidelines for the     Evaluation of Probiotics in Food, (2002). -   9. Setlow P. Spore Resistance Properties. Microbiol Spectr. 2014;     2(5). doi: 10.1128/microbiolspec.TBS-0003-2012. PubMed PM ID:     26104355. -   10. Tam N K, Uyen N Q, Hong H A, Duc le H, Hoa T T, Serra C R, et     al. The intestinal life cycle of Bacillus subtilis and close     relatives. J Bacteriol. 2006; 188(7):2692-700. doi:     10.1128/JB.188.7.2692-2700.2006. PubMed PMID: 16547057; PubMed     Central PMCID: PMCPMC1428398. -   11. EFSA-BIOHAZ. Scientific Opinion on the update of the list of     QPS-recommended biological agents intentionally added to food and     feed as notified to EFSA, European Food Safety Authority Panel on     Biological Hazards (EFSA-BIOHAZ). EFSA Journal 2017; 15(3):4664.     doi: 10.2903/j.efsa.2017.4664 -   12. Cutting S M. Bacillus probiotics. Food Microbiol. 2011;     28(2):214-20. doi: 10.1016/j.fm.2010.03.007. PubMed PM ID: 21315976. -   13. Bader J, Albin A, Stahl U. Spore-forming bacteria and their     utilisation as probiotics. Benef Microbes. 2012; 3(1):67-75. doi:     10.3920/BM2011.0039. PubMed PMID: 22348911. -   14. Kunst F, Ogasawara N, Moszer I, Albertini A M, Alloni G, Azevedo     V, et al. The complete genome sequence of the gram-positive     bacterium Bacillus subtilis. Nature. 1997; 390(6657):249-56. doi:     10.1038/36786. PubMed PMID: 9384377. -   15. Harwood C R, Cutting S M. Chemically defined growth media and     supplements. In: Harwood C R, Cutting S M, editors. Molecular     biological methods for Bacillus. Chichester, UK: John Wiley & Sons     Ltd; 1990. p. 548. -   16. EFSA-FEEDAP. Guidance on the assessment of bacterial     susceptibility to antimicrobials of human and veterinary importance,     European Food Safety Authority Panel on Additives and Products or     Substances used in Animal Feed (EFSA-FEEDAP). EFSA Journal. 2012;     10(6):2740. -   17. Serra C R, Earl A M, Barbosa T M, Kolter R, Henriques A O.     Sporulation during growth in a gut isolate of Bacillus subtilis. J     Bacteriol. 2014; 196(23):4184-96. doi: 10.1128/J6.01993-14. PubMed     PMID: 25225273; PubMed Central PMCID: PMCPMC4248874. -   18. Casula G, Cutting S M. Bacillus probiotics: spore germination in     the gastrointestinal tract. Appl Environ Microbiol. 2002;     68(5):2344-52. PubMed PMID: 11976107; PubMed Central PMCID:     PMCPMC127533. -   19. Xue Z, Zhang W, Wang L, Hou R, Zhang M, Fei L, et al. The     bamboo-eating giant panda harbors a carnivore-like gut microbiota,     with excessive seasonal variations. MBio. 2015; 6(3):e00022-15. doi:     10.1128/mBio.00022-15. PubMed PMID: 25991678; PubMed Central PMCID:     PMCPMC4442137. -   20. Zhou Z, Zhou X, Li I, Zhong Z, Li W, Liu X, et al.     Transcriptional regulation and adaptation to a high-fiber     environment in Bacillus subtilis HH2 isolated from feces of the     giant panda. PLoS One. 2015; 10(2):e0116935. doi:     10.1371/journal.pone.0116935. PubMed PMID: 25658435; PubMed Central     PMCID: PMCPMC4319723. -   21. EFSA-FEEDAP. Guidance for the preparation of dossiers for     technological additives, European Food Safety Authority Panel on     Additives and Products or Substances used in Animal Feed     (EFSA-FEEDAP). EFSA Journal. 2012; 10(1). -   22. EFSA-FEEDAP. Guidance on the assessment of the toxigenic     potential of Bacillus species used in animal nutrition, European     Food Safety Authority Panel on Additives and Products or Substances     used in Animal Feed (EFSA-FEEDAP). EFSA Journal 2014; 12(5). -   23. Cabello F C, Godfrey H P, Buschmann A H, Dolz H J. Aquaculture     as yet another environmental gateway to the development and     globalisation of antimicrobial resistance. Lancet Infect Dis. 2016.     doi: 10.1016/S1473-3099(16)00100-6. PubMed PMID: 27083976. 

The invention claimed is:
 1. A method for feeding an aquatic animal present in an aquaculture comprising the step of feeding the aquatic animal with a composition comprising a bacterial strain selected from the group consisting of: ABP1 with a deposit under the accession number CECT 9675, of 8 Jun. 2018, at Colección Espanola de Cultivos Tipo, ABP2 with a deposit under the accession number CECT 9676, of 8 Jun. 2018, at Coleccion Espanola de Cultivos Tipo, and a mixture thereof.
 2. The method of claim 1, wherein the step of feeding the aquatic animal is carried out during the life span of the aquatic animal.
 3. The method of claim 1, wherein the aquatic animal is selected from the group consisting of: a shellfish, fish, amberjack, arapaima, barb, bass, bluefish, bocachico, bream, bullhead, cachama, carp, catfish, catla, chanos, char, cichlid, cobia, cod, crappie, dorada, drum, eel, goby, goldfish, gourami, grouper, guapote, halibut, java, labeo, lai, loach, mackerel, milkfish, mojarra, mudfish, mullet, paco, pearlspot, pejerrey, perch, pike, pompano, roach, salmon, Atlantic salmon, sampa, sauger, sea bass, European sea bass, seabream, gilthead seabream, white seabream, shiner, sleeper, snakehead, snapper, snook, sole, spinefoot, sturgeon, sunfish, sweetfish, tench, terror, tilapia, trout, tuna, turbot, vendace, walleye, halibut, whitefish, and shrimp. 